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Abstract 
 
Tertiary lymphoid organs (TLOs) are a hallmark of many chronic immune-mediated 
inflammatory diseases. However, till date the series of events leading to stromal cell 
activation in TLOs and their role in the inflammatory process remain unclear. 
Using a model of inducible TLO formation in the salivary glands of mice we explored the role 
of gp38+LTR+ lymphoid-like stromal cells (LLSc) during TLO development and show that 
they acquire the capability to produce lymphoid chemokines (CKs)/cytokine and drive 
lymphocyte compartmentalization. In this thesis, we provide evidence that stromal cell 
activation is a multi-step process with three distinct phases mediated by three major 
cytokines (IL-13, IL-22 and LTβ).  
We demonstrate that during TLO formation, IL-4Rα engagement via IL-13 on quiescent 
tissue-resident fibroblasts induces the phenotypic acquisition of lymphoid features by LLSc. 
IL22 then initiates the proliferation and expansion of the LLSc population, required for the 
expression of lymphoid CKs/cytokines and ANA autoantibody production. Finally, we show 
that LTβR ligation is necessary for the establishment of a fully mature TLO structure once IL-
22 driven LLSc proliferation has occurred. Based on our findings we have identified three 
different phases of stromal cell activation in TLOs which are all potentially targets of future 
therapy. 
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Chapter 1 
Introduction 
1.1 General 
The functioning of the immune system requires highly complex and dynamic interactions 
between various cell populations which protect the body against insults by pathogens and 
noxious antigens. This includes a wide range of physiological phenomena such as 
generation of diverse and functionally mature (albeit naïve) T and B lymphocytes, regulation 
of immune tolerance through T- and B-cell receptor repertoire screening and selection to 
control escape of auto-reactive lymphocytes, antigen drainage from peripheral tissues and 
blood, initiation of the adaptive immune response, generation of immunological memory and 
control of commensal microbiota homeostasis. Over the years, many studies have 
documented the location and organization of these complex activities within specialized 
lymphoid organs [1-4].  
Broadly the immune system is made up of primary and secondary lymphoid organs. Primary 
lymphoid organs like bone marrow and thymus are specialized environments where 
lymphocytes are produced, differentiated and selected according to their ‘non-self-reactive’ 
specificity but all of this happens in an antigen-independent manner [5]. Secondary lymphoid 
organs (SLOs) are anatomically distinct tissues that are situated throughout the body at 
strategic sites where foreign antigens are most likely to be encountered, thus each SLO is 
uniquely equipped to ‘sample’ antigens, efficiently trap and concentrate these foreign 
antigens to be delivered to lymphocytes that recirculate in these SLOs, [1-4] in order to 
mount an appropriate adaptive immune response. The spleen, for example, is important for 
detection of and protection against blood-borne pathogens, whereas draining lymph nodes 
are found along the lymphatic bed that drains antigen and antigen-presenting cells (APC) 
from the peripheral tissue [1-4].  
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The mucosal lymphoid organs, Peyer’s patches (PP), nasal-associated lymphoid tissue 
(NALT), cryptopatches and inducible lymphoid follicles (ILF) provide protection at mucosal 
surfaces, ‘collecting’ antigens directly from the local environment via the mucosal epithelium. 
These lymphoid organs lack afferent lymphatic vessels. Taken together these SLOs form a 
highly diverse and complex system that provide a specialized architecture and 
microenvironment to support the controlled interactions between APCs and rare, antigen-
specific lymphocytes, provide the necessary factors for the survival and differentiation of 
lymphocytes to pre-empt a rapid and appropriate immunological response to foreign agents 
and also promote stimulation of long-lived, protective immunity. Furthermore they have been 
recently recognized as sites for regulation of peripheral tolerance to control escape of auto-
reactive lymphocytes that escape central tolerance barriers operating in primary lymphoid 
organs [1-4]. 
Over the past years, numerous studies have described immune cell location and 
organization in both primary and secondary lymphoid organs. For all these years, stromal 
cells which form the lymphoid tissue parenchyma have been assigned to play only a 
structural role of forming the scaffold of the lymphoid organs within which the immune cells 
perform their functions. However, it’s only recently that studies have started to highlight how 
the leukocytes in these lymphoid organs are actively engaged in functional interactions by 
the non-haematopoietic stromal cells (which include mesenchymal and endothelial stromal 
cell subsets and in case of thymus also includes epithelial cells) [1, 6, 7]. 
In the thymus, stromal cells have been demonstrated to be necessary for survival and 
proliferation of thymocytes. Furthermore, the active interaction between stromal cells and 
immature thymocytes has been shown to be critical to drive the self-tolerant T cell maturation 
process in the thymus [8]. Correspondingly in SLOs, the stromal cell compartment provides 
lymphocyte survival signals, chemokine cues which allows migration of T and B cells within 
SLOs that allows appropriate conservation of SLO architecture and function, Stromal cells 
also provide channels for delivery of antigen and inflammatory stimuli within SLOs [1].  
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Stromal cell networks are a dynamic component of SLOs which consist of a variety of cell 
subsets with specific but overlapping functions [1, 6, 7]. Moreover, stromal cells are not only 
important for proper functioning of the lymphoid organs in adulthood; studies have also 
underlined their necessity in development of these lymphoid organs. For example, a study in 
1960 showed that removal of the surrounding mesenchymal layer from 12-day-old embryonic 
thymus lobes prevented normal thymus development [8, 9]. The importance of thymic 
mesenchymal stromal cells was further emphasized in a study where extirpation of the neural 
crest cells- resulting in lack of thymic mesenchymal stromal cells- led to abortive thymic 
formation and function [8, 10]. Similarly, in SLOs (such as LNs) lack of lymphoid stromal cell 
maturation signals during development results in disrupted LN formation [6, 11]. 
For the purpose of this thesis only aspects of SLO (in particular LN) development, structure 
(including different lymphoid stromal subsets) and function will be further discussed. This 
introductory chapter will also discuss tertiary lymphoid organs (TLOs) in detail.  TLOs are 
ectopic accumulations of lymphocytes commonly found at non-lymphoid site of inflammation 
and infection. They architecturally resemble SLOs, with segregated T and B cell areas, 
presence of specialized populations of DCs, differentiated lymphoid stromal cells and high 
endothelial venules (HEVs). Even though TLOs are often associated with local pathology 
observed in chronic inflammatory or infectious diseases but there are also examples in which 
TLOs are reported to contribute to protective immune responses like their SLO counterparts 
[12-14] . Therefore, it remains unclear whether TLOs are beneficial or not and whether their 
presence in tissues should be encouraged or prevented. 
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1.2 Development of secondary lymphoid organs (SLOs) 
Irrespective of differences in anatomical location and organization, the development of most 
SLOs follows a similar script with some variations. A relatively common programme of 
organogenesis seems to underlie the development of LNs, PP, NALT and ILF whereas the 
organogenesis of the more complex organ the spleen, which consists of white and red pulp, 
involves different genes [4, 11, 15, 16]. For the purpose of this thesis we will not discuss the 
development of spleen. 
The process of secondary lymphoid organ development (also termed secondary lymphoid 
organogenesis) occurs mostly independent of antigen or pathogen recognition with the 
exception of ILF development which only takes place when the intestine is colonized by 
bacteria. The foundation for lymphoid tissue ontogeny is established at predetermined sites 
throughout the body as a result of complex and critical interactions between hematopoietic, 
mesenchymal and endothelial cells [4, 11, 15, 16]. The knowledge on the cellular and 
molecular interactions involved in the formation and maintenance of SLO architecture has 
mostly derived from the analysis of various gene-deficient mice that show different degrees 
of defective lymphoid organogenesis [4, 11, 15, 16]. The results of deletion of individual 
cytokines, chemokines, receptors and transcription factors have been catalogued in Table 
1.2A. 
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Table 1.2A 
Mutation  Signalling 
pathway 
Cells 
affected  
mLN  pLNs  PPs  NALT References 
Lta−/− LTβR stroma ± * − − ± ** [17-20] 
Ltb−/− LTβR stroma ± − − ± [17, 20, 21] 
Ltbr−/− LTβR stroma − − − ± [17, 20, 22] 
Light−/− LTβR stroma + + + ND  [23] 
Light/Ltb−/− LTβR stroma − − − ND [23] 
Aly/aly LTβR stroma − − − ± [17, 20, 24] 
Il7ra−/− IL-7R LTi + + − ± [17, 20, 25, 
26] 
Il2rg/rag−/− IL-7R LTi + + − − [27] 
Jak3−/− IL-7R LTi + + − ND [25, 26] 
Trance−/− TRANCE-R LTi − − + + [20, 28, 29] 
Rank−/− TRANCE-R LTi − − + ND [30] 
Traf6−/− TRANCE-R LTi − − + ND [31] 
Rorc−/−  LTi − − − + [20, 32, 33] 
Id2−/−  LTi − − − − [17, 34] 
Ikaros−/−  LTi − − − ND [35] 
Cxcl13−/− CXCR5 LTi/B − − − ± [36, 37] 
Cxcr5−/− CXCR5 LTi/B − − − ND [38] 
Plt/plt CCR7 LTi/B/T + + + + [24, 37] 
Ccr7−/− CCR7 LTi/B/T + + + ND [39] 
Cxcl13/Ccl19/21−/− CXCR5/CCR7 LTi/B/T − − − ± [37] 
Ret−/− RET LTin ND ND − ND [40] 
Graf51/51 RET LTin ND ND ± ND [40] 
 
(Adapted from Randall et al., 2008; Mebius 2003 [11, 16]) 
*small mLNs developed in few mice 
*small disorganized NALT developed 
ND, not determined 
 
Table 1.2A Mutations that impair lymphoid organogenesis.  
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LN and PP Organogenesis 
The development of LNs and PP is initiated approximately at E11 and E15 respectively and 
continues for several weeks after birth. The process starts with LN and PP anlagen formation 
that entails development of the necessary stromal microenvironment which contains reticular 
cells, fibroblasts and endothelial cells, and the recruitment of lymphoid tissue inducer (LTi) 
cells of hematopoietic origin. The iterative interaction between stromal cells (referred as 
lymphoid tissue organizer cells or LTo) and LTi, which is reinforced by several 
cytokine/chemokine feedback loops, lays the foundation for the subsequent development of 
mature lymphoid organ [11, 16, 41].  
In this section the development of LN and PP will be discussed, with a focus on LTi and LTo 
cells, the cellular and molecular axis involved in the organogenesis of these lymphoid tissues 
and finally the organization of LN and PP in their characteristic mature architecture with 
segregated T and B cell areas. 
Generation of lymphoid tissue inducer (LTi) cells during secondary lymphoid organogenesis: 
The Hematopoietic Instructor Paradigm 
Cells of hematopoietic origin which include CD3-CD4+cKit+IL7Rα+α4β7+ LTi cells and a 
distinct population of CD3-CD4-cKit+IL7Rα-α4β7+CD11c+ lymphoid initiator (LTin) cells, 
start to colonize pre-defined future sites of lymphoid organs between embryonic day 9.5 
(E9.5) and 16.5 (E16.5), depending on the type and location of the SLO [11, 16, 42-48].  
LTi were first discovered by Kelly and Scollay in 1992, in a study designed to better 
understand the initial colonization of neonatal LNs by T cells. The study showed that during 
the first few days of life a high proportion of neonatal CD45+ cells in the LN were CD4+CD8- 
cells but the majority of them were CD3- cells. These cells lacked surface expression of 
B220 and Mac-1 and were found to be Thy-1loCD44+. The CD3-CD4+ population did not 
increase greatly in number after birth and rapidly diminished in proportion as the number of 
CD3+ cells increased [49].  
7 
 
Several years’ later CD45+CD4+CD3- cells were found to be the earliest hematopoietic cells 
colonizing the fetal LN and PP anlagen. CD45+CD4+CD3- cells were found in mice lacking 
spleen (HOX11-/- mice) or thymus (nude mice), demonstrating that these organs were not 
mandatory for generation of fetal LTi cells [47, 50, 51]. Fetal LTi cells are the progeny of Lin-
cKit+IL7Rα+ common lymphoid progenitors (CLPs) residing in the fetal liver, which can also 
give rise to NK, DC, T and B cells [50, 52, 53]. IL7Rα+ precursor cells depend on Ikaros for 
their development, since Ikaros deficiency results in the absence of LTi, NK, DC, T and B 
cells [42, 54].  LTi differentiate from common IL7Rα+ precursor by suppression of E2A-
encoded protein, by expression of the helix-loop-helix protein inhibitor of DNA binding 2 
(ID2), which prevents differentiation to B cells [55, 56]. Down modulation of Notch signalling 
prevents their differentiation to T cells and results in up-regulation of α4β7 expression [57]. 
Finally expression of transcription factor retinoic acid-related orphan receptor γt (RORγt) is 
required for final differentiation of LTi cells [33, 48, 56, 58].  
Detailed phenotype analysis of LTi cells over the years, has revealed that apart from CD4, 
they are negative for lymphoid and erythroid lineage markers, can be identified by expression 
of RORγt in conjugation with IL7Rα chain (nearly 75% of these cells also express IL-2Rγ and 
IL-2Rα), in addition they express c-Kit, integrins α4β7 and α4β1, TRANCE-TRANCE-R 
(RANKL-RANK), chemokine receptors CXCR5, CCR7 and most importantly lymphotoxin (LT) 
α1β2. Signalling either through IL7Rα or tumor necrosis factor-related activation induced 
cytokine receptor (TRANCE-R) leads to expression of LTα1β2 by LTi cells, which allows 
them to be functional instructor cells for lymphoid tissue formation [11, 26, 28, 46, 56, 59]. In 
view of the necessity of lymphotoxin in lymphoid organ development, LTi are main 
protagonists of SLO development. Absence of LTi, as documented in mice deficient in 
Ikaros, Inhibitor of DNA-binding 2 (Id-2) or RORγt result in LNs and PP development failure 
[54, 55, 58]. Moreover, reaggregate LN grafting assays showed that addition of wild-type LTi 
cells to E15 LTα-/- iLNs resulted in formation of mature lymphoid structures [60]. Besides, 
adoptive transfer of LTi cells in mice with impaired SLO development was shown to rescue 
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the organogenesis of PP [61] and NALT [17]. Moreover increased LTi numbers caused by 
transgenic overexpression of IL7 resulted in formation of higher number of LN and PP [62]. 
Interestingly, even though treatment with LTβR agonist can rescue development of LN and 
PP in LTα-/- mice, the same treatment fails to rescue development in RORγt-/- mice [58] and 
TRANCE deficient mice (which have severely reduced number of LTi cells) [28, 46]. This 
indicates that LTi cells apart from providing LTα1β2 also provide additional signals to the 
developing anlage. Overall, these lines of evidence support a role of LTi as instructor cells in 
lymphoid organ formation.  
LTin cells were first described in the gut anlage in 2007 [40, 63-65] where it was 
demonstrated that partial depletion of LTin cells, through administration of diphtheria toxin 
(DT) to CD11c-DT receptor embryos, or deficiency of tyrosine kinase receptor RET (a 
neuroregulator) expression on LTin cells resulted in abrogated PP formation. This suggests 
that LTi cells are necessary but not sufficient for PP development. Further supporting this 
concept, RET ligand (ARTN) induced formation of ectopic lymphoid primordial structures and 
LTin are the first hematopoietic cells to cluster with VCAM-1+ stromal cell at the site of PP 
formation, although LTi cells are scarcely detected at this stage, but a subsequent extensive 
accumulation of LTi cells follows LTin cell aggregation [40, 43]. 
Generation of lymphoid tissue organizer (LTo) cells during secondary lymphoid 
organogenesis: The Stromacentric Illustration 
Upon arrival in the SLO anlagen, LTi (and LTin in case of PP genesis) cells are believed to 
establish an interplay with their mesenchymal counterparts, lymphoid organizer (LTo) cells, 
in order to trigger lymphoid organogenesis [11, 16].  
Stromal organiser cells are believed to develop from mesenchymal cells. It has been 
suggested that this mesenchymal specification to lymph node organiser cell occurs 
independently from LTβR signalling [60, 66]. The mesenchymal progenitor cells are 
characterized as CD45-, PDGFRα+, LTβR+, VCAM-1-, ICAM-1- [67]. The origin and identity 
of signals that induce specification of mesenchymal progenitor cells prior to LTi arrival at the 
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site of lymph node formation to assure SLO organogenesis to take place at defined positions 
along the body axis remain largely unknown [67].  
A century ago, Sabin identified that the earliest event underpining the developing LN anlage 
is the formation of lymph sacs (that are earliest developments of the lymphatic vasculature) 
by endothelial-cell budding from the larger veins around embryonic day 10.5 (E10.5) [68-71]. 
Subsequently, the lymph sac endothelial cells sprout, to give rise to the lymphatic 
vasculature network and to the LN subcapsular sinus. This process requires expression of 
the early lymphatic markers such as homebox gene Prox-1 and Lyve-1 and, later, podoplanin 
(human) or gp38 (mouse) [11, 45, 72]. At E13, the primitive LN anlage consists of a spherical 
shaped bud of tightly packed gp38/podoplanin+ endothelial cells forming lymph sac 
surrounded by layers of fibroblastic-like cells, which express several molecules characteristic 
of mesenchymal cells, such a PDGFRα, the extracellular matrix protein ERTR7, fibronectin, 
and hyaluronic acid receptor CD44. In contrast, the central bud of gp38+ cells expresses 
endothelial markers ICAM-1, CCL21 and extracellular matrix proteins laminin α5 and 
collagen type 1 which is separated from the outer layers of ER-TR7+ fibroblastic cells by an 
intact and thin layer of Perlecan+ basement membrane [66]. By E14.5 ERTR7+ cells start to 
invade the endothelial core and migrate to form proper internal stromal compartment of LN 
anlage, it is at this stage when first entry of CD4+ and CD4- LTi cells is detected [60, 66]. 
Detailed FACS analysis of CD45- cell populations in E14.5 LN anlagen identified the 
presence of newly specified mesenchymal cells that are positive for PDGFRα but negative 
for ICAM-1 and VCAM-1(I-V-) and which correlate with the fibroblast-like cells of the 
mesenchyme that surround the gp38/podplanin+ lymph sac and I+V-gp38+MadCAM-
1+VEGFR3- endothelial cells. The I+V- endothelial population becomes positive for both 
VEGFR3 and lymphatic marker Lyve-1 between E15-E17 [66], indicating the ongoing 
differentiation process towards lymphatic endothelial cells. This topologically and 
chronologically controlled process led to the hypothesis that LNs arise from lymph sacs [45, 
66, 67].  
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However, Vodenhoff et al. have shown that Prox-1 null and Prox1 conditional mutant 
embryos that lack lymphatic vasculature, the LN anlage still forms and hence initiation of LN 
development does not require lymph sacs. However, the LN anlage is hypoplastic and fails to 
efficiently cluster LTi cells, which are reduced in number. These findings indicate that 
lymphatic endothelium might not be required for positioning of LTi, but signals from lymphatic 
endothelial cells do play an important role in generation and/or maintenance of the LN 
hematopoietic cell niche by specifying the surrounding mesenchyme in order to complete 
lymphoid organ formation [72, 73]. Furthermore, Onder et al. recently reported that 
endothelial cells (EC)-specific ablation of LTβR in mouse embryo resulted in failure to 
develop 20% to 40% of all peripheral LNs in these mice. This study identifies endothelial 
cells as a potential LTo population, but further studies are required to understand which of 
the two EC populations; lymphatic endothelial cells or blood endothelial cells, function as an 
endothelial LTo cells [74]. This observation by Onder et al. where they suggest endothelial 
cells as potential source of LTo cells is supported by a previous study in 2007, where 
analysis of LN anlage not only identified presence of I+V- endothelial cells which expressed 
Prox-1 and Lyve-1 but this population expressed similar mRNA levels of LTβR, Relb, NFĸb2, 
and target genes of this pathway [60]. 
By E15.5, these I-V- mesenchymal cells precursors differentiate into 
PDGFRα+IintVintgp38+RANKLint “primed” mesenchymal LTo cells independently of LTi cells 
and LTβR signalling as accumulation of this intermediate population is present in RORc-/-, 
LTβR-/- and LTα-/- embryonic LNs. The signal/s that prime I-V- to IintVint mesenchymal cells 
are still not very well understood. However, by E17 primed IintVint cells further differentiate into 
IhiVhiMADCAM+RANKLhi mature LTo cells, this maturation step is instead dependent on the 
presence of both LTi cells and LTβR signalling as IhiVhi LTo cells are absent in LN anlagen of 
RORc-/-, LTα-/- and LTβR-/- and thus LN development is regressed in these mice. 
Interestingly, differentiation of IintVint cells to IhiVhiMADCAM+RANKLhi mature LTo cells 
coincides with accumulation of LTi cells in the LN anlagen [66]. 
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Gene expression profiles of the three CD45- stromal cell populations present in the LN 
anlagen (I-V-, IintVint and IhiVhi), surprisingly showed expression of TNFR1, CCL21 along with 
LTβR on all three subsets but the LTβR signalling downstream effector, the transcription 
factors Relb and NFκb2 (members of the NFĸb family member) were only detected in the 
IintVint and IhiVhi cells correlating with their higher levels of expression of CCL21, CCL19, 
CXCL13, RANKL and IL7 with respect to the I-V- precursor cells. However, the highest 
expression of these genes is detected in the IhiVhi cells, confirming their greater potential to 
attract LTi [60, 66, 75]. mLN from E15-16.5 LTβR-/- embryos, whose stromal cells are 
blocked at the IintVint cell stage showed similar level of CXCL13 and IL7 transcripts as found 
in E15 mLN anlagen of WT mice, indicating that these genes are less dependent on LTβR 
engagement at this stage [66]. These results are in agreement with findings of Moyron-
Quiroz et al. showing LT independent expression of CXCL13 and CCL21 during iBALT 
formation [76].  
In contrast IintVint cells showed a failure to induce RANKL and MadCAM in LTβR-/- stromal 
cells, highlighting the importance of LTβR in expression of these molecules [66]. Absence of 
RANKL compromise the survival and maturation of LTi cells, which are dependent in the 
RANK signalling, indicated by the reduced number of LTi found in the mLN of newborn mice 
deficient in RANKL/RANK or TRAF6, the intracellular adaptor protein via which RANK 
signals as well as mice that are treated with RANK-Ig fusion protein [28, 31, 46]. Recent 
reports from Hess et al. [77] and Sugiyama et al. [78], have indicated a function of RANK 
signalling in LN stromal cell proliferation and development of LN microarchitecture. 
Therefore, in absence of full maturation of stromal cells as in case LTβR-/- mice, only 
rudimentary mLN are found in these mice at birth. 
Various studies in SLO organogenesis have identified two LTo populations based on their 
differential expression of ICAM-1 and VCAM-1, the IintVint and IhiVhi both in LNs and PP [79, 
80]. LTo cells are not identical in all SLOs, for example LTo from LNs express RANKL while 
their PP counterparts lack expression of this molecule. In addition, microarray analysis of LN 
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and PP LTo showed that mLN LTo cells express high levels of chemokines and cytokines 
CCL11, CXCL1, CCL7, IL7 and IL6, LTo cells from PP have higher levels of CXCL13, CCL19 
and CCL21. Moreover, LN and PP LTo cells also displayed differences in expression of 
various transcription factors such as Meox2, Prrx1 and Lhx8, functional relevance of these 
factors is unclear [80]. LTo show differences between LNs. The IintVint LTo cells are relatively 
more abundant in mLN when compared to other peripheral LNs where LTo cells mainly 
comprise of IhiVhi subset [79]. This study proposes that the difference in representation of the 
LTo subsets provides a reasonable explanation for differential developmental requirements 
between mLN and pLN. For example, targeted deletion of either LTβ, CXCL13/CXCR5 pair 
or components of the IL7R signalling complex [21, 38, 41, 79, 81, 82] has little effect on mLN 
development but disrupts the development of pLN. The authors argue that because IintVint 
LTo cells express higher level of LTβR, the decrease of this population in pLNs could be the 
limiting factor in case of sub-optimal LTβR stimulation during development, as in the case of 
LTβ-/- mice. Furthermore, in absence of IL-7R signalling, RANK/RANKL is still able to induce 
surface expression of LTα1β2 on LTi cells [26, 79]. However, if a reduction in LTα1β2-
inducing signals leads to reduced numbers of cells with LT signals, again LTβR levels could 
be limiting. The same holds true for CXCL13/CXCR5 disruption which controls the 
accumulation of LT expressing inducer cells at sites of LN development [41, 50, 79, 81, 82]. 
Overall, these differences in SLO LTo cells strongly support the notion that heterogeneity 
might result in different LTo cells which preferentially interact and provide different cues to 
different hematopoietic cells, and thus consequently determines the key molecular signalling 
axes that are used in different organs. 
In 2009, van de Pavert et al. showed nerve fibres that are near the site of developing LNs 
express RALDH2, main enzyme crucial for generation of retinoic acid (RA) which induces 
expression of CXCL13 in mesenchymal cells, suggesting this to be a possible mechanism for 
mesenchymal cell specification [83]. This expression of CXCL13 is required for the initial 
recruitment of LTi cells to form clusters at the site of LN formation, as in absence of RALDH2 
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LTi clusters failed to form and hence most peripheral LNs were absent in in RALDH2 mutant 
mice. Further evidence that supports the notion that CXCL13 expression by early LN 
mesenchyme is part of the initiating event and precedes LTβR signalling comes from the 
observation that CXCL13 can be detected in the developing LN of LTα-/- embryos [56, 66, 
83]. In addition majority of LNs (except mesenteric and cervical LNs) fail to develop in the 
absence of CXCL13 or its receptor CXCR5, and analysis of embryos of these mice showed 
that initial clustering of LTi cells did not occur in the absence of CXCL13 or CXCR5. Overall, 
van de Pavert et al. proposed that neuron-derived RA induces mesenchymal specification by 
inducing CXCL13 expression in these cells and this process determines the location of lymph 
nodes by attracting the first LTi. The mechanism by which RA is transferred from nerve fibers 
to adjacent mesenchymal cells is unknown, but effects of RA in the immune system has 
been described previously [56, 84, 85]. Furthermore, even though the RALDH2 is expressed 
throughout the nerve fibre, but LNs are not formed the entire length of the neurons, based on 
observations that LNs always form at location where blood vessels branch, its suggested that 
these locations somehow instruct nerve fibers to release RA, but exact mechanism is still to 
be elucidated. Given the pleiotropic role of RA during vertebrate development in processes 
such as regulation of cell-fate and differentiation [56, 85], it is likely that in addition to 
CXCL13, RA activates a set of downstream target genes, for example HOX genes, required 
for organ patterning and cell fate specification during embryogenesis, thus representing them 
to be candidate factors involved in specifying the mesenchymal cells and patterning of the 
early LN anlage. It has already been shown by Okuda et al. [44] that LTo cells from 
mesenteric LNs and PP express different HOX genes [67]. Moreover, presence of 
mesenteric and/or cervical LNs in CXCL13-/-, CXCR5-/- and RALDH2-/-, argues that 
different specification signals exist depending on location of the organs [83]. CCL21 derived 
from lymphatic endothelium is shown to be involved in guiding LTi cells to the developing 
cervical LNs in CXCL13-/-, CXCR5-/- and RALDH2-/- mutant embryos, and hence allow 
interaction between the LTi and mesenchymal organizer cells [83]. In line with this conclusion 
cervical LNs fail to form in CXCR5-/- CCR7-/- mice, which lack ability to respond to both 
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CXCL13 and CCL21. However, plt/plt CXCL13-/- mice which retain CCL21 expression on 
lymphatic endothelium, still develop cervical LNs [81-83].  
Recent work from Benezech et al. have demonstrated that adipocyte precursor cells (pre-
adipocytes) that develop into adipose cells, also have the potential to give rise to lymphoid 
tissue organizer cells on LTβR engagement, which represents the key molecular switch in 
the choice between the two cell lineages, whereby LTβR ligation by LTα1β2-expressing 
hematopoietic cells activates the alternative NFĸB signalling pathway in pre-adipocytes 
which blocks adipogenic differentiation and induces their maturation towards lymphoid tissue 
stromal cells (LTo). The pre-adipocytes on LTβR engagement begin to express group of 
genes characteristic of LTo namely those encoding cell-adhesion molecules, such as ICAM-1 
and VCAM-1, chemokines such as CXCL13, CCL19 and CCL21 and additionally the survival 
factor IL-7. Embryonic adipocyte precursor cells expressed stem cell marker CD24, Sca-1, 
CD34, Pref-1 (a transmembrane protein expressed in mesenchyme and adipocyte 
progenitors but down-regulated in adipocytes), in addition showed high gp38 and LTβR 
expression but were negative for mature adipocyte markers C/EBPα and Perilipin along with 
being c-Kit- and CD31-. Consistent with their mesenchymal origin adipocyte precursors were 
PDGFRα+ and VCAM-1+. Phenotypically pre-adipocytes strongly resembled the 
PDGFRα+VCAM-1+ gp38+ LTβR+ LTo mesenchymal progenitor cells previously described 
in E14-15 LN anlage [86]. Embryonic adipocyte precursors were localized around 
vasculature in the developing fat pads and also found surrounding and residing within the 
developing LN anlage. The perivascular location of these cells and their LTβR expression 
makes them appropriately positioned and equipped to interact with incoming LTα1β2+ LTi 
cells during LN formation. Interestingly, the pre-adipocytes found in adult mice fat pad, were 
phenotypically and functionally similar to their embryonic counterparts [86, 87]. 
Intriguingly, nerve endings are positioned in the very specific regions of the fat pad that 
eventually encapsulate the developing LN. Hence this could suggest that paracrine provision 
of retinoic acid from nerve cells to pre-adipocytes might initiate their spatially restricted 
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cellular differentiation into CXCL13 expressing prospective LN organizer cells, that lead to 
LTi recruitment and clustering, which in turn allows efficient LTβR engagement on locally 
present pre-adipocytes, resulting in their maturation into LTo. This will also ensure only some 
but not all pre-adipocytes in the fat pad are engaged by LTβR signalling [87]. 
Cellular and Molecular signalling axis in LN and PP development 
On the basis of various gene-targeted mice (overviewed in table 1) that lack some or all LNs 
and PP a generally accepted model of lymphoid organogenesis has been developed. The 
first signalling pathway shown to be critical for LN and PP formation was LTβR triggering via 
LTα1β2, which results in downstream activation of the NFκB pathway leading to expression 
of adhesion molecules and chemokines that are central to lymphoid tissue formation and 
maturation. Histological analysis of LN and PP anlagen formation at different stages and 
experiments with mutant chimeric mice showed the source of LTα1β2 was circulating cells 
(LTi) whereas LTβR+ cells that express NFκB must be resident stromal cells (LTo) [11, 16, 
67, 88, 89]. More recently new insights in the initiating events during LN and PP have further 
helped complete this picture.  
The lymph node anlagen was described to be formed at locations where the lymph sac 
(which gives rise to the lymphatic vasculature) forms around larger blood vessel that consist 
of VEGFR1+VEGFR2+MECA32+ endothelial cells. For decades lymph sacs were thought to 
be pre-requisite for LN formation [59, 72]. However, this concept was challenged in 2009 by 
Vodenhoff et al. This study revealed that initiation of LN development, marked by recruitment 
of LTi cells, was unaffected in Prox-1 null and conditional embryos which lack lymph sac 
formation. Nevertheless, LTi cell clustering was less efficient in the prospective LN site in 
these mutant mice [73], strongly suggesting that lymphatic endothelial cells are important in 
generating an environment conducive for LN development [60, 74]. The current paradigm of 
LN development (illustrated in Figure1.2A) suggests that the first instructive signal for LN 
anlage formation might derive from outgrowing nerves in which neurons express enzyme 
RALDH2 that converts retinal to retinoic acid. Retonic acid then induces CXCL13 expression 
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in local mesenchymal cells. This allows initial attraction of CXCR5+ LTi cells and initiation of 
LN development. Owing to the importance of CXCL13 in LN formation, CXCL13-/- and 
CXCR5-/- embryos lacked clusters of LTi cells and LN anlagen (except some cervical or 
facial LNs). In addition to its role in recruitment of LTi cells [83], CXCL13-mediated triggering 
of CXCR5 has been shown to activate α4β1 intergrin on LTi cells [61].  This enhances their 
binding to VCAM-1+ stromal cells and form tight clusters of LTi-LTo cells which is essential 
for LTβR signalling. Early expression of CXCL13 was detected between E12.5-13.5 in LN 
anlage and was shown to be independent of LTβR signalling, as comparable levels of 
CXCL13 mRNA was detected in WT and LTα-/- mice at this stage. However, at later stages, 
CXCL13 production is dependent on LT mediated signalling [83]. To further support this 
concept, studies have shown that LTi recruitment is independent of LT, since LTi cells are 
observed in LTα-/- mice at the site of anlage formation [59]. Interestingly, the first CXCR5+ 
LTi cells, recruited to the site of LN formation, express both RANK (TRANCE-R) and it ligand 
RANKL (TRANCE) rather than LTα1β2 [59].  
At later stages in LN development, RANKL has been shown to be majorly expressed by LTo 
cells [59, 78]. The RANK-RANKL mediated paracrine interaction between LTi cells is 
important for initial clustering of LTis and up-regulation of LTα1β2 on these cells [46, 75]. 
LTα1β2 then signals via LTβR to drive surrounding stromal cells or pre-adipocyte cells to 
differentiate into LTo [11, 67, 75, 86].  LTα1β2/LTβR axis results in initiation of two sequential 
NFĸB signalling pathways (Fig1.2B). The first signal belongs to the classical pathway which 
involves RelA, p50 and IκBα, and initiates the expression of adhesion molecules such as 
VCAM-1 [11, 88, 89]. Increased expression of VCAM-1 aids in retention and prolonged 
interaction of the LTi (which α4β1, ligand for VCAM-1) with LTo cells. The prolonged 
triggering of LTβR, results in activation of alternative NFĸB pathway via the NFĸB-inducing 
kinase (NIK), IκB kinase α and RelB [11, 88, 89]. This second pathway leads to production of 
chemokines (CXCL13, CCL21 and CCL19), expression of adhesion molecules (VCAM-1, 
ICAM-1 and MADCAM-1) and up-regulation of IL-7 and RANKL in LTo [11, 66, 75, 88, 89]. 
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Moreover, LTβR triggering is mandatory for stromal cell proliferation and survival. This 
stromal cell activation allows establishing a positive feedback loop which allows the further 
recruitment, retention and survival of haematopoietic cells from circulation in the expanding 
lymphoid anlagen [11, 60, 88, 90]. Accordingly, combined ablation of CXCR5 and CCR7 or 
CXCL13, CCL21 and CCL19 resulted in failure of LN and PP development [81, 82, 90]. 
Various studies have shown that for successful formation of LNs, its absolute necessary not 
only to recruit but also to maintain a critical number of LTi which express LTα1β2. Mice 
deficient in TRANCE, TRANCE-R or a critical component of TRANCE signalling pathway, 
TRAF6, all did not develop any LNs (although some cervical LNs have been observed in 
TRANCE-/- mice, but even these LNs are small and poorly populated), however, PP 
formation is intact in these mice. The defect observed in LN development in TRANCE-
TRANCE-R-/- mice is not due to the absence of LTi cells, but due to severely reduced 
numbers of LTi cells which fail to properly induce the differentiation of LTo cells.  Hence, in 
the absence of TRANCE signalling, the VCAM-1+ ICAM-1+ LTo cells fail to appear and thus 
LNs fail to complete their program of development. This is supported by the fact that upon 
transgenic expression of TRANCE in TRANCE-/-, numbers of LTi increase, rescuing 
formation of several LNs. However, transgenic expression of TRANCE in LTα-/- mice, which 
have significant number of LTi cells to start with, fails to restore LN formation. The LTi cells 
recruited in LTα-/- at sites of LN formation fail to cluster due to their inability to activate 
stromal cells which results in abrogated LN formation [28, 31, 46]. Overall, these 
observations suggest that both TRANCE and LTα1β2 regulate the colonization and cluster 
formation by LTi cells which is important for surrounding stromal cell activation, thereby 
establishing a positive feedback loop, allowing a successful cross talk between inducer and 
organizer cells that involves ligands-receptors of the tumour necrosis family (TNF), various 
chemokines and cytokines which allows completing the process of LN organogenesis. 
The steps in the organogenesis of PP are similar to LN development. However, there are 
some differences. Firstly, unlike LNs development that always occurs at pre-defined 
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positions in the body, the PPs form in variable numbers and not in fixed positions along the 
gut [16, 45, 47, 51]. Secondly, in addition to LTi cells, another subset of hematopoietic cells, 
the LTin has been demonstrated to be crucial for PP formation [40, 45, 63, 64]. Another 
major difference in PP and LN development is in their requirement of IL-7 and TRANCE. In 
contrast to LNs, PP development is completely intact in TRANCE-/- mice whereas it is 
absent in IL-7Rα-/- mice [15, 16, 45]. Another signalling pathway, which is differently used in 
LN and PP genesis, is the TNFR1. Even though LN development is intact in TNFR1-/- mice, 
the PP development has been shown to be defective in these mice [15, 16, 45]. 
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Figure 1.2A Model of Lymph node (lymph node) organogenesis. Step 1: Retinoic acid 
produced by neurons, stimulate LTo precursor cells to express chemokine CXCL13. CXCL13 
expression by LTo precursor cells attracts CXCR5+ LTi cells to the site where LNs will 
develop. LTi cells will cluster and signal in trans to each other through RANKL-RANK. RANK 
signalling on LTi cells will induce high expression levels of LTα1β2. Step 2 and 3: Binding of 
the LTα1β2 to LTβR on LTo precursor will induce differentiation into mature LTo cells that 
express cell adhesion molecules VCAM-1, ICAM-1, and MAdCAM-1 as well as CXCL13, 
CCL21, and CCL19. This will subsequently attract large numbers of LTi cells which are now 
in close contact with increasing numbers of stromal cells. This results in increased LTβR 
triggering and thereby a positive-feedback loop is initiated which leads to accumulation of 
more haematopoietic cells (such as B and T lymphocytes), differentation of LTo cells to 
various stromal cell subsets and formation of HEVs. Thus the formation of the structure of 
the organs (Adapted from [6, 22, 26, 29, 30, 32, 33, 46, 59, 66, 67, 74, 75, 78, 83, 91-97])  
Figure 1.2A 
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Figure 1.2B Activation of NF-κB via the classical and the alternative pathway. Signalling 
via the LTβR can initiate both NF-κB activation pathways. The classical pathway leads to the 
expression of the inflammatory molecules VCAM1, MIP-1β and MIP-2, and an increase of 
p100. The first step in this cascade is the activation of the β unit of the IKK complex. This 
activated IKKβ complex leads to phosphorylation and ubiquitination of the IκBα, which allows 
the p50-RelA heterodimer to translocate to the nucleus and bind to the DNA. The alternative 
pathway follows a similar mechanism: after activation of the IKKα complex, p100 is 
phosphorylated and processed to p52. The remaining p52-RelB heterodimer induces the 
expression of the homeostatic cytokines CCL19, CCL21, CXCL13 and CXCL12, after 
translocation into the nucleus (Taken from Blum and Pabst 2006 [88]).   
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Lymphocyte Recruitment and Formation of Follicular Structures in Lymph 
Nodes and Peyer’s Patches during their organogenesis 
Clusters of IL7Rα+CD4+CD3-LTi cells and VCAM-1+ICAM-1+ mesenchymal LTo cells begin 
to segregate into follicular micro-domains around E18 in PP and day 1 postnatally in LNs, 
with LTi cells at the centre and LTo cells at the periphery [11, 16, 94, 98, 99].  Around the 
same time, CD11c+ cells are also seen at the periphery of these follicle-like sub-regions in 
the PP, though it’s still unclear if these cells are CD11c+ LTin cells or whether they are 
CD11c+ DCs that have differentiated in situ from LTi cells [16, 50, 52]. The initial follicular 
structure micro-domain formation is dependent on LTαβ expression, but not  B and T cells, 
demonstrated by the fact that the initial architectural organization is intact in SCID mice [16, 
94, 98]. The recruitment of lymphocytes, segregation of T and B cell in separate zones and 
formation of mature B cell follicles occurs in the final stages of mature LN and PP 
development. In mouse LNs this process occurs at day2-3 after birth [100] following the 
expression of PNAd on HEVs [16, 100, 101]. Before day 2-3, HEVs only express MAdCAM-1 
[100], therefore the only cells that can enter the developing LNs at this time are α4β7 integrin 
expressing IL7Rα+CD4+CD3- LTi cells and γδ T cells [16, 50, 52, 101]. However, around 
day 3 onwards, LN HEVs down-regulate the expression of MAdCAM-1 and start expressing 
PNAd, which allows entry of mature naïve T and B cells [16, 100] that express CD62L, ligand 
for PNAd. When B and T cells enter in the LNs, they ultimately “replace” the LTi cells in their 
role, providing the LTαβ necessary to maintain differentiation and survival of the LTβR 
expressing stromal cells. At this stage, CXCL13 expression is still dependent on LTαβ+ LTi 
cells [11, 16, 94] as the first B cells that enter in the LN lack expression of LTαβ [11, 16, 94]. 
B and T cell then start to segregate leading to formation of more organized LN [16]. This 
initial segregation is independent from CXCL13, as at this stage only LTi cells can respond to 
this chemokine. From day 4, B cells start expressing LTαβ and respond to CXCL13. At this 
stage their segregation into distinct follicular structures begins [11, 16, 94]. Mice lacking T, B 
and NK cells develop initial LN anlagen but fail to persist after birth [16, 27].  
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SLO Organogenesis is confined to a strict developmental window  
LNs have been demonstrated to develop in a characteristic order based upon in vivo 
blocking experiments with LTβR-Ig fusion proteins. They begin to be formed at E10.5 with 
the mesenteric lymph nodes, followed by cervical lymph nodes at E11.5 and then the 
brachial and axillary lymph nodes after E12.5 [11, 16, 102, 103]. The development of inguinal 
LNs and PP begins at E16 but the PP continues development until after birth. Finally, the 
NALT develops after birth. The development of PP and NALT appears to be last, as LT 
signalling disruption, just before birth, blocked PP formation [16, 102], whereas the adoptive 
transfer of LTi cells restored development of PP in CXCR5-/- [16, 61] and development of 
NALT in Id2-/- mice [16, 17]. Each LN has been shown to have its own set of developmental 
cues and signalling, because when different elements are blocked in the signalling pathway, 
varying LNs are differentially affected [11, 102-104]. It is possible that these differences are 
sustained by the differences in the stromal cell compartment of the diverse LNs [11, 16, 79].  
In fact, the organogenesis of LN and PP must occur within a strict developmental window, 
because once this window has passed, their development cannot take place even if LT 
signalling pathway is restored [11, 16].  In contrast, ILF formation does not follow a strict 
developmental window. Even though, LT signalling has been shown to be necessary for 
mature ILF development [16, 105, 106], ILF structures were restored in adult LTα-/- mice, 
when these mice were reconstituted with normal (LTα+) hematopoietic cells [16, 106]. 
However, it is not very clear why ILFs lack a fixed developmental window. ILFs are derived 
from cryptopatches and RORγt expressing adult LTi cells, and are majorly found at these 
sites in adults [16, 32]. Thus availability of LTi cells at the location of each lymphoid organ 
might confine it to a particular developmental window [16]. Interestingly, gp38+ stromal cells 
in the T cell area of the spleen, are also restricted to a developmental window, and require 
LTαβ expressing B cells during this neonatal period [16, 107]. As a result, splenic gp38+ 
stromal cells cannot be restored in adult LTα-/- or B-cell knockout mice even after 
reconstitution with normal bone-marrow derived hematopoietic cells [16, 107]. However, 
most of the other splenic architecture defects, including the expression of homeostatic 
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chemokines, FDC differentiation and formation of germinal centres post-immunization, can 
be reversed in LTα-/- mice when they are reconstituted with LTα+/+ bone-marrow cells from 
adult WT mice [16, 108-111]. 
The development of the NALT and ILF follows a slightly different dynamic to that described 
for LN. This will not be discussed in this dissertation. 
Role of Lymphotoxin and TNF in the maintenance of lymphoid architecture   
Both LT and TNF expression has been demonstrated to be essential for proper homing and 
segregation of T and B lymphocytes within SLOs as well as for the maintenance of SLO  
architecture. For instance, the spleens of LTαKO mice exhibit disorganized T and B cell 
zones, germinal centres and marginal zones. Furthermore, failure in FDC development is 
noticed in the absence of LT or TNF signalling [16, 18, 19, 108-110, 112, 113]. LT expression 
has also been demonstrated to be important for development of CCL21 expressing gp38 
stromal cells and subsequent T cell organization in the spleen [16, 107, 114]. As in LN 
organogenesis the expression of LT and constitutive lymphoid chemokines 
(CXCL13,CCL19,CCL21) are inter-dependent on a positive-feedback loop; similarly in adult 
SLOs, LT promotes expression of lymphoid chemokines by stromal cells [16, 115-117]. This 
controls steady state homing and correct positioning of T and B cells and lymphoid 
chemokines particularly CXCL13 also play a role in maintenance of LTαβ expression on 
lymphocytes, thereby sustaining the positive feedback loop to maintain the structure and 
function of SLOs [16, 36, 115-117]. Evidence suggests that the maintenance of lymphoid 
chemokine expression and FDCs in B cell follicles is dependent on LTαβ and TNFα 
expression on mature B cells [16, 108, 118]. However, normal levels of chemokines, and B 
cell follicles with FDCs were detected in the LNs of mice that lack LTβ, specifically on B cells. 
Hence, in this case, it was been shown that LTαβ-expressing T lymphocytes are sufficient to 
maintain LN structure and function [16, 119, 120]. Altogether, this data indicates that 
expression of LTαβ by both T and B lymphocytes is necessary for proper conservation of 
lymphoid architecture in adult SLOs. In addition, LT has been suggested to play a role in 
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maintenance of DC numbers [121], as well as their activation and maturation during an 
immune response [122]. Furthermore, continual expression of PNAd and structural integrity 
of HEVs is dependent upon LTβR signalling, because in its absence the HEVs collapse [96, 
123, 124]. Interestingly, soluble LTα3, membrane bound LTαβ and TNFα have overlapping 
yet distinctive functions in regulating many aspects of SLO micro-architecture, for example, 
spleens of LTαKO [19] and LTβRKO [22] showed more severe disorganization of the T and B 
cell zones than spleens of LTβKO [21], indicating that LTα3 signalling through TNFR1 as well 
as LTβR mediated signalling are important for appropriate organization of lymphocytes within 
SLOs [16]. Similarly, FDC differentiation and maintenance requires TNFα, LTα and LTαβ 
[108, 110, 111, 125]. On the contrary, the presence of DC in spleens, expression of 
MADCAM-1 in splenic marginal zones, and development and function of HEVs in LNs are 
dependent on LTαβ/LTβR axis and not on TNFα, LTα, or TNFR1 [16, 103, 121]. 
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1.3 Adult SLO Organization and Function 
SLOs are highly organized encapsulated aggregations of lymphocytes in a framework of 
non-leukocyte stromal cells, which not only provide basic structural organization to the tissue 
but also provide survival signals to help sustain lymphocyte survival. In addition to 
lymphocytes, SLOs also contain resident macrophages and dendritic cells [3].  
Of all SLOs, the microarchitecture of LNs (Fig1.3A) has been most fully characterized and 
hence, is commonly studied as the prototypical SLO. LNs are situated at the points of 
convergence of vessels of the lymphatic system throughout the body.  A LN consists of sub-
capsular sinus (SCS), an outermost cortex, paracortex and an inner medulla [3, 88, 126]. 
Immediately beneath the LN capsule is the SCS, in which the afferent lymphatics empty their 
content, delivering antigens, molecules and APCs from the draining tissues and organs. 
Lymphatic endothelial vessels express Lyve 1, as well as other adhesion molecules and 
CCL21, which are all involved in cell entry into the lymphatics. LN resident-macrophages line 
the SCS and capture antigens and particles that enter via the lymph [3, 88, 126].  
Lymphocytes enter LNs from the blood by extravasation across specialized high endothelial 
venules (HEVs). HEVs are arranged in regions between the B and T cell zones known as 
cortical ridges. HEVs have a distinct morphology (a cobblestone like appearance) and 
express molecules that are crucial for lymphocyte entry into the lymph node, such as 
peripheral noode addressin (PNAd) and CCL21 [3, 88, 126]. Below the SCS, is the cortex 
that contains lymphoid nodules called primary follicles. These are composed of B cells and 
follicular dendritic cells (FDCs). It is here that B cells undergo proliferation after encountering 
their specific antigen and their cognate T cells, thus forming secondary follicles termed 
germinal centres. Inside the cortex is the paracortex which is composed of T cells and DCs 
[3, 88, 126].  
The medulla consists of strings of macrophages and antibody secreting plasma cells known 
as the medullary cords. Filtered lymph and cells leave the LN via efferent lymphatics for later 
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delivery to the venous blood. The structure and organization of the LN allows maximal 
interaction between antigen presenting cells and the few lymphocytes, specific for any given 
antigen. Such features make LNs optimal sites for inducing adaptive immune response.  The 
antigen-bearing DCs and macrophages actively migrate into the lymph node under the 
chemotactic influence of the lymphoid chemokines such as CCL21 and CCL19 [3, 88, 126]. 
The same chemokines also attract lymphocytes from the blood, and these enter via the 
HEVs. Since both lymphocytes and antigen presenting cells are attracted to the same 
chemokines, they become localized in the same area of the LN. Free antigen diffusing 
through the LN becomes trapped on resident DCs. The juxtaposition of the antigen, antigen-
bearing cells and naïve T cells creates an ideal environment where naïve T cells can bind 
their antigen and become activated. Since both B and T cell lymphocytes enter the LN via 
the paracortical area where HEVs are situated, this ensures that before entering the follicles, 
naïve B cells pass through the T cell zone, where they can encounter both their antigen and 
their cognate helper CD4 T cells and become activated. These activated B cells undergo 
intense proliferation and form germinal centres where they differentiate into antibody-
producing plasma cells and memory B cells. Of note, B cells also express receptor for 
lymphoid chemokine CXCL13 which allows their homing to the follicular compartment after 
their entry via HEVs [3, 88, 126, 127]. 
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Figure 1.3A Lymph node structure  
The lymph node consists of three main regions; the cortex, paracortex and medulla. The 
cortex consists mainly of B cells organised as primary or secondary follicles. The migration of 
these cells towards the follicles is mediated by follicular dendritic cells (FDC). T cells migrate 
to the paracortical region, neighbouring the cortex, and interact with the interdigitating 
dendritic cells (IDC). The central region, the medulla, mostly contains plasma cells and B 
cells. The lymphocytes enter the lymph node via the afferent lymphatic vessel or through 
transmigration of the high endothelial venules (HEV). Both systems, the lymph vasculature 
and the blood vasculature, are connected via a conduit system (Adapted from Blum et al, 
2006 [88]). 
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Mucosa associated lymphoid tissues (MALT) including PP, NALT have a general structure 
similar to LNs, with T and B cells segregated in distinct areas. The T cell areas contain 
substantial number of DCs and primary B cell follicles, where antigen activated B cells 
undergo germinal centre reaction, during which B cells expand and mature to become 
antibody producing cells and memory B cells [127-129]. However, MALT differs to LNs in the 
pathway by which antigen gains entry. Unlike LNs where antigen traffics through afferent 
lymphatic vessels, antigen enters MALT directly across mucosal epithelium (known as FAE 
i.e follicle associated epithelium), immediately overlying the follicles of MALT. The FAE has 
specialized antigen sampling cells termed Microfold (M) cells, which can directly uptake 
antigen from the lumen of the mucosa and deliver antigens by trans-epithelial vesicular 
transport to the sub-epithelial lymphoid tissue (such as lamina propria of intestinal and 
respiratory tracts and nasopharynx glandular tissue). M cells are capable of transporting 
particles as large as intact micro-organisms. Lymphocytes enter the blood circulation via 
efferent lymphatic vessels located at abluminal surface of the MALT. These lymphatic 
vessels ultimately join the thoracic duct like efferent lymphatic vessels from LNs [127-129]. 
The spleen, the single largest lymphoid organ in mammals, contains up to 25% of the body’s 
mature lymphocytes, and is separated into two major compartments; the red pulp and the 
white pulp [127, 130]. The red pulp consists of reticular network containing stromal cells and 
large proportion of macrophages. It primarily serves as a site where aged or damaged 
erythrocytes are filtered out of circulation. The white pulp represents the organized lymphoid 
compartment of the spleen where activation and maturation of antigen specific T and B cells 
occur. Immune cells and antigens enter the spleen with blood via single vascular supply, the 
splenic artery which branches into trabecular arteries and ultimately into central arterioles 
that penetrate the periarteriolar lymphoid sheath (PALS) in the white pulp. PALS are T cell- 
rich compartments surrounding the central arterioles. This area also contains abundant inter-
digitating DCs that serve as important APCs early in immune response in the spleen [127, 
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130]. After penetrating the PALS, the central arteriole forms a marginal sinus that is lined by 
MADCAM-1 expressing endothelium.  
A specialized layer of metallophilic macrophages are associated with marginal sinus 
endothelium, and are thought to regulate entry of antigen into the white pulp area. Within the 
white pulp, B cells are organized into two compartments. The first is the marginal zone B 
cells, which includes of naïve B cells and at least some memory B cells, located adjacent to 
MADCAM-1 expressing marginal sinus. The other compartment of B cells is the FDC 
containing primary B follicles surrounding PALS. The arrangement of these follicles 
resembles primary follicles in LN. This highly ordered structure of the splenic white pulp is 
critical for proper regulation of immune responses within the spleen [127, 130]. 
Stromal cell subsets in SLOs 
Stromal cells are important for the organization, maintenance and function of secondary 
lymphoid organs both in resting and inflammatory conditions.  Lack of stromal cells in SLOs 
results in aberrant T/ B cell segregation and failure to generate appropriate immune 
responses [126]. Stromal Cell subsets in SLOs are overviewed in Table 1.3A. 
Mesenchymal organizer stromal cells are thought to represent the precursors of three mature 
stromal cell subsets observed in the T and B cell areas in adult LNs (described below) [6]. 
However, the contributions of the organizer cells to stromal subsets in adult organs, and 
signals that induce their differentiation are still poorly understood. 
Fibroblastic reticular cells (FRCs)  
In the T cell zones of LN, FRCs surround HEVs forming a dense network filled with CD4+ T 
cells, CD8+ T cells and subsets of DCs. FRCs produce CCL21 and CCL19 to attract CCR7+ 
T cell and DCs to the T zone in the LN [126, 131-133]. The CCL21 protein can attach to the 
negatively charged glycosaminoglycans on the surface of FRCs; this promotes lymphocyte 
motility on the FRC network that can contribute to increased lymphocyte-DC encounters 
[126, 131, 134]. Besides regulating T cell trafficking, FRCs produce extracellular matrix, 
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forming a system of microchannels (conduits) connecting the SCS with the paracortex and 
the HEVs. This allows rapid transport of small soluble molecules, such as antigens, to DCs in 
the T cell zone, and thereby has a functional role in antigen presentation, and transport of 
chemokines to HEVs, which are then presented on the luminal side of HEVs which will 
ultimately affect lymphocyte entry [126]. FRCs are also a source of IL-7 which in combination 
with CCL19, sustains naïve T cell survival within the LN T zone and thereby maintains T cell 
homeostasis in the periphery [135].  
Owing to the above mentioned features, FRC are actively involved as positive regulators of T 
cell responses during immune responses. However, during an acute immune response the 
FRCs also attenuate excessive proliferation of neighbouring T cells by transiently expressing 
nitric oxide, thus preventing excessive expansion and inflammatory activity of antigen 
specific T cells. This helps conserve LN integrity and function during rapid LN growth [136-
139]. FRC express and present a range of peripheral tissue antigens, thus participating in 
peripheral tolerance induction of self-reactive T cells [136, 140]. 
FRCs is usually defined on the basis of expression of gp38, ER-TR7 and high levels of 
VCAM-1 and ICAM-1. They are also  known to express intracellular molecules  which are 
found in some fibroblasts, including desmin, α-smooth muscle actin, and transglutaminase,  
and are involved in the formation, expansion, and contraction of their collagen rich reticular 
fibres [126]. The full function of FRCs, at least in vitro, depends on expression of LTαβ by 
lymphocytes, presumably due to LTβR:LTαβ cross-talk between FRCs and lymphocytes 
[141]. However, it has recently been shown that myofibroblastic FRC precursor cells are able 
to generate the basic T cell zone infrastructure even in absence of LTβR triggering. However 
their full maturation and function was dependent on LTβR [142]. 
Follicular dendritic cells (FDCs) 
FDCs are the main B cell zone stromal cell population where they are the main source of 
CXCL13, which is critical for homing of CXCR5+ B cells to the follicular compartment. FDCs 
cluster in the centre of B cell follicles and form a dense network in which B cells search for 
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antigens and receive differentiation signals after they are activated [6, 126, 143-145]. FDCs 
express Fc receptors such as CD16, CD23, and CD32 and complement receptors such as 
CD21 and CD35 that enables FDCs to capture and present unprocessed antigen, particularly 
in the form of immune complexes [145]. Furthermore, FDCs secrete cytokines and growth 
factors that support germinal centre B cell survival and activation such as BAFF [145, 146].  
FDCs are characterized by expression of markers such as FDC-M1 (milk fat globule 
epidermal growth factor 8), FDC-M2 (complement C4) and CD157 (BP-3). They also express 
high levels of VCAM-1 and MAdCAM-1, as well as molecules that are common to other 
lymphoid stromal cell populations such as vimentin and desmin [6, 126, 145].  
Recently, it has been shown that FDCs originate from perivascular progenitor cells 
expressing PDGFRβ and Mfge8 genes, and ablation of PDGFRβ+ cells induces collapse of 
FDC networks [147]. Of note, TNFR and LTβR signalling is critically required for the 
maintenance of FDCs, as evidenced by their rapid disappearance upon TNFR or LTβR-Ig 
treatment in mice [145, 148]. 
Marginal reticular cells (MRCs) 
More recently, another lymphoid stromal cell population, localized underneath the SCS in 
LNs, has been characterized as marginal reticular cells (MRCs)  because they exhibit a 
phenotype that is distinct from B and T cell zone stroma zones [149, 150]. Although MRCs 
express many markers (VCAM-1, ICAM-1, MadCAM-1, BP-3 and gp38), which are in 
common with other subsets of lymphoid stromal cells [6, 126, 149], they seem to uniquely 
express RANKL and thus, are thought to be the adult equivalent of embryonic LTo cells with 
a role in organising the structure of adult SLOs [149, 150]. MRCs are localized at the edges 
of the B cell follicles and express CXCL13, similar to the centrally located FDCs. They also 
form conduit network that can deliver Ag from the LN SCS to the B cell follicles [6, 126, 149, 
151, 152]. Altogether, this suggests an important role for MRCs in the homeostasis of B cells 
and capture and delivery of Ag [6, 126, 149, 150]. MRCs maintenance, like FDCs, fully 
depends on continuous LTβR signalling [6, 126, 149, 151].  
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Table 1.3A 
 
(Adapted from Mueller and Germain 2009 [126]; Fritz and Gommerman 2011 [7]) 
 
Table 1.3A Stromal cell subsets in SLOs. 
 
 
 
 
 
 
Tissue & location Phenotype Functions
Fibroblastic 
Reticular cells 
(FRC)
Lymph nodes, spleen, 
peyer's patches, 
MALT, tertiary 
lymphoid tissues.                               
T cell zones.
ER-TR7, podoplanin (gp38), laminin, desmin, α-
SMA, fascin, 1BL-10, 1BL-11, LTβR, TNFR1/2, VCAM-
1, ICAM-1, PDGFRα/β, CD171, CD157, hyaluronan, 
CD44, transglutaminase, collagen I, II, IV, 
cytokeratin 8 & 18, fibronectin, vitronectin, 
vimentin, fibrillin, tenascin, hepatocyte growth 
factor, integrin α1, α4, β1, MHC-I, VEGF, CXCL16, 
CCL21, CCL19, IL-7.
Structural support; production & 
secretion of reticular fibers & formation 
of conduit network; chemokine 
production & expression; substrate for 
lymphocyte migration; substrate for DC 
adhesion; IL-7 production & T cell 
homeostasis; antigen presentation.
Follicular 
Dendritic cells 
(FDC)
Lymph nodes, spleen, 
peyer's patches, 
MALT, tertiary 
lymphoid tissues.                               
B cell zones.
CD35 (CR-1), CD21 (CR-2), FcγR-IIb (CD32), FceR-II 
(CD23), FcγR-III (CD16), FDC-M1, FDC-M2 
(complement C4), CD157, VCAM-1, ICAM-1, 
MAdCAM-1, CD40, CD73, laminin, desmin, 
fibronectin, tenascin, α-SMA, CXCL13, CXCL12, 
BAFF.
Antigen capture & presentation of 
immune complexes; chemokine 
production & presentation; B cell 
homeostasis.
Marginal 
Reticular cells 
(MRC)
Lymph nodes, spleen, 
peyer's patches, 
MALT.                                      
SCS (LN) & MZ 
ER-TR7, VCAM-1, ICAM-1, MAdCAM-1, TRANCE 
(RANKL), laminin, desmin, PDGFRa/b, 1BL-11, 
CD157, CXCL13.
Structural support; chemokine 
production (CXCL13); conduit function.
Red-pulp 
fibroblasts
Spleen.
ER-TR7, desmin, laminin, perlecan, integrin α3, 
α4, α5, β1, PDGFRα/β, ICAM-1, IL-6, CXCL12, IL-2.
Construct splenic cords & direct blood 
flow; assist in removal of dying red 
blood cells; expansion & contractile 
capabilities to control splenic blood flow 
& function, macrophage and plasma cell 
attraction and retention.
LN medullary 
fibroblasts
Lymph node ER-TR7, desmin, laminin, collagen III, CXCL12(?).
Macrophage and plasma cell attraction 
and retention?, Mast cell retention and 
function?
Lymphatic 
endothelial cells 
(LEC)
Lymph nodes, spleen 
(?), peyer's patches, 
MALT, tertiary 
lymphoid tissues.
CD31, LYVE-1, VCAM-1, ICAM-1, ICAM-2, ER-TR7, 
podoplanin (gp38), laminin, VE-cadherin, VEGFR3, 
catenin, claudin-5, JAM-A, Prox1, Toll-like 
receptors, CCL21, S1P.
Transport of lymph from the tissues; 
transport of antigens & cells; allow entry 
of lymphocytes & APC into lymphatics, 
chemokine production & presentation.
Vascular 
endothelial cells 
(VEC)
Lymph nodes, spleen, 
peyer's patches, 
MALT, tertiary 
lymphoid tissues.
PNAd (LN), CD31, CD34, VE-Cadherin, TNFR1, 
LTβR, VEGFR2, laminin, collagen IV, JAM-A/B/C, 
ZO-1/2, ESAM-1, claudin-5, catenin, desmoplakin, 
endoglin, meca-32, CCL21 (mice).
Transport of blood; entry of cells 
including lymphocytes from the blood 
into tissues.
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Germinal centre reaction 
Germinal centres (Figure1.3B) develop in B-cell follicles of SLOs in response to antigen 
challenge. Mature B cells continuously recirculate through SLOs in search of signs of 
infection. Migrant B cells pick up antigens from sub capsular sinus macrophages and bring 
them to the centre of the follicles. The selective localization of B cells within follicles of SLOs 
is mediated by CXCL13 (i.e. produced by follicular stromal cells mainly FDCs) which is 
recognized by the receptor CXCR5 and are highly expressed on B cells [153-156]. 
On antigen encounter, B cells up-regulate the chemokine receptor CCR7 (specific for 
chemokine found in T cell area) and congregate at the boundary between B-cell and T-cell 
areas in search of T-cell help. Cognate encounters with activated T cells, specific for the 
same antigen, at the T-B boundary drive initial B-cell proliferation. This is particularly 
mediated by a synapse of CD40 and ICOSL, which is constitutively expressed by B cells, 
and its ligand, CD40L (CD154) and ICOS, which is expressed by activated T helper cells 
[153-156]. At this stage B cells can generate an extra follicular immune response where they 
undergo rapid transformation into plasmablasts (that give rise to short-lived plasma cells) or 
migrate back into the follicle where they undergo intense proliferation accompanied by the 
process of somatic hypermutation (SHM). SHM is regulated by the enzyme activation-
induced cytidine deaminase (AID), which introduces single base-pair substitutions into the 
variable regions of antibody gene segments. Thus, SHM drives B cell receptor (BCR) 
diversification and creates a series of related clones of B cells that differ subtly in their 
specificity and affinity for the same antigen.  
Following SHM, B cells stop proliferating and undergo the process of affinity maturation.  
During this process, the BCR presented on the surface of generated B cell clones interact 
with the antigens trapped on FDCs networks. The B cells bearing receptors with the highest 
affinity for the antigen are favoured for survival and can undergo further rounds of 
proliferation and SHM. B cell clones that do not bind antigen, or bind with very low affinity, do 
not receive survival signals from the FDCs and die in situ by apoptosis and are engulfed by 
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tingible body macrophages in the GC. FDCs have been shown to be important source of IL-6 
and BAFF during the GC reaction. These signals are important for terminal differentiation 
process such as SHM and B cell survival respectively [153-156].  
After BCR selection, B cells undergo class switch recombination (CSR), i.e. the process of 
isotype switching and this is also regulated by AID. The specificity of the B cell response is 
determined by processes of SHM and affinity maturation (mentioned above), but its effector 
actions is determined by CSR that helps produce the immunoglobulins isotype more 
appropriate for the type and the site of the immune response (eg. IgA for mucosal sites) 
[153-156]. 
GC B cells, bearing high affinity BCR, strongly express Bcl-6. This promotes their survival 
and it is down regulated once these cells terminate their cycles of proliferation, followed by 
strong expression of Blimp-1. Blimp-1 drives B cell commitment towards the plasma cell fate. 
GC B cells bearing intermediate-affinity BCR are committed to become memory B cells. They 
do not express Blimp-1 and maintain a low level of Bcl-6 expression (that is sufficient to 
inhibit plasma cell differentiation) [153-156].   
Of note, a GC reaction is heavily dependent on CD4 T helper cells. In addition to expressing 
CD40L, activated T helper cells also secrete cytokines such as IL-21 and IL-4 that deliver 
signals to drive B-cell proliferation, survival and differentiation [153-156]. 
In summary, the primary function of GCs is to generate the high-affinity antibody-secreting 
plasma cells and memory B cells that will not only ensure sustained immune protection but 
also a rapid recall response against the previously encountered foreign antigens. However, 
the processes such as SHM during an active germinal centre reaction, carry potential risks; 
generation of potentially pathogenic autoantibody specificities and unintended oncogenic 
mutations [154, 156]. 
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Figure 1.3B Germinal centre reaction. 
A small number of activated B cells seed the follicles to grow and initiate germinal centre 
(GC) reactions. T follicular helper (TFH) cells that have established stable interactions with B 
cells at the outer T cell zone also enter follicles. Proliferation of GC B cells displaces naive 
circulating B cells that now form the follicular mantle zone. Two zones can be identified: the 
dark zone and the light zone. The dark zone is full of dividing GC B cells, known as 
centroblasts, although some proliferating B cells can also be found in the light zone. The light 
zone is rich in follicular dendritic cells (FDCs) that have antigen bound on their surface. 
Antigen can be picked up by subcapsular sinus macrophages from the lymph and delivered 
to non-cognate B cells that transfer the antigen to FDCs. FDCs bind the antigen in the form 
of immune complexes. Dividing centroblasts acquire somatic hypermutation (SHM) in their 
immunoglobulin variable-region genes; their non-dividing progeny, centrocytes, are selected 
after a successful interaction with FDCs, uptake of antigen through the B cell receptor and 
presentation of this antigen to TFH cells. Selection can lead to terminal differentiation into 
long-lived plasma cells or memory B cells or can induce centrocytes to re-enter the cell cycle 
and undergo further rounds of SHM. It is possible that selection signals are also received by 
B cells in the dark zone. Failure to receive these survival signals leads to apoptosis in situ. 
Apoptotic cells are cleared by tangible body macrophages (Vinuesa C.G et al., 2009 [154]).   
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1.4 Ectopic Lymphoid Neogenesis: The process of tertiary lymphoid 
organ formation 
Tertiary lymphoid Organs (TLOs) are accumulations of lymphoid cells within non-lymphoid 
organs that share the cellular compartments, spatial organization, vasculature, chemokines 
and function with SLOs, especially LNs. TLOs organize into a separate T cell compartment 
and B cell compartment which contain germinal centres with follicular dendritic cells (FDCs). 
In most cases TLOs contain PNAd (Peripheral Node addressin) expressing high endothelial 
venules (HEVs). TLOs are also commonly referred to as ectopic lymphoid structures owing 
to their propensity to develop in typically non-lymphoid locations. TLOs have been described 
in various mouse models of inflammation (overview in Table 1.4A) and shown to be 
associated with a wide range of autoimmune diseases. Lymphoid neogenesis has also been 
documented in a few chronic infections that include Helicobactor pylori-induced gastritis 
where high degree of TLO organization and a large number of locally generated IgA-
producing plasma cells, specific for H.pylori antigens, have been detected. TLO formation 
has also been reported in chronic hepatitis C virus (HCV) infection, in lyme disease and 
influenza A virus infection. Other than these, TLOs have been described in chronic allograft 
rejection, atherosclerosis, allergic lung disease and cancer (for example ectopic and 
functional germinal centres have been detected in breast cancer) (overview in Table 1.4B) [4, 
12, 14]. 
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Table 1.4A 
 
(Adapted from Aloisi 2006; Drayton 2006 [4, 14]) 
Table1.4A Mouse models of inflammation and transgenic mouse models accompanied 
by ectopic lymphoneogenesis. 
Disease Target tissue
Microarchitecture of lymphoid 
infiltrates
Immunological correlates
Autoimmune gastritis Stomach
B-cell follicles with FDCs but rare 
PNA+ GCs; no 
CCL21+PNAD+ HEVs
Increased titre of serum gastric-
mucosa-specific autoantibodies; TH1-
cellbiased microenvironment
Autoimmune thyroiditis 
(Autoimmune-prone biobreeding 
(BB) rats were used in these 
experiments)
Thyroid gland B-cell follicles and HEVs Serum colloid-specific antibodies
Prediabetic NOD mice
Pancreatic islets; salivary and 
lacrimal glands
Lymphoid aggregates with 
CCL21+ stromal cells and 
CCL21+HEC-
GlcNAc6ST+MADCAM1+ HEVs
Not determined
Collagen-induced arthritis Joints B-cell follicles with GL7+ GCs Not determined
Experimental autoimmune 
encephalomyelitis 
(chronicrelapsing form)
Central nervous system
Intrameningeal B-cell follicles with 
FDCs and GCs
Not determined
Airway antigenic challenge Lungs
B-cell follicles with FDCs and 
PNA+ GCs
IgE production
Helicobacter pylori-induced 
gastritis
Stomach
B-cell follicles with GCs; T-cell 
areas with CD62Lhi naive T cells 
and MADCAM1+PNAD+HEVs
Weak correlation with H. pylori-
specific antibody responses
Propionibacterium acnes-
induced granulomatous liver 
disease
Liver
B-cell follicles with FDCs without 
GCs; T-cell areas with 
PNAD+ HEVs
Not determined
Influenza A virus Lungs
B-cell follicles with FDCs and GCs; 
T-cell areas with 
CCL21+PNAD+ HEVs
Influenza-virus-specific CD8+ T cells 
and antibodies
Allograft rejection Heart
B-cell follicles; T-cell areas with 
PNAD+ HEVs
Not determined
Lymphotoxin-α Pancreatic islets, kidneys
B-cell follicles with or without FDCs; 
T-cell areas with 
CCL21+MADCAM1+PNAD+ HEVs
Production of antibodies to foreign 
antigen
Tumours
T-cell responses against tumour 
antigens
Lymphotoxin-αβ Pancreatic islets
B-cell follicles with FDCs; T-cell 
areas with CD62Lhi naive T cells, 
CD11c+ DCs and CCL21+HEC-
GlcNAc6ST+MADCAM1+PNAD+ H
EVs
Not determined
LIGHT Tumours
Infiltrating CD62Lhi naive T cells and 
CCL21+MADCAM1+ stromal cells
Intratumoral expansion and activation 
of tumourantigen-specific T cells
CCL19 Pancreatic islets
Non-organized B- and T-cell 
infiltrates; MADCAM1+PNAD+ HEVs
Not determined
CCL21 Pancreatic islets, thyroid gland
B-cell follicles without FDCs; T-cell 
areas with CD11c+ DCs, 
MADCAM1+PNAD+ HEVs and 
stromal cells
Not determined
CXCL12 Pancreatic islets B-cell, plasma-cell and DC infiltrates Not determined
CXCL13 Pancreatic islets
B-cell aggregates without FDCs; T-
cell areas with stromal cells and 
MADCAM1+PNAD+ HEVs
Not determined
Autoimmune disease
Allergic disease
Infectious disease
Transplantation
Ectopic expression of:
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Table 1.4B  
Disease Target tissue
Percentage of patients 
with ectopic follicles that 
contain 
CD21+ CD35+ FDCs or 
GCs
T-cell aggregates with 
CCL19+CCL21+stromal 
cells, DCs and HEV-like 
vessels
Antigen recognized by 
antibodies generated in 
ectopic GCs
Rheumatoid 
arthritis Diarthrodial joints 10–35%
Present; 
PNAD–CCL21+ blood 
vessels and 
PNAD+CCL21+HEVs Rheumatoid factor 
Hashimoto's 
thyroiditis 
(hypothyroidism) Thyroid gland 100%
Present; HECA-
452+CCL21+HEVs Thyroglobulin, thyroperoxidase
Graves' disease 
(hyperthyroidism) Thyroid gland 54–63%
Present; HECA-
452+CCL21+HEVs Thyroglobulin, thyroperoxidase
Myasthenia gravis Thymus
Mainly patients with early-
onset myasthenia gravis Present Nicotinic acetylcholine receptor
Sjogren's syndrome Salivary glands 17%
Present; 
PNAD+CCL21+ HEVs SSA/Ro; SSB/La
Multiple sclerosis
Central nervous 
system
30–40% of patients with 
secondary progressive 
multiple sclerosis Absent Not determined
Cryptogenic 
fibrosing alveolitis Lungs 83–90% Not determined Not determined
Primary sclerosing 
cholangitis and 
primary biliary 
cirrhosis Liver None
Present; 
CCL21+MADCAM1+HEVs Not determined
Ulcerative colitis* Gut 27%
Present; CCL21+PNAD-
 blood vessels Not determined
Crohn's disease* Gut Not determined
Present; CCL21+PNAD-
 blood vessels Not determined
Atherosclerosis Arteries 32% Present; HECA-452+ HEVs Not determined
Chronic hepatitis C Liver 33–85% Not determined Not determined
Helicobacter pylori-
(orCampylobacter 
pylori)-induced 
gastritis Stomach 27–100% Present; PNAD+ HEVs Bacterial antigens
Chronic Lyme 
disease Joints 17% Present Not determined
Ductal breast 
carcinoma Breasts 33–100% Not determined
Tumour-associated and normal 
breast tissue antigens
Autoimmune diseases
Other chronic inflammatory diseases
Infectious diseases
Tumours
(Adapted from Aloisi 2006; Lambrecht 2012 [12, 14]) 
 Table1.4B Human inflammatory diseases, infections and cancer with lymphoid neogenesis. 
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Lessons Learnt From Transgenic Models of TLO Formation  
Transgenic (Tg) mouse models of chronic inflammation that over-express inflammatory 
cytokines, for example TNF and LTα develop TLOs [157-160]. For example, LTα over-
expression in mice pancreas, under the control of rat insulin promoter (RIP), led to formation 
of inflammatory lesions that were organized like LNs with separate T and B cell areas, 
specialized stromal cells (FDC and ER-TR7+ stromal networks) and HEVs, in the pancreas 
and kidney of these RIP-LTα Tg mice. LTα expression in the pancreas can promote 
expression of lymphoid chemokines CCL21 and CXCL13 that enable T and B cell 
organization, germinal centres formation and isotype switching in B cells. This process is 
dependent on TNFR1 suggesting that signals through TNFR1, rather than LTβR, are 
sufficient for TLO development [157-160].  
Similarly, engineered LTα expression in tumor cells has been demonstrated to lead the 
formation of intratumoral lymphoid tissue, able to sustain an efficient immune response, 
suggesting that signalling through LT and its receptors play a role in the induction of 
functionally competent TLOs [161]. However, the mice that expressed both LTα and LTβ in 
the pancreas had much larger infiltrates with better segregated T and B cell areas and higher 
expression of lymphoid chemokines CXCL13, CCL19 and CCL21 in the pancreatic islets 
than those observed in the LTα single Tg mice [4]. This suggests that the simultaneous 
expression of LTα and LTβ is more efficient in promoting TLO formation, and highlights 
distinct roles for LTα and LTαβ in lymphoid neogenesis [4].  
LIGHT which is also known to signal via the LTβR, has also been implicated in formation of 
TLOs [23, 162, 163]. LIGHT expression has been reported in the islets of NOD mice that 
develop TLO and diabetes [163, 164], and LIGHT overexpression in the pancreas of NOD 
mice has been shown to accelerate  diabetes [163, 164]. Hence, blockade of LTβR in NOD 
mice has been shown to disrupt organization of TLOs and prevent diabetes [164]. These 
studies are the first line of evidence to support the notion that lymphoid neogenesis during 
inflammation could involve the same signalling pathways which are involved in the 
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physiological development of lymphoid organs, and clearly endorse the view that expression 
of LTα, LTαβ and LIGHT can all contribute to formation of TLOs via signalling through 
TNFR1 and LTβR. [159, 165]. However, the inflammatory environment in RIP-TNFα Tg, RIP-
LTα Tg and RIP-LTα/LTβ Tg mice did not lead to tissue destruction and type 1 diabetes, 
unless an additional co-stimulatory signal was provided in the form of B7.1 or IFNg or IL-2 
co-expression in the islets, which could activate infiltrating T cells resulting in beta cell 
destruction [166-168].  
Further studies by Cyster’s group and others, addressed the role of individual chemokines in 
TLO formation [169-174] . Mice expressing CXCL13 in the pancreas developed TLOs that 
contained B and T cell zones. CD11c+ DCs were also present in the T cell area, and in most 
cases the T cells and DC co-localized. A dense BP-3+ stromal cell network was observed 
extending through most of the ectopic lymphoid structures, PNAd+ and MadCAM-1+ HEVs 
were also evident in these structures and remarkably, CCL21 was detectable on a subset of 
HEVs as well as in a dense network in the T cell-rich area. The authors further demonstrated 
that this phenomenon of TLO development was dependent on B cells and LTα1β2 [169]. 
Likewise, other studies showed that overexpression of CCL21 in non-lymphoid tissue, such 
as the pancreas (under the control of rat insulin promoter) [173, 174] and thyroid (under the 
control of thyroglobulin promoter) [170-172], is sufficient to activate a pathway of events that 
promote development of TLOs. Pancreatic islets of RIP-CCL21Tg mice contained infiltrates 
that consolidated into organized lymphoid tissues, containing T cell/DC clusters with B cells 
at the perimeter. gp38+, BP-3+ and ERTR7+ stromal cell networks, as well as MadCAM-1 
and PNAd expression on vascular endothelium (that showed morphological resemblance to 
HEVs) were detected in these ectopic lymphoid structures. However, neither of the CCL21Tg 
mouse models showed evidence of development of CD35+ FDC or CXCL13-expressing 
stromal cells. Though, Chen et al. [174] reported occasional weak staining for FDC-M1, a 
marker of FDC, within B cell follicles in CCL21-induced TLOs.  
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Similarly, TLOs formed in the thyroid had separate T and B cell areas, as well as HEV and 
lymphatic vessels, surrounding the ectopic follicles. Further investigation revealed that even 
though HEVs expressing PNAd were frequently observed in the thyroid tissue, lymphocyte 
recruitment was independent of L-selectin and LTα but does require CCR7. However, the 
ability to form segregated lymphoid aggregates in the thyroid tissue that develop PNAd+ HEV 
and lymphatic vessels was dependent on LTα expression and LTβR signalling as well as on 
the activities of lymphocytes. Interestingly, initiation of lymphangiogenesis in this model was 
dependent on LT-expressing CD4 T cells rather than B cells [170-172].  
Of note, CXCL13, CCL21, CCL19 and CXCL12 are not equal in their ability to promote TLO 
neogenesis.  Overexpression of CCL19 or CXCL12 is not able to induce fully mature 
aggregates. Possibly this is related to their differential ability to promote LTαβ expression on 
lymphocytes. CXCL13 has been shown to trigger LTαβ expression on B cells, while CCL21, 
and to lesser extent CCL19 but not CXCL12, promotes LTαβ expression on CD4 T cells 
[175]. Interestingly, in particular for human pathology, cytokines such as IL-7 and IL-4 have 
been shown to be able to induce LTαβ expression on naïve T [175]. In this context Tg co-
expression of IL-6 and IL-6R under the Class I and β-actin promoters, as well as IL-5 
overexpression has been shown to induce the formation of iBALT in the lung [176]. Not in all 
cases the  transgene induced TLO formation is accompanied by pathology [13]. 
Lymphoid Neogenesis in Experimental Disease Models and Human Disease  
More direct evidence for the cellular and molecular mechanisms in TLO ontogeny  is derived 
from immunohistochemical and gene expression analysis of patient tissue specimens (such 
as salivary glands from Sjogren’s patient and synovium of rheumatoid arthritis patients), as 
well as experimental disease models (for example NOD mice). Increased expression of 
lymphoid chemokines (CXCL13, CCL21, CCL19 and CXCL12), LTα, LTβand PNAd+ and/or 
MadCAM-1+ HEVs have been reported in most of the chronically inflamed tissues that 
harbour TLOs. Remarkably, a correlation between the expression of LTα/LTβ and/or 
lymphoid chemokines and lymphoid organization has been observed in experimental disease 
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mouse models and human autoimmune lesions, which supports a causative involvement of 
these mediators in TLO formation [12-14, 177-183].  
Features of ectopic lymphoid neogenesis have also been detected in animal models of 
autoimmunity, such as insulitis that spontaneously develops in non-obese diabetic (NOD) 
mice, with most organized structures generally being associated with the chronic disease 
phases. Astorri et al. have recently demonstrated in the pancreas of NOD mice that TLOs 
are critical in promoting chronic inflammation during autoimmune insulitis and diabetes. They 
showed that T and B cell infiltration follows a highly regulated process with the formation of 
lymphoid aggregates characterized by T/B cell segregation, follicular dendritic cell networks, 
and differentiation of germinal center B cells during progression from peri- to intrainsulitis in 
early diabetic mice. This process is preceded by local upregulation of lymphotoxins 
alpha/beta and lymphoid chemokines CXCL13 and CCL19. Upon development, TLOs were 
fully functional in supporting autoreactive B cell differentiation in situ, indicated by the 
expression of activation-induced cytidine deaminase, the enzyme required for B-cell affinity 
maturation and class switching, and the presence of plasma cells displaying anti-insulin 
reactivity [181].  
Increased size and organization of TLOs in various autoimmune tissues have been shown to 
correlate with increased local expression of homoeostatic cytokines and chemokines 
including LTα, LTβ, CXCL13, CCL21 [13, 14, 160, 179, 180, 183-186] and CXCL12 [13, 14, 
160, 186, 187]. Although different patterns of lymphoid arrangements usually coexist in the 
same patient tissues, tissues with highly organized ectopic lymphoid follicles tend to express 
much higher levels of LTα, CXCL13 and CCL21 than those with diffuse lymphoid infiltrates 
[13, 14, 160, 179, 180, 182, 184, 186, 188]. In fact, the expression levels of CXCL13 and LTβ 
has been suggested to be highly predictive of the presence of ectopic GC in synovial 
biopsies of patients with RA. The expression of CXCL13 also correlates with the presence of 
highly organized B cell follicles in patients with Sjogren’s syndrome [13, 14, 177, 180, 188]. 
Expression of CXCL13 and BAFF were shown to be increased with meninges associated 
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ectopic GC formation in a mouse model of CNS inflammation [189]. In a spontaneous mouse 
model of autoimmune gastritis, CXCL13 and LTβ were highly expressed in the ectopic 
lymphoid follicles that develop in the stomach of these mice. The number and size of these 
follicles correlated with the serum autoantibody titre [190]. Formation of TLOs has also been 
documented in Helicobacter pylori-induced gastritis, which is dependent on the 
CXCL13/CXCR5 signalling axis since these structures fail to form in CXCR5-/- mice [191]. In 
fact Wegner et al. demonstrated in a mice model of chronic antigen-induced arthritis that the 
development and organization of TLOs was impaired in absence of CXCR5 and CCR7 [192].  
Apart from autoimmune and infectious diseases, TLO formation has also been reported in 
other diseases such as atherosclerosis and allergic lung disease. LTβR signalling was 
demonstrated to promote the adventitial aortic tertiary lymphoid organs (ATLOs) and 
interruption of this signalling axis achieved by administering LTβR-Ig fusion protein to a 
mouse model of ATLO, strongly reduced CXCL13 and CCL21 expression and HEV 
structures and disrupted the structure and maintenance of ATLOs in these mice [193]. LTβR-
Ig administration in other mouse model such as NOD mice also resulted in disruption of 
TLOs [163].  
The ability of local TLOs to locally produce antibodies is still debated. Highly organised TLOs 
are characterised by FDC expression, that associate with the expression of AID (activation 
induced cytidine deaminase), enzyme important for B-cell somatic mutation and isotype class 
switching, and have been detected in the TLOs [194]. Accordingly, analysis of the DNA 
sequence analysis of synovial isolated germinal centre B cells demonstrated a restricted 
number of heavy and light chain rearrangements, consistent with oligoclonal B cell expansion 
in the inflamed synovial tissue [195, 196]. Furthermore, demonstration that these cells 
undergo somatic hypermutation in the Ig variable regions in situ has been provided [196]. A 
similar phenomenon of oligoclonal B cell expansion and somatic hypermutation of Ig variable 
genes have also been demonstrated within the TLOs that form in the salivary glands of 
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patients with SS, in the thymus of patients with myasthenia gravis and in the CSF of multiple 
sclerosis patients [4, 14, 197-201].  
Finally, plasma cell-derived autoantibodies have been detected in TLO associated GC in 
rheumatoid arthritis, Hashimoto thyroiditis and Sjogren’s syndrome, as well as plasma cells 
secreting anti-SRBC antibodies in RIP-LTα Tg mice kidneys after SRBC immunization [159, 
202]. Likewise, large numbers of locally generated IgA-producing plasma cells specific for 
H.pylori antigens have been detected in Helicobacter pylori-induced TLOs. In some studies, 
a correlation has been found between autoantibody serum levels and ectopic GCs which has 
raised the possibility that TLOs contribute to the disease process [14, 178, 190, 203-206]. 
However, it remains unclear whether plasma cells actually develop in TLOs or migrate from 
canonical SLOs. Nonetheless, all these studies in several human diseases and animal 
models collectively suggest that TLOs can support germinal centre reaction characterized by 
somatic hypermutation of Ig variable genes, affinity maturation, isotype switching and 
terminal differentiation of B cells differentiation into plasma cells.  
T cell priming and epitope spreading have been shown to occur in TLOs formed in the brain 
of experimental models. Reactivity to CNS antigens has been observed [207] as well as 
proliferation of adoptively transferred T cells only in the CNS but not in the draining LN [207]. 
In addition, there is another study which has reported presence of restricted T cell repertoire 
in tumor-associated TLOs suggesting that naïve T cell priming can occur within TLOs [161]. 
There has been a long-standing conundrum surrounding the functionality of ectopic GCs to 
mount and sustain local immune responses. This question has been elegantly addressed by 
Moyron-Quiroz et al. [76] in spleen-, lymph node-, Peyer’s patch-deficient (SLP) mice, in 
which iBALT (inducible bronchus-associated lymphoid tissue) formed in the lung of SLP mice 
upon influenza virus infection  were able to generate a robust primary T and B cell responses 
to influenza, and clear influenza infection. The investigators found the generation of 
influenza-specific CD8α T cells in these iBALT structures. Additionally GL7+PNA+ GC B cells 
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were detected in iBALT and they were shown to support production of influenza specific 
antibodies. Interestingly, these mice were able to survive higher doses of virus compared to 
wild-type mice [76]. Likewise, another study using SLO deficient mice provided evidence that 
TLOs formed at the site of allografts post-transplantation were able to generate effector and 
memory T cells from transferred naïve T cells, which lead to allograft rejection in these mice 
[208]. 
TLOs and their potential role in tumors 
Various studies have reported lymphoid neogenesis at tumor sites. Schrama et al. and Yu et 
al. have shown that induction of TLOs at the site of tumors results in regression of the tumor. 
Moreover, analysis of T cell within these TLOs revealed presence of tumor-specific T cells 
and these T cells exhibited enhanced proliferation activity. Both these studies suggested that 
TLOs may be beneficial for local presentation of tumor antigens and induction of anti-tumor 
immunity [161] [209]. On the contrary, TLOs have also been demonstrated to promote tumor 
formation and metastasis. For example in some chronic inflammatory diseases, such as 
Hashimoto thyroiditis and SS, TLOs have been indicated to provide local molecular 
environment to support continual B cell proliferation which results in development of 
lymphomas in these diseases [160, 194]. Similarly, in hepatitis C virus infection and 
Helicobacter pylori infection, chronic inflammation has been reported to lead to progression 
of TLO into cancer [210, 211].  
Role of LTi cells in TLO formation  
The role of LTi cells in the formation of TLO is still controversial. Adoptive transfer of LTi cells 
to ectopic sites, such as skin in neonatal mice, triggers TLO development [212]. Similarly, Tg 
overexpression of IL-7 which results in abnormally high number of LTi cells in these mice 
form TLOs in the pancreas and salivary glands. Interestingly, when IL-7 transgenic mice are 
crossed with RORγ-/- mice, which lack LTi, these mice do not develop any SLOs (LNs and 
PPs) or TLOs. Thus, in this model, IL-7 by itself is not sufficient to drive development of 
these ectopic lymphoid tissues, but in fact requires LTi cells [62].  Furthermore, in transgenic 
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mice, that overexpress CXCL13 in the pancreas, CD4+CD3- cells are the first hematopoietic 
cell type recruited to the pancreatic islets very early after birth, suggesting that LTi cells may 
be involved in formation of the TLO that eventually develop in this location [169, 213]. 
However, in these models, lymphoid neogenesis is triggered before birth or at the neonatal 
stage and not in the adult, which means that the requirement of LTi cells could be 
overestimated. It therefore remains unclear from these studies whether this is due to a 
coincidence in timing or due to a causal relationship of LTi and TLO development. This 
notion is further supported in an adoptive transfer study, where adoptive transfer of LTi into 
the skin of adult mice results in disorganized accumulations of lymphocytes with no FDC and 
HEVs [212]. However, there are some human TLOs, such as those seen in idiopathic 
pulmonary arterial hypertension (IPAH), where RORc+CD4-cKit+ LTi have been detected 
[12]. 
Id2-/- or RORγt-/- mice, which lack LTi cells, when infected with influenza virus or exposed to 
LPS, develop normal iBALT structures in the lung [76, 214, 215]. Similarly, another study 
demonstrated development of TLOs in colon of RORγt-/-mice [216]. Studies using mice that 
express CCL21 in the thyroid suggested that LTi cells are not required for TLO neogenesis, 
instead, in this model, CD3+CD4+ T cells were the first cell to appear in the thyroid and 
interact with local DCs. This subsequently leads to production of homoeostatic and 
inflammatory chemokines, recruitment of lymphocytes and DCs which organize into lymphoid 
structures with appearance of PNAd+ HEV like vessels. Importantly, when CCL21 transgenic 
mice were crossed with Id2-/- mice, they still formed TLOs in the thyroid despite absence of 
LTi cells [217]. This suggests that the formation of TLOs does not require Id2-dependent LTi 
cells but depends on program initiated by mature CD4+T cells. During chronic inflammation, 
within TLOs, the presence of inflammatory lymphocytes that are able to express LTαβ is 
likely to compensate for the lack of LTi. [36, 217] [218-220]. Finally, the role of DCs has been 
highlighted in TLO development. DC might contribute to this by providing antigen 
presentation to the T cells or directly providing LTβ and lymphoid chemokines CXCL13 and 
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CCL21/CCL19. Hence, depletion of DCs result in disappearance of existing TLO structures 
[218-220].  
Stromal cells in Ectopic Lymphoneogenesis 
It is believed that stromal cells, in particular fibroblasts, contribute to the microenvironment in 
chronic inflammation, by providing pro-survival and retention signals via production of 
factors, such as B cell survival factors (BAFF) and the inflammatory chemokines (e.g., IL-8, 
CCL5, CXCL1). Pathogenic tissue fibroblasts play, not only a key role in immune cell 
recruitment to the site of inflammation, but have also been implicated in the formation of 
organized aggregation of infiltrating immune cells (TLOs) at these sites by virtue of their 
capability to produce lymphoid chemokines CXCL12, CCL21 and CXCL13 [221-223]. 
The central role of stromal cells in the development of TLOs was shown by intradermal 
injections of cell suspensions obtained from the neonatal LNs. These injections resulted in 
ectopic LN like structure formation and the cells that were of donor origin within these 
structures turned out to be stromal cells, which not only demonstrated the capacity to attract 
and retain host- derived T and B lymphocytes, but organize themselves into distinctive micro-
domains [212]. The central role of stromal cells for TLO formation is further supported by 
studies in which artificial LNs were created by implantation of stromal cell scaffolds under the 
kidney capsule. These structures were shown to attract cells that are present in a normal LN 
and organize them in distinctive B and T cell areas, which support bona fide immune 
responses [126, 224]. Thus, these studies indicate an overriding capacity of stromal cells to 
contribute to TLO development and predict stromal cells pivotal role in the formation of 
ectopic lymphoid structures that develop during chronic inflammation. Indeed, in a model of 
atherosclerosis which develops adventitial aortic tertiary lymphoid organs (ATLOs), the 
investigators showed that the mouse aorta smooth muscle cells (SMC) were activated and 
acquired features of LTo cells, such as expression of VCAM-1 and lymphorganogenic 
chemokines CXCL13 and CCL21, that supported formation of ATLOs [193]. Signalling 
through both LTβR and TNFR1 was shown to activate SMCs [225]. Once established, the 
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ATLOs could be disrupted by LTβR blockade in vivo [193].  Likewise, Peduto et al., [226] 
elegantly demonstrated that local resident fibroblasts give rise to LTo-like cells in 
experimental models of cancer and local inflammation by mechanical and inflammatory 
stimuli.  Intriguingly, the induction of LTo like cells was shown to be independent of TLR or 
TNF signalling, but most probably linked to the presence of polymorphonucleated cells in the 
first phases of the inflammatory process. gp38, marker of lymph node stromal cell, was used 
to identify and isolate these LTo-like stromal cells that acquire during inflammation the 
capability to express genes essential in lymphoid tissue genesis and in the recruitment and 
survival of leukocytes. The gp38+LTo like cells expressed elevated levels of IL-7, CXCL13, 
CCL19, CCL21, CXCL12, TRANCE, VCAM-1, BP-3, etc [226].  
Reticular networks of ER-TR7+, podoplanin+ and BP-3+ stromal cells have also been 
observed in pancreatic infiltrates of RIP-CXCL13, RIP-LTα/LTβ Tg and NOD mice [213] [159, 
169, 227] and other refs). These cells, like lymphoid stromal cells, expressed LTβR, VCAM-
1, CCL19, CCL21 and IL-7 and have been suggested to differentiate from tissue-resident 
myofibroblasts [213]. Additionally, podoplanin+ stromal networks, co-localizing with lymphoid 
chemokines such as CCL21, CCL19, have been detected in ectopic infiltrates associated 
with human diseases such as rheumatoid arthritis [179, 228] and Sjogren’s syndrome [213]. 
Moreover, numerous reports in mice models and human diseases have documented the 
presence of CD35+/FDC-M1+ FDCs networks within B-cell areas of TLOs. Like their SLO 
counterparts these FDCs are also associated with CXCL13 expression [229] Recently, 
Krautler et al., showed that PDGFRβ+ stromal-vascular cells from non-lymphoid organs have 
the capacity to differentiate into FDCs upon LTβR and TNF triggering, suggesting that this 
cell population may be the source of FDC in TLOs. Moreover, this study further reiterates the 
capability of non-lymphoid tissue-resident stromal to undergo lymphoid conversion [147].  
Altogether, these observations suggest that the stromal cells in inflammation recapitulate the 
ontogeny of lymphoid stromal cells, which lays the foundation for the development of TLOs, 
by providing factors and signals critical for lymphoid neogenesis. 
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TLO development does not necessarily copy secondary lymphoid 
organogensis 
The similarities between SLO and TLOs, in terms of structure and to an extent function as 
well as insights from mouse and human studies, suggest that SLO and TLO development 
might employ similar pathways. However, studies from some groups have challenged this 
paradigm. Randall’s group in 2011 proposed the idea that inflammatory cytokines such as IL-
17 could initiate TLO formation using a mouse model of iBALT formation. The study 
demonstrated that the formation of iBALT did not require LTi and lymphotoxin mediated 
signals; instead it was dependent on IL-17 produced by CD4+ T cells, indicated by failure to 
form iBALT structures in the lungs of IL-17Rα-/- and IL-17-/- mice. More surprising was the 
finding that IL-17, in addition to its ability to induce expression of inflammatory chemokines, 
such as CXCL10, CXCL11 and CXCL9 (which in turn recruit inflammatory cells at the 
effector site), could also directly stimulate the expression of CXCL13 and CCL21 in stromal 
cells [214]. This observation explained their previous finding in 2004, which had shown that 
expression of homeostatic chemokines expressed within iBALT in lungs of influenza infected 
mice was independent of LTα and TNFα mediated signals [76]. Even though induction of 
iBALT was independent of lymphotoxin signalling, it was crucial for maintenance and 
organization of these structures in the infected lung tissues, as these lymphoid structures 
were highly disrupted in LTα-/- mice [214]. Supporting a role for IL-17 in TLO formation, 
Kuchroo’s group showed that Th17 cells specifically induced ectopic lymphoid follicles in the 
CNS, in the experimental autoimmune encephalomyelitis (EAE) mouse model. Intriguingly, 
the Th17 cell signature cytokine IL-17 and cell surface molecule podoplanin (expressed on 
CNS infiltrating Th17 cells) directly contributed to TLO formation in this model, as the 
lymphoid follicle were significantly reduced in IL-17Rα-deficient mice, and inhibition of 
podoplanin with blocking antibody also partially inhibited the formation of these ectopic 
lymphoid follicles [230].  
Overall, these recent studies propose an interesting possibility that ectopic organogenesis 
can be driven by inflammatory cytokines rather than constitutive lymphoid cytokines. This 
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opens a new perspective to understand the role of stromal cells and cytokine signalling 
pathways involved in TLO formation.   
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(Adapted from [4, 12, 14, 76, 154, 157, 160, 165, 169, 171, 173-175, 180, 181, 183, 185, 
188, 193, 194, 214, 216, 217, 220, 226, 227, 230-235]. 
Step 2. Recruitment of peripherally activated 
lymphocytes which express LTα3 and LTα1β2. 
Step 3. Engagement of LTβR and TNFR via 
lymphotoxin-expressing lymphocytes leads to 
further activation of tissue-resident into lymphoid 
phenotype. These stromal cells express 
adhesion molecules (ICAM-1 and VCAM-1) and 
expression of lymphoid chemokines CCL19, 
CCL21, CXCL13. This leads to further 
recruitment and organization of activated as well 
as naïve lymphocytes into TLOs at the site of 
inflammation. The activated stromal cells also 
produce lymphoid cytokines such as IL-7 and 
BAFF which enhance survival of lymphocytes.  
Under the influence of LT and TNF, stromal cells 
would acquire the phenotypic and functional 
properties of FDCs, including CXCL13 
production, which promote germinal-centre 
organization. Cytokines that mediate lymphocyte 
survival, differentiation and/or proliferation, such 
as BAFF, IL-2-family members (IL-2, IL-4, IL-7, 
IL-15 and IL-21) and IL-6, might contribute, 
together with antigen, to establish optimal 
niches for germinal centre reaction. 
 
Figure 1.4A Model of Tertiary Lymphoid 
Organ (TLO) formation. 
 
Step 1. Inflammatory responses are initiated by 
innate immune cells (such as macrophages, NK 
cells, ILCs and dendritic cells, DCs). This leads 
to production of cytokines such as tumour-
necrosis factor (TNF), IL-17. 
Inflammatory cytokines induce activation of 
tissue stromal cells to produce inflammatory 
chemokines (CXCL10 and CXCL9) as well as 
lymphoid chemokines (CCL21, CCL19, 
CXCL13). 
Figure 1.4A 
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1.5 Sjogren’s syndrome: An illustration of ectopic 
lymphoneogenesis in inflammation, infection and cancer 
Sjogren’s Syndrome (SS) is a chronic inflammatory disease that primarily affects the 
exocrine glands (particularly salivary and lacrimal glands) and leads to their functional 
impairment. SS occurs either independently as a primary disease or as a secondary 
manifestation to other rheumatic diseases, most commonly rheumatoid arthritis [23-25]. 
Primary SS is a common autoimmune disease, affecting 0.1-0.4% of general population, and 
is more prevalent in females with a female to male ratio of 9:1. Being commonly affected and 
easily accessible, salivary glands are the most studied exocrine glands in SS. SS is an 
intriguing example of an immune mediated inflammatory disease in which there is evidence 
of an antigen driven immune response to infection, autoimmunity and development of cancer 
[18, 23-25].  
Pathology 
SS is characterized by peri-epithelial mononuclear cell infiltration of exocrine glands. 
Histopathologically, these are focal aggregates of at least 50 lymphocytes, plasma cells and 
macrophages that surround the ducts and subsequently replace the acini which are the 
secretory units leading to sicca symptoms of dry eyes and dry mouth (typical clinical 
manifestations studied in patients with SS). There is progressive acquisition of lymphoid 
features by salivary gland inflammatory aggregates observed in patients of Sjogren’s 
syndrome. Within the inflammatory foci the presence of T/B cell segregation, formation of 
follicular dendritic cell networks within the germinal centres (GC) [178, 180] and local 
expression of AID (activation induced cytidine deaminase), the enzyme, instrumental for B 
cell affinity maturation, has been demonstrated [194].  
Salivary gland lymphoid organization is accompanied by the ectopic production of the 
chemokines (CKs) CXCL13, CCL21 and CXCL12. The cellular localization of these 
molecules is mostly consistent with that observed in B- and T-cell areas of SLOs. Such 
pathological lesions are indicative of chronic lymphocytic sialadenitis [177, 180, 183, 231]. 
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Moreover, deregulated B-cell hyperactivity, expressed by the presence of anti-SSA and anti-
SSB autoantibodies, hypergammaglobulinemia and cryoglobulinemia, is a common finding in 
SS patients. Other autoantibodies found in 50% of SS patients include autoantibodies 
against muscarinic M3 receptors that can induce decreased secretory function. This category 
is associated with increased morbidity and risk for lymphoma development [24, 25]. The 
expression of lymphoid chemokines significantly increases, together with the production of B 
cell survival factors, in patients with SS as they develop Mucosal Associated Lymphoid 
Tissue (MALT) lymphoma [18, 236].  
Sjogren’s Syndrome: Genetic factors 
The high incidence of autoimmune diseases in families of patients with SS is supportive of a 
genetic predilection to the disease. Alleles of HLA-DR and HLA-DQ, which are a region 
within the major histocompatibility complex (MHC) class II gene, are implicated in the 
pathogenesis of SS. Patients of diverse ethnic origin that carry different HLA susceptibility 
alleles. Patients from North America and from Northern and Western Europe show a high 
prevalence of B8, DRw52 and DR3 genes whereas Greek and Scandinavian patients with 
SS display strong linkages to the DR5 and DR2 genes. However, it has been shown that 
these HLA class II alleles are associated with the presence of specific subtypes of 
autoantibodies rather than the disease itself. For instance, presence of the MHC class II 
alleles DRB1*0301, DRB1*0201 and DRB1*0501 is linked with production of anti-Ro52 
autoantibodies [23, 24, 26]. 
Genome-wide association studies (GWAS) in patients with SS have highlighted several other 
gene polymorphisms of genes outside the HLA locus. These include IRF5 and STAT4, 
pivotal genes that encode transcription factors involved in IFN pathways. One study has 
confirmed the genetic association of IRF5 rs2004640 T allele with predisposition to develop 
SS and in another study it revealed a correlation between development of SS and in SNP 
rs10488631 within IRF5 gene and SNP rs7582694 within STAT4 gene. Moreover, studies at 
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both glandular and systemic levels have demonstrated the presence of type1 IFN and IFN-
producing cells in salivary glands of patients with SS, activation of IFN pathways in PBMCs 
of these patients. Furthermore, the IFN signature is enhanced in patients with autoantibodies 
and suggests a relationship between IFN pathways and B-cell activation. Overall, these 
findings suggest that a genetic susceptibility favouring a higher interferon (IFN) response to 
different stimuli (classically stimulated by infectious agents such a viruses) could be a key 
event in the onset of the disease [23, 24, 26]. 
Sjogren’s Syndrome: Hormonal factors 
SS is predominantly observed in postmenopausal women, and moreover, results from 
several experimental mouse models have indicated a role for estrogen deficiency in SS. 
Mice, that lack aromatase and therefore have deficiency in estrogen, develop a 
lymphoproliferative disease that resembles SS. In another mouse model, overexpression of 
retinoblastoma-associated protein 48 (also known as histone binding protein RBBP4) in the 
exocrine glands, induced estrogen-deficiency-dependent apoptosis which resulted in an age-
dependent SS-like autoimmune exocrinopathy. Further analysis revealed that the salivary 
gland epithelial cells in these transgenic mice functioned as antigen-presenting cells that 
directly up-regulated MHC class II molecules expression, secreted IL-18 and IFNγ and hence 
led to CD4+ T cell activation and glandular inflammation. These findings strongly indicate 
that estrogen deficiency could stimulate epithelial cells via up-regulation of RBBF4, to 
present an autoantigen to T cells in order to perpetuate disease pathogenesis and induce 
lesions observed in SS [23-25]. 
Infection and Sjogren’s Syndrome 
A number of infectious agents have been implicated in the initiation and pathogenesis of SS. 
Diseases and pathogens that may drive SS include tuberculosis, leprosy, hepatitis C, dengue 
fever, malaria, subacute bacterial endocarditis, HIV, infections by parvovirus B19 and 
spirochetes. Certain viruses display tropism for lacrimal and salivary glandular tissue, 
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especially the Herpesviridae family, which is a large family of DNA viruses that include 
Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human herpes virus (HHV). 
Furthermore, several serological, epidemiological and experimental pieces of evidence 
incriminate retroviral infections- especially human T-lymphotropic virus type 1 (HTLV-1), HIV 
and human retrovirus-5 (HRV-5) - as triggering factors for the development of SS. Although a 
number of viruses have been implicated in SS, the evidence is circumstantial and not 
conclusive in regard to their exact role in the disease. It has been suggested that cryptic 
antigens displayed on the cellular surface of the glandular epithelium upon virus-mediated 
infection in the association with the aberrant class II MHC expression, by same epithelial 
cells, play a key role favouring the activation of self-reacting lymphocytes and perpetuating 
the inflammatory process. The presence of molecular memory between viral antigens and 
self-epitopes has been widely supported [23, 24, 26, 28]. 
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1.6 Cannulation model of salivary gland inflammation 
To address the aims and objectives of this thesis we will validate and utilize a new transient 
mice model of salivary gland inflammation established in Prof. Pitzalis’s lab by Dr. Francesca 
Barone and Dr Michele Bombardieri. In this mice model we can induce salivary gland 
inflammation in wild-type animals, in response to selective submandibular gland 
administration of a replication-defective adenovirus 5 (AdV5) [237]. The replication deficient 
AdV5, encoding for the firefly luciferase gene (LucAdV) is administered into the 
submandibular salivary glands using customised glass cannulae via the excretory duct. 
Using this technique of cannulation preliminary experiments showed that increasing 
luciferase activity was observed using increasing doses of LucAdV within the first week post-
cannulation (p.c.), which then decreased over the next two weeks (Fig 1.6.1). Histological 
analysis of the cannulated glands demonstrated that AdV doses of 10^8 pfu per gland, but 
not vehicle control (or doses <10^7 pfu, data not shown), induced the formation of periductal 
inflammatory infiltrates organized as TLOs (Fig 1.6.2), similar to human SS, with evidence of 
ectopic expression of lymphoid chemokines and functional B cell activation, that 
spontaneously resolves with virus clearance. Importantly, not only AdV5 infection reproduces 
the phenotypic features of SS, but also functionally leads to the development of humoral 
autoimmunity to nuclear antigens and decrease in salivary flow [237]. Thus, this novel model 
offers the unique possibility to dissect the cellular and molecular mechanisms regulating TLO 
formation during inflammation. 
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Figure 1.6.1 Representative dose-response time-course 
experiments of luciferase activity following delivery of 
LucAdV at 10^6, 10^7 and 10^8pfu/gland and vehicle 
control showing dose-dependent enzymatic activity within 
the first week. Dose dependency is lost at week 2 and 3 
despite persistent transgene expression. 
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Figure 1.6.2 Representative microphotographs showing inflammatory responses induced by local 
administration of either vehicle (A-C), LucAdV (D-F). After AdV delivery, diffuse lymphomonocytic 
infiltration in the first week (D) is followed by progressive organization of periductal inflammatory 
aggregates during week 2 (E) and week 3 pc (F). Vehicle delivery induces negligible inflammation (A-
C).  
The mean ± SEM of the number of periductal foci/gland following LucAdV delivery at different time 
points is reported in G. (**p<0.01 between AdV and vehicle-treated mice at each time point, minimum 
of 10 mice per time point). 
High sensitivity luciferase activity assay in LucAdV-infected glands shows persistent signal well above 
background levels up to three weeks pc (K, mean ± SEM of luciferase activity. Original magnification 
in A-F x100. (***p<0.001 between AdV-treated and vehicle-treated mice at each time point, minimum 
of 10 mice per time point). 
Quantitative TaqMan real-time PCR time-course analysis of CCL19 (I) CXCL13 (J), and AID (K) 
mRNA transcripts showing abundant up-regulation following AdV-delivery in the submandibular 
glands. Data are expressed as mean ± SEM of the fold-increase compared to an internal calibrator. 
(*p<0.05, **p<0.01 and ***p<0.001 between AdV-treated and vehicle-treated mice at each time point, 
minimum of 10 mice per time point). 
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1.7 Aims and Objectives of Thesis 
Lymphoid stromal cell activation and maturation is crucial for the development of SLOs. 
Stromal cells not only provide the structural framework for immune cells to mount an effective 
immune response but they also actively direct the course of the inflammatory process that 
takes place within SLOs.  
The formation of tertiary lymphoid organs (TLOs), defined as aggregates of lymphoid cells, 
developing ectopically in non-lymphoid locations, characterized by B/T cell segregation, 
differentiation of high endothelial venules (HEV), and development of follicular dendritic 
cells (FDC) networks, supporting a germinal centre response, is a common histological 
feature associated with autoimmunity, chronic inflammation and cancer [14]. This ectopic 
lymphoid organization of immune cells is accompanied by the production of lymphoid 
chemokines and cytokines, responsible for leukocyte organization and survival. 
Interestingly, many of these factors detected within lymphoid structures are derived from 
non-hematopoietic stromal cells [222]. This suggests that stromal cell activation is critically 
important for the maintenance and organization of tertiary lymphoid organs in inflammatory 
conditions.  
However, relatively little is known about the structure and function of stromal cells in TLOs. 
gp38 or podoplanin expressed on stromal cells in secondary lymphoid organs has recently 
been utilized to identify and isolate activated stromal cells at sites of transient inflammation, 
autoimmunity and cancer. These gp38+ stromal cells secrete and bind soluble factors 
similar to their lymhoid organ counterparts suggesting that inflammation “ recapitulates the 
ontegeny of lymphoid stromal cells” [226]. Of late, effector cytokines such as IL-17 have 
been shown to directly stimulate the expression of lymphoid chemokines in stromal cells at 
sites of TLO formation [214]. Nonetheless, the signals that drive the aquisition of a lymphoid 
phenotype by tissue-resident stromal cells, and differences in the degree of stromal cell 
activation during TLO compared to SLO formation, remain contentious.  
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Hypothesis 
Stromal cells, at the site of TLO development during an inflammatory process, undergo 
dramatic changes in order to acquire phenotypic and functional features that resemble 
lymphoid stromal cells. We propose that distinct signals are involved in the induction, 
proliferation and maintenance of these lymphoid like stromal cells in a dynamic 
model of TLO formation. 
Aims of the thesis 
1. To examine the dynamic changes occurring in the stromal component during TLO 
formation in a resolving model of salivary gland inflammation.  
2. Identify signal/s that regulate(s) lymphoid stromal cell activation at different phases of 
the inflammatory process using knockout and cytokine blocking strategy. 
Plan of Investigation 
We planned to perform the following set of experiments: 
 Validation of the model of TLO formation during salivary gland inflammation by 
adenoviral cannulation and identification of the different stages of the inflammatory 
process in a detailed time course analysis.  
 Phenotypical and functional characterization of lymphoid stromal cells in inflamed 
salivary glands at different phases of the inflammatory process, by using 
immunofluorescence (IF), flow cytometry and quantitative RT-PCR in tissue isolated 
from WT, KO and mice challenged with blocking agents.  
 Phenotypical and functional analysis of the effect of lymphocyte interactions on 
stromal cell induction, maturation and maintenance by using KO mice for lymphocyte, 
lymphocyte-derived factors or blocking antibody experiments. 
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Chapter 2 
Materials and Methods 
2.1 Mice  
il4rαko [238], il4ko [239], il13ko [240], il22ko (generated at Lexicon Genetics in collaboration 
with Pfizer, Boston), il22rαko (sourced from EMMA (European Mouse Mutant Archive) 
Sanger Center, UK), rorγko [33], ltβrko [22], ragko [241] , cd3εtg26 [242] and b-cell knockout 
(ko) mice (generated from breeding out the QM IgH transgene from QM mice, which have 
the other IgH locus inactivated) [243, 244], were bred in the Biomedical Service Unit (BMSU) 
at the University of Birmingham. c57bl/6 mice were from external supplier Harlan and balb/c 
mice were from an internal colony of BMSU. All mice were maintained under specific 
pathogen-free conditions in the Biomedical Service Unit at the University of Birmingham 
according to Home Office and local ethics committee regulations. All mice used were 8-12 
weeks old. 
il13gfp bone-marrow chimera experiments were performed at University of York in 
collaboration with Dr. Mark Coles. c57bl/6 mice were irradiated with two doses of 475 rad 
and were reconstituted with bone-marrow cells from il13gfp mice [245]. The il13gfp mice had 
the il13 gene locus replaced (knocked-in) with the gfp gene [245], and therefore, these mice 
not only help track il13 producing cells but also serve as il13ko mice. All il13gfp bone-marrow 
chimera mice were maintained under specific pathogen-free conditions in the Biomedical 
Service Unit at the University of York according to Home Office and local ethics committee 
regulations.  
2.2 Virus preparation and salivary gland cannulation 
Concentrated stocks of E1-E3 replication-deficient human AdV5 (adenovirus serotype 5) 
encoding for firefly luciferase (LucAdV) (obtained from our collaborator Dr. Michele 
Bombardieri at Queen Mary University of London [237], were used to produce bulk amount of 
viral particles. Hek293 cells were infected with the concentrated stock of AdV5. The AdV5 
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infected Hek293 cells were then subjected to freeze-thaw cycles three times to ensure lysis 
of infected cells and release of virus particles in the supernatant. This supernatant was 
centrifuged to get a supernatant with only virus particles and clear off any cell debris. The 
virus particles in the supernatant were purified using a discontinuous CsCl gradient. Finally, 
AdV particles  were transferred into a Slide-a-lyzer dialysis cassette (Slide-A-Lyzer 3.5K 
MWCO, Thermo Scientific) and dialyzed overnight against a solution consisting of 1 mM 
MgCl2, 10 mM Tris (pH 7.4), and 150 mM NaCl with 10% glycerol (vol/vol)[237]. AdV 
particles collected from dialysis cassette were titrated using the BD ClontechTM Adeno-X 
Rapid Titre Kit (Clontech Laboratories.inc) as per manufacturer’s instructions. In brief serial 
dilutions of the AdV solution was prepared and seeded with Hek293 cells in a 12 well culture 
plate, incubated for 48 hours at 370C. On day 3, cells are fixed and stained with a HRP- 
conjugated AdV specific antibody followed by staining with DAB, a chromogenic substrate for 
HRP. The infected cells turned brown in contrast to infected cells. The numbers of infected 
cells were counted in a given area and the titre was determined using a formula as per to 
manufacturer’s instructions.  
Retrograde mouse submandibular salivary gland cannulation was performed, as described in 
[237]. Briefly, mice were anaesthetized with ketamine (76mg/kg) and domitor (1mg/kg) (i.p.). 
Mice were also injected subcutaneously with analgesia Buprenorephine (0.03mg/kg). Then 
the submandibular salivary glands of the mice were cannulated (Figure 2.2.1) via the 
excretory duct using heat-drawn glass gas chromatography tubing (0.1 mm internal diameter; 
Sigma Aldrich). Approximately 30 μl of adenovirus solution, corresponding to 1×108-1×109  
pfu of luciferase reporter-encoding AdV5, was injected into the salivary gland using an 
attached Hamilton syringe (Sigma Aldrich) [237]. After cannulation procedure, mice were 
then recovered with atipamezole at a dose of 0.15mg/mouse (s.c.). 
Blood was obtained by performing cardiac puncture on mice under anesthesia (Isoflurane) 
and then these mice were sacrificed with terminal anesthesia (Euthal) after 3 hours, or at day 
2, 5, 8, 15 and 23, post-cannulation (p.c.). Salivary glands were dissected from these mice.  
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In-vivo stimulation of salivary glands with recombinant cytokines and IL-22 blocking 
2ug/ml of recombinant cytokine/s in PBS or PBS (Table 2.1A) was directly cannulated into 
the submandibular glands of anaesthetized female c57bl/6 mice (8-12 weeks old). Glands 
were harvested 48 hours p.c.  
Rat anti mouse IL22 Ab-03 and Rat IgG2a isotype antibody was obtained from Pfizer, Boston 
and used as previously described [17]. Briefly, starting at either day 2 or day 8 post-
cannulation mice were administered a dose of 200ug of anti-IL22 antibody via i.p injection 
followed by subsequent injections at the same dose at a frequency of three times per week. 
Anti-IL22 treated and untreated matched control mice were taken for analysis at indicated 
time-points.  
Sample processing 
Submandibular glands from cannulated mice were harvested at designated/various time-
points. Every gland was split for histology, stromal digestion, evaluation of the mRNA levels 
of molecules of interest and a very tiny piece to test luciferase activity. 
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Figure 2.2.1 
 
 
  
 
Figure 2.2.1 AdV delivery via retrograde mouse submandibular gland excretory duct 
cannulation. (A-B) A glass cannula is inserted in the excretory orifice of the submandibular 
gland of a 12 weeks-old c57bl/6 mouse. (C) Representative picture of a cannulated NOD 
mouse demonstrating that delivery of 50μl of bromophenol blue dye is sufficient to permeate 
the cannulated submandibular gland with no spillage to the contralateral gland or the 
adjacent sublingual gland (arrow). (D) Expression of luciferase activity (normalised to protein 
levels) in pieces of tissue taken from cannulated glands infused with AdV containing the 
luciferase transgene [237].   
 
Table 2.1 Reagents used for the in vivo cytokine cannulation experiments 
 
Recombinant 
cytokine/PBS 
Clone/Catalogue 
number 
Supplier 
IL-4 214-14 Peprotech 
IL-13 210-13 Peprotech 
IL-22 210-22 Peprotech 
LTβR agonist 
antibody 
clone 4H8 Novus Biologicals 
TNFα 315-01A Peprotech 
Dulbecco’s 
Phosphate 
Buffered Saline  
D5652 Sigma-Aldrich 
 
 
 
 
3h  2   5   8  15  18 20 23 26 control 
  days p.c. 
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2.3 Luciferase Assay 
At the time of dissection, a small portion of AdV cannulated salivary gland was stored in 50μL 
of RNAlaterR (Life Technologies Corporation) at ‐200C. This tissue was processed to 
quantify the degree of viral infection in the salivary gland. Samples were thawed and salivary 
gland pieces removed from RNAlaterR. These salivary gland pieces were transferred into 
bijous containing 350μL of GloLysis Buffer (Promega Corporation) and homogenised. 
Homogenised cell suspensions were centrifuged at 1300rpm for 10 minutes to sediment the 
cell debris and leave a supernatant. 25μL of the supernatant was the transferred in triplicates 
to a flat-bottomed, 96-well plate. 25μL of Luciferase substrate (Promega Corporation) was 
added to each well and incubated for 5 minutes. The Luciferase activity was determined 
using Berthold Technologies CentroLB 960 with MikroWin 2000 software. 
2.4 Histology 
Tissue processing and sectioning 
Salivary glands from cannulated and control mice were dissected, snap-frozen in OCT over 
liquid nitrogen. All tissues were then stored in −80 °C until use. Six-seven microns sections 
were obtained by cutting the specimens in a cryostat (Bright) and mounted on X-tra Adhesive 
glass slides (Leica). Salivary gland sections were taken from the cutting level at which 
cellular infiltration was detected by Toluidine blue staining. Slides were left overnight at room 
temperature to dry. The next day, slides were stored in slide boxes at −80 °C until required.  
Immunofluorescence (IF) Staining 
Prior to staining, each slide was allowed to come to room temperature and then fixed for 20 
minutes in ice-cold acetone; slides were then left to dry for at least 30 minutes and hydrated 
in PBS. For immunofluorescence staining, all dilutions of reagents and antibodies were made 
in PBS with 1% BSA (Sigma Aldrich) and slides were always incubated in a humid chamber 
in the dark. Firstly, to block endogenous biotin, sections were treated with 0.05% Avidin 
(Sigma Aldrich) and then 0.005% Biotin (Sigma Aldrich) for 15 minutes each. The slides were 
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washed for 5 minutes with PBS in between the two incubations. Following avidin-biotin 
blocking step, the sections were treated with 10% horse serum solution for 10 minutes to 
prevent non-specific staining by blocking Fc receptors. Excess horse serum was removed 
from the slides and sections were then incubated with primary antibodies for one hour, and 
then washed for 10 minutes with PBS. Wherever relevant, sections were then stained with 
sequential secondary, tertiary and quaternary antibodies for 30 minutes each. After each 
incubation, slides were washed for 10 minutes in PBS. All secondary, tertiary and secondary 
antibodies were pre-adsorbed in 100ul of 10% mouse serum for 30 minutes prior to their use. 
Finally, after the final incubation, slides were mounted with Prolong Gold (Invitrogen) and 
stored in -800C until acquisition of images. 
Image acquisition  
Images were acquired on a Zeiss LSM 510 laser scanning confocal head with a Zeiss Axio 
Imager Z1 microscope. Digital images were recorded in four separately scanned channels 
with no overlap in detection of emissions from the respective fluorochromes. Confocal 
micrographs were stored as digital arrays of 1024×1024 or 2048×2048 pixels with 8-bit 
sensitivity; detectors were routinely set so that intensities in each channel spanned the 0-255 
scale optimally. The LSM510 Image Examiner Software was used to process these images. 
Leica DM6000 Fluorescent Microscope was used to obtain tile scans for the whole salivary 
gland section in order to perform fraction area analysis (as described in image analysis 
section). 
Image analysis 
Fraction area analysis 
In order to assess the dimension of lymphocytic aggregates and the degree of lymphoid 
organization in cannulated salivary glands over a time-course, fraction area analysis system 
was used. For this analysis system we used CD3 and CD19 for identifying T cells and B cells 
respectively. CD3/CD19 double stained slides were analysed on Leica DM6000 Fluorescent 
66 
 
Microscope and tile scans for the whole salivary gland section were taken (Figure 2.4.1). A 
region around the aggregates was manually drawn on the electronic pictures in the ImageJ 
software, and then both, the area of the aggregates and the area for the whole tissue 
section, were determined using the software. This numerical data was used to calculate the 
size of the aggregates i.e. the ratio of the aggregate area to the total tissue area, expressed 
in percentage. Thus, size of the aggregates was calculated as percentage of total tissue area 
(fraction area analysis).  
On the basis of CD3/CD19 double staining, we also counted foci that were segregated (i.e. 
aggregates in which T and B cells are organised in separate areas) as an indicator of 
lymphoid organization. Single images (Figure 2.4.1) were acquired for all lymphoid follicles 
observed in the tile scans to calculate the size of lymphoid follicle size, the numerical data 
was expressed as µm2.  All measurements were performed in a masked fashion by 
observers in a blinded manner. 
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Figure 2.4.1 Example of a tile scan taken to study T cell (green) and B cell 
(blue) infiltration  virus infected salivary gland at day 15 p.c. 
CD3/CD19 day 15 p.c. 
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Quantitation of T and B cell densities 
CD3/CD19 double stained slides were visualized on LSM510 confocal microscope (Zeiss, 
Germany) and images taken using Zeiss LSM image software (Zeiss). Image of T/B cell 
infiltrates, indicated by CD3 and CD19 positive staining respectively, were acquired and this 
was repeated in several fields of view, covering the whole tissue section. Images were 
processed in the ImageJ software. A binary histogram was created by thresholding the red 
colour of CD3 (T cell) staining and blue colour of CD19 (B cell) staining respectively, and a 
threshold was chosen, based on the staining intensity. Using the histogram, the software 
estimated the area positive for the staining and it calculated the volume fraction area 
between the staining positive and negative areas. This value was used to determine the T 
and B cell densities for each image. The data was plotted as a ratio of B/T cell. All 
measurements were performed in a masked fashion by two observers. 
Quantitation of gp38 and CD4 immunostaining 
CD4/gp38 double stained slides were visualized on LSM510 confocal microscope and 
images taken using Zeiss LSM image software. Image of the aggregate indicated with CD4 
and its underlying gp38+ stromal cells were acquired and this was repeated in several fields 
of view, covering the whole tissue section. The LSM510 Image Examiner Software was used 
to analyze the images. A region around aggregate was drawn, its area was determined  and 
pixels count for gp38 and CD4 channel is calculated by the software. Correlation analysis 
between gp38 (no. of pixels/unit area) and CD4 (no. of pixels/ unit area) was then performed. 
All measurements were performed in a masked fashion. 
Antinuclear antibodies (ANA) Detection 
Hep-2 slides (IMMCO Diagnostics) were taken and were washed in PBS. Animal sera, 
obtained from spinning whole blood at 13000 r.p.m., and isolating the non-corpuscular 
component, was diluted in PBS (1:80) and deposited on each well. WT and KO mice sera 
were incubated for 1 h at room temperature, washed twice in PBS, and incubated with FITC 
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anti-mouse IgG (Sigma, Poole, U.K.) for 30 min in the dark. Slides were washed twice in 
PBS, mounted, and observed at fluorescence microscope for ANA staining. 
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Table 2.4.1 Primary Antibodies used for Confocal Microscopy 
Antibody Clone Format Supplier Dilution Used 
Hamster anti-
mouse gp38 
8.1.1 unconjugated In house 1:10 
Goat anti-mouse 
CXCL13 
AF470 unconjugated R&D Systems 1:100 
Goat anti-mouse 
CCL21 
AF457 unconjugated R&D Systems 1:100 
Hamster anti-
mouse CD3e 
eBio500A2 
(500A2) 
biotin ebiosciences 1:50 
Rat anti-
mouse/human 
B220 
RA3-6B2 eFluor450 ebiosciences 1:50 
Rat anti-mouse 
CD19 
eBio1D3 (1D3) eFluor660 ebiosciences 1:50 
Rat anti-mouse 
CD19 
eBio1D3 (1D3) Alexa-Fluor647 ebiosciences 1:50 
Rat anti-mouse 
CD31 
390 FITC ebiosciences 1:100 
Rat anti-mouse 
CD21/CD35 
eBio4E3 (4E3) FITC BD biosciences 1:50 
Hamster anti-
mouse CD11c 
biotin 
N418 biotin ebiosciences 1:50 
Rat anti-mouse 
IL-22Rα 
MAB4294 unconjugated R&D Systems 1:50 
Rat anti-
mouse/human 
RORγt 
AFKJS-9 unconjugated ebiosciences 1:20 
Rat anti-mouse 
IL-7Rα 
A7R34 Alexa-Fluor647 ebiosciences 1:20 
Rat anti-mouse 
CD4 
RM4-5 Alexa-Fluor647 ebiosciences 1:200 
Rat anti-mouse 
FDCM1 
FDCM1  unconjugated BD biosciences 1:50 
Rat anti-mouse 
EpCAM 
G8.8 APC ebiosciences 1:50 
Rat anti-mouse 
CD8α 
53-6.7 PE/ biotin ebiosciences 1:50 
Rat anti-mouse 
CD11b 
MCA74G unconjugated AbD Serotech 1:100 
Rat anti-mouse 
Gr1 
RB6-8C5 biotin AbD Serotech 1:100 
Rat anti-mouse 
F4/80 
MCA497G unconjugated AbD Serotech 1:100 
Rat anti-mouse 
PNAd 
MECA-79 unconjugated BD biosciences 1:50 
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             Table 2.4.2 Secondary Antibodies used for Confocal Microscopy 
Antibody Format Supplier Dilution Used 
Goat anti-hamster biotin Biolegend 1:100 
Goat anti-rabbit 
FITC 
Alexa-Fluor488 Invitrogen 1:100 
Rabbit anti-FITC unconjugated Invitrogen 1:200 
Goat anti-mouse 
IgG 
FITC Southern Biotech 1:100 
Donkey anti-goat FITC 
Jackson 
Immunoresearch 
Laboratoies Inc. 
1:100 
Donkey anti-rabbit Alexa-Fluor647 
 
Invitrogen 
1:100 
Goat anti-rat IgG Alexa-Fluor546 Invitrogen 1:100 
Donkey anti-rat 
IgG 
FITC Southern Biotech 1:100 
Goat anti-rat IgM Alexa-Fluor594 Invitrogen 1:100 
Goat anti-gfp FITC Abcam 1:50 
Streptavidin 555 555 Invitrogen 1:500 
Streptavidin 647 647 Invitrogen 1:300 
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2.5 Flow cytometry 
Isolation of stromal cells  
Harvested salivary glands from mice were cut into small pieces and digested for 40 min at 
370C with gentle stirring in 1.5 ml RPMI 1640 (Sigma Aldrich) medium containing 
collagenase D (3.7 mg/ml; from Roche), DNAse I (30ug/ml; from Sigma Aldrich) and 2% 
(vol/vol) FCS. The suspension was gently pipetted at 15min intervals to break up aggregates. 
The remaining fragments were further digested for 20 min at 37 °C with medium containing 
collagenase dispase (3.7 mg/ml; from Roche) and DNAse I (30ug/ml). The suspension was 
then gently pipetted to break up remaining aggregates until no visible fragments remained. 
During the final pipetting, EDTA (Sigma Aldrich) was added to a final concentration of 5 mM 
to further reduce cell aggregates. Cells were then passed through a 70-um mesh, were 
washed twice and were re-suspended in RPMI 1640 medium containing 10% (vol/vol) FCS.  
Isolation of leukocytes  
Cannulated salivary glands were harvested and chopped into small pieces and digested for 
20 min at 370C with gentle stirring in 2 ml RPMI 1640 medium, containing collagenase 
dispase (250ug/ml; from Roche), DNAse I (25ug/ml; from Sigma) and 2% (vol/vol) FCS. The 
suspension was gently pipetted to break up aggregates. During the final pipetting, EDTA was 
added to a final concentration of 10mM to further reduce cell aggregates. Cells were then 
passed through a 70-um mesh with a syringe, were washed twice and re-suspended in 
MACS buffer and kept on ice until staining. 
In-vitro stimulation for cytokine production 
Isolated leukocyte or stromal cells were re-suspended in DMEM (with 10% FCS, 1%GPS, 
1% NEAA, 1%HEPES and 50µM β-mercaptoethanol) for in vitro stimulation culture and were 
incubated with 50ng/ml PMA (Phorbol 12 Myristate 13 Acetate), 750ng/ml Inonomycin, 
10ug/ml BrefeldinA (all from SIGMA), 10ul of 108-109 pfu of adenovirus for 4 h at 37°C. 
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10ug/ml recombinant IL-23 (Biolegend) was also added to the stimulation media for 
intracellular IL-22 cytokine assay. 
Flow cytometric staining and analysis 
Single cells suspensions were stained for 30 minutes in PBS (with 0.5% BSA and 2Mm 
EDTA) with desired ‘cocktails’ of antibodies indicated in Table 3.2. 
Intracellular staining for cytokine production was performed (BD Cytofix/Cytoperm) according 
to the manufacturer’s protocol. In brief, following surface staining with cocktails of desired 
antibodies, cells were washed in PBS (with 0.5% BSA and 2Mm EDTA), re-suspended in 
150 µl Cytofix/Cytoperm (BD Pharmingen) and incubated overnight at 4°C. Cells were 
washed twice with the BD Perm/Wash Buffer, and subsequently, intra-cellular cytokine 
antibody was added and incubated at 4°C for 30–40 minutes. Afterwards, cells were washed 
twice, re-suspended in MAC buffer.  
Data was acquired using a Cyan-ADP (Dako) with forward/side scatter gates set to exclude 
non-viable cells. Data were analyzed with FlowJo software (Tree Star).  
For cell sorting, stained cells were sorted using MoFlo-XDP (Beckman Coulter Inc). The 
purity of sorted stromal populations routinely exceeded 96%. Gating strategy for stromal cell 
sorting is shown in (Figure 2.5.1). 
In vitro stimulation of sorted stromal cells with recombinant cytokines  
Isolated stromal cells subsets were re-suspended at the same cell density in 500µl of DMEM 
(with 10% FCS, 1%GPS, 1% NEAA, 1%HEPES and 50µM β-mercaptoethanol) for in vitro 
cytokine stimulation assay in 48 well plates. All recombinant cytokines were reconstituted in 
DPBS (Sigma Aldrich). Cells were then incubated with 2ug/ml of recombinant IL-22 
(Peprotech) alone, 2ug/ml LTβR agonist antibody (Novus Biologicals) plus 500ng/ml 
recombinant TNFα (Peprotech), 2ug/ml IL-22ug/ml plus LTβR agonist antibody plus 
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500ng/ml TNFα or only DPBS (Sigma Aldrich)  for 24 hours at 37°C. Cells were harvested 
after 24 hours and taken for quantitative PCR analysis. 
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Figure 2.5.1 
 
Sorting Strategy 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.1 Gating strategy for different stromal cell subset analysis and sorting. The 
cells from the forward scatter and side scatter gate were plotted with CD45 against EPCAM, 
this allowed exclusion of CD45 hematopoietic cells and enrichement of CD45-EPCAM+ 
(epithelial) cells as well as the CD45-EPCAM- l cell component (consisting of endothelial 
cells and non-hematopoiteic, non-epithelial, non-endothelial stromal cells). Further gating of 
the CD45-EPCAM- cells with gp38 (stromal and lymphatic cell marker) and CD31 
(endothelial cell marker) allowed us to identify gp38+CD31- lymphoid like stromal cells 
(LLSc) and gp38-CD31- double negative (DN) cells. The graphs show gene expression 
analysis for CD45, EPCAM, CD31 and gp38 in the three stromal subsets post-sorting, to 
confirm purity of the sort.  
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Table 2.5.1 List of Antibodies used for Flow Cytometry 
Antibody 
specificity 
Isotype Clone Format Supplier 
Dilution 
used 
CD45 (all 
isoforms) 
LCA, Ly-5 
Rat IgG2b 30-F11 
PERCPCy5.5/ 
PECy7/ 
APC-Cy7 
ebiosciences 
1:200/1:500/ 
1:800 
Podoplanin (gp38) 
Hamster 
IgG 
ebio8.1.1 PE ebiosciences 1:50 
CD31 (PECAM-1) Rat IgG2a 390 FITC/PECy7 ebiosciences 1:50 
CD326 (EpCAM) Rat IgG2b G8.8 PECy7 ebiosciences 1:200 
ICAM-1 Rat IgG2b YN1/1.7.4 APC Biolegend 1:200 
VCAM-1 Rat IgG2a 
429 
(MVCAM.A) 
PERCPCy5.5 Biolegend 1:50 
RANKL Rat IgG2a IK22/5 Biotin Biolegend 1:50 
MadCAM-1 Rat IgG2a MECA-367 Biotin Biolegend 1:50 
IL-22Rα Rat IgG2a FAB42941A APC R&D Systems 1:50 
Ki67 
Mouse 
IgG1 
B56 
Alexa-
Fluor647 
BD 
biosciences 
1:50 
BrdU 
Mouse 
IgG1 
3D4 
Alexa-
Fluor647 
BD 
biosciences 
1:50 
CD3e 
Hamster 
IgG 
145-2C11 PECy7 
BD 
biosciences 
1:100 
B220 (CD45R) Rat IgG2a RA3-6B2 APCCy7 
BD 
biosciences 
1:100 
CD4 Rat IgG2a RM4-5 efluor 450 ebiosciences 1:50 
CD8α Rat IgG2a 53-6.7 PE-TexasRed 
BD 
biosciences 
1:200 
CD62L Rat IgG2a MEL-14 PE ebiosciences 1:100 
CD44 Rat IgG2b IM7 FITC ebiosciences 1:100 
CD19 Rat IgG2a eBio1D3 (1D3) APC ebiosciences 1:100 
NK1.1 Rat IgG2a 
 
   PK136  
 
FITC ebiosciences 1:50 
CD11b Rat IgG2b M1/70 PERCPCy5.5 ebiosciences 1:200 
Gr1 Rat IgG2b RB6-8C5 FITC ebiosciences 1:50 
CD11c 
Hamster 
IgG 
N418 PE/PECy7 ebiosciences 1:100 
IL-7Rα Rat IgG2a 
A7R34 
 
Alexa-
Fluor647 
ebiosciences 1:50 
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2.6 Enzyme-linked immunosorbent assay (ELISA) 
Relative virus-specific serum antibody titres were evaluated by ELISA (protocol adapted from 
Ruth Elizabeth Coughlan, Prof. Adam Cunningham’s Lab at University of Birmingham). 
Peripheral blood obtained by cardiac puncture from wt and gene knockout mice at specified 
time-points, post cannulation, was allowed to clot at room temperature and serum was 
separated from corpuscular component by spinning at 13000 r.p.m for 10 minutes. Sera were 
aliquoted and frozen at -200C until further use. To measure for viral-specific antibody titre, the 
AdV solution (that is used to cannulate mice) was used to coat ELISA plates (MaxiSorp 
plates, Nunc) at 5µg/ml in coating buffer (1 capsule of Sigma carbonate-bicarbonate buffer 
/100mldH2O). After an overnight incubation at 4
0C, plates were washed three times with PBS 
and blocked with 100µl of PBS/1% BSA for 1 hour at 370C, to prevent non-specific binding in 
subsequent steps. Post incubation, plates were washed again three times with PBS. Sera 
were diluted at 1:20 ratio in PBS/1% BSA/0.05%Tween 20 and added to the first row of the 
96 well ELISA plate. For each of the samples further four-fold serial dilutions in PBS/1% 
BSA/0.05%Tween 20 were prepared in each column and then the plate was incubated for 1 
hour at 37°C followed by three times washing with PBS. AP-conjugated goat anti-mouse IgM 
and IgG secondary antibodies (all from Southern Biotechnology) diluted at 1:1000 in PBS/1% 
BSA/0.05%Tween 20, were added to the appropriate wells, and incubated for 1 hour at 370C. 
Plates were then washed three times with PBS. Antibodies were detected using Sigma fast 
p-Nitrophenyl phosphate solution (prepared using manufacturer’s instructions). 100µl of 
substrate was added to each well and incubated at 370C until the desired positivity was 
obtained. Optical densities (O.D.) values at 405nm were obtained using the softmax Pro 
programme. Relative antibody titres for each sample were obtained by plotting the dilution 
against the O.D. values and then taking the dilution at which the O.D. value was set in the 
mid-exponential phase of the curve. 
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2.7 Quantitative Real-Time Polymerase Chain Reaction  
Extraction of total RNA from mouse tissues  
Samples of cannulated salivary glands for RNA extraction were obtained by tissue sectioning 
at the cutting level, which showed infiltration detected by Toluidine blue staining. Briefly, after 
cryosectioning tissues for histology, a further five 25 microns thick tissue sections were taken 
and transferred in a RNAase-free tube for each sample, which were stored at -80ºC until 
further use. RNA was extracted using the Qiagen RNeasy mini kit, according to 
manufacturer’s instructions. Tissues stored at -80°C were defrosted on ice, and 200ul of RLT 
buffer (containing 10ul of β-Mercaptethanol/ ml of buffer) were added to each tube. The 
tissue lysis was carried out by vortexing each sample tube for at least 30-50 seconds until 
the sample was uniformly homogeneous. Tissue lysates were centrifuged very briefly at 
maximum speed (13000rpm) to collect the sample at the bottom of the tube. An equal 
volume of 70% ethanol was added to the lysate and immediately mixed by pipetting in order 
to precipitate RNA, which remains in the aqueous phase. The sample (400ul) were added to 
the RNeasy mini column placed in a 2 ml collection tube and centrifuged for 1 minute at 
13,000 rpm to allow the RNA to bind to the silica column. The flow-through was discarded, 
and 350 µl of RW1 Buffer were added to the column, centrifuged for 1 minute at 13,000 rpm 
and the flow-through discarded. To avoid any possible DNA contamination, a DNase step 
was included according to manufacturer’ instructions.10 µl of DNAse I stock solution 
(previously prepared by dissolving solid DNase I (1500 Kunitz units) in 550 µl of RNase-free 
water) were added to 70µl of Buffer RDD, gently mixed and added to the RNeasy mini 
column silica-gel membrane. Following 15 min incubation at room temperature (RT), 350 µl 
of Buffer RW1 were added to the column, centrifuged for 1 minute at 13,000 rpm and the 
flow-through discarded. The RNeasy column was transferred into a new 2 ml RNase free 
collection tube. In order to wash away contaminants (residual DNA and proteins) in the 
organic phase, 500 µl of Buffer RPE were placed onto the RNeasy column and centrifuged 
for 1 minute at 13,000 rpm to wash the column. The flow-through was then discarded and 
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another 500 µl Buffer RPE added to the RNeasy column. The tube was centrifuged for 2 min 
at 13,000 rpm to dry the RNeasy silica-gel membrane and the flow-through discarded. To 
eliminate any chance of possible Buffer RPE carryover, the tube was centrifuged again for 1 
min at 13,000 rpm. For elution, the RNeasy column was transferred to a new RNAse free 1.5 
ml collection tube, and 25 µl of RNase-free water were pipetted directly onto the RNeasy 
silica-gel membrane and the tube centrifuged for 1 min at 13,000 rpm. The eluted RNA for 
each sample was immediately frozen at -80°C until required.  
Extraction of total RNA from mouse cells 
Isolated stromal cell subsets were obtained by cell sorting (described in section 2.5). 
Following sorting, cells were centrifuged and cell pellets were stored at -80ºC until further 
use. Prior to RNA extraction cell pellets were thawed and lysed in 350µl buffer RLT (Qiagen). 
Then RNA was extracted from cell lysates using the QiagenRNAeasy Micro Kit following 
manufacturer’s instructions. Cell lysates were centrifuged very briefly at maximum speed 
(13000 r.p.m) to collect the sample at the bottom of the tube. An equal volume of 70% 
ethanol was added to the lysate and immediately mixed by pipetting in order to precipitate 
RNA, which remains in the aqueous phase. The sample (700µl) were added to the RNeasy 
mini column placed in a 2 ml collection tube and centrifuged for 1 minute at 13,000 rpm to 
allow the RNA to bind to the silica column. The flow-through was discarded, and 350 µl of 
RW1 Buffer were added to the column, centrifuged for 1 minute at 13,000 rpm and the flow-
through discarded. To avoid any possible DNA contamination, a DNase step was included 
according to manufacturer’ instructions.10 µl of DNAse I stock solution (previously prepared 
by dissolving solid DNase I (1500 Kunitz units) in 550 µl of RNase-free water) were added to 
70µl of Buffer RDD, gently mixed and added to the RNeasy mini column silica-gel 
membrane. Following 15 min incubation at room temperature (RT), 350 µl of Buffer RW1 
were added to the column, centrifuged for 1 minute at 13,000 rpm and the flow-through 
discarded. The RNeasy column was transferred into a new 2 ml RNase free collection tube. 
In order to wash away contaminants (residual DNA and proteins) in the organic phase, 500 µl 
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of Buffer RPE were placed onto the RNeasy column and centrifuged for 1 minute at 13,000 
rpm to wash the column. The flow-through was discarded and then 500 µl Buffer of 80% 
ethanol was added to the RNeasy column. The tube was centrifuged for 2 min at 13,000 rpm 
to dry the RNeasy silica-gel membrane and the flow-through discarded. To eliminate any 
chance of possible ethanol carryover, the tube was centrifuged again for 1 min at 13,000 
rpm. For elution, the RNeasy column was transferred to a new RNAse free 1.5 ml collection 
tube, and 12.5 µl of RNase-free water were pipetted directly onto the RNeasy silica-gel 
membrane and the tube centrifuged for 1 min at 13,000 rpm. The eluted RNA for each 
sample was immediately frozen at -80°C until required.  
Reverse Transcription PCR and generation of a cDNA template 
In Reverse-Transcription PCR (RT-PCR), complementary DNA (cDNA) is synthesized from 
mRNA using a reverse transcriptase. Reverse transcription was carried out using the High 
capacity reverse transcription cDNA synthesis kit (Applied biosystems) according to the 
manufacturer’s guidelines in a 96 well plate. Briefly, 25ul of total RNA for each sample was 
mixed with 5 ul 10x Buffer, 5ul 10x Random Primers, 2ul 100nM dNTPs, 2.5ul Reverse 
transcriptase enzyme and brought to 50ul volume reaction with DNase/RNase-free water 
After mixing and a brief spin down of the 96 well plate, the reverse transcription to cDNA was 
carried out on Techne 312 Thermal Cycler PCR machine using the following conditions: 25ºC 
for 10 min and 37ºC for 120 min. Finally, the completed cDNA was diluted with 50ul 
DNase/RNase-free water in a 1:1 ratio. The cDNA was then stored at -20ºC until further use. 
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Quantitative Taqman real-time PCR (qPCR) 
Relative expression of the gene of interest was quantified by TaqMan RT-PCR. Reactions 
were carried out in a 384-well optical reaction PCR plate (Applied Biosystems) in a final 
volume of 5.1μl. The reaction mix contained a forward primer, a reverse primer and a probe, 
specific to the gene of interest or the housekeeping gene (β-actin). Already published 
TaqMan probes and primers from Applied Biosystems were used. Primer and probe 
sequences can be viewed in table 2. These were diluted to their optimal pre-determined 
working concentrations. Probes for both the house-keeping and target gene were labelled 
with FAM. 2.8µl of Taqman gene expression master mix (Applied Biosystems) was also 
added to each reaction, along with 2.3µl of cDNA template.  Before running the reaction, the 
plate was sealed using a MicroAmp™ Clear Adhesive Film (Applied Biosystems) and 
centrifuged for 1 min at 350 x g. The quantitative real-time PCR were run in duplicates per 
gene for each sample and detected by the ABI PRISM 7900HT Instrument. The standard 
thermal cycling conditions were used that comprised of a 2 min UNG activation step at 50 ºC, 
a 95 ºC Taq polymerase enzyme activation step for 10 min, and cycles of 95 ºC denaturation 
for 15 sec and 60 ºC anneal/extension for 60 sec. Results were then analysed after 40 cycles 
of amplification using the ABI PRISM 7900HT Sequence Detection System Version 2.1 (SDS 
2.1). Cycle thresholds (Ct) were determined within the logarithmic phase of the PCR for the 
house-keeping gene and the target gene. β-actin and PDGFRβ were used as an 
endogenous control. We used the mean of two technical replicates (Ct values) to calculate 
the ΔCt value for which the Ct of the β-actin was subtracted from the Ct of the target gene Ct 
value and the relative amount was calculated as 2−ΔCt. Stromal cell dependent genes were 
normalized to PDGFRβ instead for β-actin in order to account for differences in percentage of 
infiltrating cells between wt and ko mice. RQ values were calculated as 2−ΔΔCt where ΔΔCt is 
the difference between the ΔCt values of cannulated salivary glands and the ΔCt of non-
cannulated salivary glands. Ct values above 34 were not accepted, and neither were 
technical replicates with more than two cycle differences between them.   
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        Table 2.7.1 Primers and probes used for Quantitative PCR 
Gene  mRNA Accession number Assay ID Source 
Mouse β-actin NM_007393.3 Mm01205647_g1 Applied Biosystems 
Mouse Pdgfrβ 
 
NM_001146268.1 
NM_008809.2 
 
Mm00435546_m1 Applied Biosystems 
Mouse AICDA NM_009645 Mm00507774_m1 Applied Biosystems 
Mouse BAFF NM_028075 Mm00840578_g1 Applied Biosystems 
Mouse CXCL13 NM_018866 Mm00444533_m1 Applied Biosystems 
Mouse CXCR5 NM_007551 Mm00432086_m1 Applied Biosystems 
Mouse CCL19 NM_011888 Mm00839967_g1 Applied Biosystems 
Mouse CCR7 NM_007719 Mm01301785_m1 Applied Biosystems 
Mouse LTβ NM_007986 Mm00484254_m1 Applied Biosystems 
Mouse LTα NM_007986 Mm00484254_m1 Applied Biosystems 
Mouse IL-7 NM_007986 Mm00484254_m1 Applied Biosystems 
Mouse IL-4 NM_007986 Mm00484254_m1 Applied Biosystems 
Mouse IL-13 NM_007986 Mm00484254_m1 Applied Biosystems 
Mouse IL-23 NM_007986 Mm00484254_m1 Applied Biosystems 
Mouse IL-22 NM_008337 Mm01168134_m1 Applied Biosystems 
Mouse IL-17α NM_007986 Mm00484254_m1 Applied Biosystems 
Mouse IL-22 NM_007986 Mm00484254_m1 Applied Biosystems 
Mouse IL-6 NM_008366 Mm00434256_m1 Applied Biosystems 
Mouse IL-2 NM_008371 Mm00434291_m1 Applied Biosystems 
Mouse IFNγ NM_008518 Mm00434774_g1 Applied Biosystems 
Mouse TNFα NM_013693 Mm00443258_m1 Applied Biosystems 
Mouse ICAM-1 NM_009506 Mm00437310_m1 Applied Biosystems 
Mouse VCAM-1 NM_001025250 Mm01281449_m1 Applied Biosystems 
Mouse LTβR NM_007986 Mm00484254_m1 Applied Biosystems 
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2.8 Statistical Analysis 
Data Set 
Each experiment was performed atleast two times with minimum of two mice used per 
experiment unless mentioned. Both salivary glands from mice were used to generate data 
sets. Each figure legend contains the information about the number of times a particular 
experiment was performed as well as the number of mice (biological replicates) used in each 
repeat experiment. 
Statistics 
Statistics were calculated using the student’s t test. All p values were calculated using the 
statistics programme included in GraphPad Prism and p values of ≤ 0.05 were accepted as 
significant.  
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Chapter 3 
Expansion of lymphoid like stromal cells in a model of TLO 
formation in the salivary glands of wild-type mice 
Introduction 
Stromal cells in SLOs, commonly termed lymphoid stromal cells, express cytokines and 
chemokines that regulate lymphocyte survival, differentiation and migration [6, 246]. In SLOs, 
mainly three different types of lymphoid stromal cells have so far been identified: fibroblastic 
reticular cells (FRCs), marginal reticular cells (MRCs) and follicular dendritic cells (FDCs) [6]. 
Podoplanin/gp38+ER-TR7+ FRCs reside in the T cell zone and produce the T cell and DC 
attracting chemokines CCL19 and CCL21 [6, 133, 141]. FRCs also secrete lymphoid 
cytokine IL-7 that is necessary for survival and homeostasis of T cells [6, 135]. MRCs 
express MAdCAM-1, RANKL as well as B cell recruiting chemokine CXCL13, and are found 
underneath the marginal sinus at the edges of the B cell follicles [6, 149, 247]. 
CD35+gp38/Podoplanin+ FDCs, located in the light zone of germinal centres, secrete 
CXCL13 and BAFF (B cell survival factor) and regulate B cells affinity maturation [6, 144].  
Numerous reports in mice and human inflammatory conditions have reported the expression 
of lymphoid stromal markers such as ICAM-1, VCAM-1, FDC markers (CD21/35) and the 
production of survival factors and chemokines in resting stroma [76, 159, 160, 177-179, 185, 
226, 248, 249].  
The differentiation and maintenance of lymphoid stromal cells in secondary lymphoid organs 
has been demonstrated to be dependent on LT and TNFα signalling [6, 7, 107, 115, 117, 
141, 144, 250]. Expression LT and TNFα has been detected in various inflammatory 
diseases. Furthermore, Tg mice over-expressing these molecules in the pancreas, develop 
functional TLOs [157, 158, 251]. Altogether, these data suggest that TLOs and secondary 
lymphoid tissues engage similar pathways in their formation [165, 252, 253].  
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However, the signals that drive the differentiation of lymphoid like stromal cells during 
inflammation and the possible functional relevance of these stromal cells during the process 
of tertiary lymphoid organogenesis are not very clear. We aimed to address these questions 
by using an inducible model of TLO formation in the salivary glands of wild-type mice [237].  
This chapter first describes in detail a new mouse model of salivary gland inflammation and 
validates its use as model of TLO formation. In particular we will discuss the acquisition of 
lymphoid features by the inflammatory infiltrates in relation to the expression of factors 
involved in TLO development. The second part of the chapter delineates the phenotypical 
and functional changes occurring to resident stromal cells in the cannulated salivary glands, 
which enable the stromal cells to modulate the formation, organization and maintenance of 
the lymphoid aggregates.  
86 
 
Results 
3.1 Histomorphological characterization of cellular infiltrates in submandibular 
glands of cannulated mice 
To assess the dynamic progression and evaluate the acquisition of lymphoid features by the 
infiltrating cells, histological analysis was performed using CD3/CD19 and FDC-M1 (to 
identify follicular dendritic cells). Total aggregate area as percentage of total tissue area and 
size of the lymphoid aggregates was calculated. Finally, the prevalence of organized 
aggregates with T/B cell segregation in discrete areas was determined using image analysis 
system as described in the material and method section.  
Peri-ductal lymphocytic infiltrates typically develop in cannulated mice. Early stage, day 5 
post cannulation (p.c.), of the inflammatory process was characterized by T cell infiltration 
with very few B cells (Figure 3.1Ai). From day 8  p.c. onwards a trend towards progressive 
increase in  T and B cells was observed (Figure 3.1Ai-ii). FDC-M1+ cells closely co-
localized with the B cell rich areas, acquiring the typical morphology of GC (Figure 3.1Bi). Of 
note, FDCs were not always present in characteristic reticular networks but showed 
scattered cellular staining within the B area (Figure 3.1Bii).  
Fraction area analysis demonstrated that day 8 p.c. was characterized by larger total 
lymphoid area i.e. ~10% of fraction area (p>0.005) with presence of T cell/B cell segregation 
in ~30% of inflammatory foci (Figure 3.1C-D). By day 15 p.c. we observed a reduction in the 
total lymphoid area (Figure 3.1C), while the aggregates displayed higher degree of 
organization both in terms of segregation (more than 45% of the foci were segregated at day 
15 p.c.) (Figure 3.1Aiii and D) and presence of FDC networks (Figure 3.1Aiii and Bi-ii). 
Nearly 30% at day 8 p.c. and 60% of mice at day 15 p.c. were positive for FDC-M1 staining 
(Figure 3.1E). The average size of lymphoid follicles observed at day 8 p.c. was around 7-
8x104 µm2 whereas at day 15 it was 10-12x104 µm2 (Figure 4.1F). At day 23 p.c. aggregates 
showed not only resolution of the structural organization but a significant decrease in the 
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fraction area; from a 8-10% total aggregate area at day 8-15 p.c. to <2% at day 23 p.c. 
(p<0.005) (Figure 3.1Aiv and C).  
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Figure 3.1 
day 5 p.c. day 8 p.c. day 15 p.c. day 23 p.c. 
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Fig 3.1 Characterization of cellular infiltrate and fraction area analysis of salivary 
glands from mice cannulated with with 10^8 pfu of replication deficient adenovirus. 
Salivary glands sections of virus infected mice at day 5, day 8, day 15 and day 23 p.c. were 
stained with CD3 (red), CD19 (blue) and FDC-M1 (green). Around day 5 p.c. only diffuse 
CD3+ infiltrates were observed, B cells are absent (Ai). Day 8 p.c cannulation is 
characterized by influx of B-cells, significant increase in the aggregates (Aii). Day 15 
aggregates are characterized by increase in organization i.e. separate T cell area and B cell 
area and presence of FDC (Aiii). FDC-M1 staining was not always detected in characteristic 
reticular networks (Bi) but also as scattered cellular staining (Bii) within B cell area. The 
software ImageJ was used to calculate; the area of the tissue and the relative area covered 
by lymphoid aggregates (C), how many of these aggregates were segregated (D), positive 
for FDC-M1 (E) and also size of lymphoid follicles (F) (*p>0.05; **p>0.01; ***p>0.001). 
CD3/CD19/FDC-M1 
B 
day 15 p.c. 
i ii 
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3.2 FACS analysis infiltrating T and B lymphocytes, and their proliferation 
status in cannulated salivary glands 
FACS analysis for CD3+ and CD19+ cells infiltrating the salivary glands supported the 
histological findings. The dynamic of T and B cell infiltration within the glands was expressed 
as percentage of the CD45+ cells. CD3+ cells were observed infiltrating salivary glands 
(Figure 3.2C) by day 2 p.c. followed by a progressive increase, and peak T cell infiltration 
observed between 8-15 p.c. However, a decline in the percentage of T cells was observed at 
day 23 p.c. Ki67 staining on CD3+ cells demonstrated their ability to proliferate in situ 
(Figure 3.2Bi and D). The dynamic of CD19+ B cell infiltration (Figure 3.2C) was different to 
T cells. Only 0.5% of B cells were observed at day 2, with a progressive increase observed 
at day 5 and day 8. Peak infiltration was observed at day 15 with ~20% of the CD45 
compartment constituted by CD19+ cells (Figure 3.2A). B cells also exhibited the capability 
to proliferate within cannulated salivary glands, verified by the Ki67+ staining on the CD19+ 
cells (Figure 3.2Bii and D).  
  
90 
 
  
Figure 3.2 
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Figure 3.2 FACS analysis of infiltrating T and B lymphocytes, and their 
proliferation status in cannulated salivary glands. Representative dot plots showing 
flow cytometry analysis of CD3e+ and CD19+ cells i.e. T and B cells respectively within 
CD45+ cells (A), Ki67+CD3e+ cells (Bi) and Ki67+CD19+ cells (Bii) from salivary 
glands isolated at day 15 p.c. Graph summarizing the percentage T and B lymphocytes 
in the CD45+ leukocyte population (C) and proliferating T and B lymphocytes (D) at day 
0, day 2, day 5, day 8, day 15 and day 23 p.c. Data are representative of three different 
experiments with three mice per experiment and expressed as differences between 
given time-points and percentage of the cell population at day 0 (*p<0.05; **p<0.01; 
***p<0.001). 
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3.3 Phenotyping of T cell subsets within salivary glands during TLO formation 
Further evaluation of the T cell subsets based on differential expression of CD62L and CD44 
revealed that 50-70% and 20-25% of the CD3+cells infiltrating virus infected salivary glands 
displayed respectively an activated (CD62L-CD44+) and memory (CD62L+CD44+) 
phenotype. Interestingly, even though only 5-10% naïve (CD62L+CD44-) T cells were 
observed at day 2 and 5, there was nearly 15-17% increase witnessed in this population at 
later time-points (Figure 3.3A). 
CD4 and CD8 staining was performed on cannulated salivary gland to further characterize 
the CD3+ T cell population. FACS analysis showed that the majority of the infiltrating T cells 
observed in the salivary glands were CD4+ T cells (p<0.05-0.001), 30% CD3+ cells were 
CD8α T cells at day 2 and 5 p.c. whereas at later-time points only 18-20% CD8α+ T cells 
were observed (Figure 3.3B).  
Of interest, CD3+ cells at day 0 were predominantly γδ T cells, however a switch in the 
phenotype of T cells was detected upon inflammation (p<0.05-0.01), 70-80% of CD3+ cells in 
inflamed salivary glands were αβ+T cells (Figure 3.3C).  
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Figure 3.3 Phenotyping of T cell subsets within salivary glands during TLO 
formation. Flow cytometry analysis was performed on salivary glands that were 
stained for CD3, CD4, CD8α, CD62L, CD44, αβTCR and γδTCR antibodies to 
differentiate between CD8 T cells (CD3+CD8α+), CD4 T cells (CD3+CD4+), αβ 
T cells (CD3+αβ+), γδ T cells (CD3+γδ+) and within T cell subsets; naïve T cells 
(CD62L+CD44), memory T cell (CD62L+CD44+) and activated effector T cells 
(CD62L-CD44+). Graph summarizing the relative distribution of naïve, memory 
and activated effector T cells (A) within cannulated salivary glands at day 2, day 
5, day 8, day 15 and day 23 p.c. Plots showing relative percentage of CD4 
versus CD8α T cells (B) and αβ versus γδ T cells (C) infiltrating cannulated 
salivary glands at different time-points p.c. Data are representative of three 
different experiments with three mice per experiment (*p<0.05; **p<0.01; 
***p<0.001). 
Figure 3.3 
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3.4 Investigation of other leukocyte populations found in cannulated salivary 
glands 
The other leukocyte cell populations apart from lymphocytes, observed in salivary glands 
were the CD11c+ cells, NK1.1 cells and CD11b+Gr1+ cells and ILCs. 
Normal SGs were characterized by the presence of a large network of CD11c+ cells by IF 
(Figure 3.4Ai). Post-cannulation there was progressive T cell infiltration observed with 
aggregation of CD11c+ cells at the edges of the infiltrated areas (Figure 3.4Aii). FACS 
analysis also showed the presence of nearly 70% CD11c+ cells, ~3% ILC (Lineage-IL-7Ra+ 
cells) and ~10% NK1.1+ cells in resting salivary glands. Interestingly, a decline (50-60%) 
was observed in CD11c+ cells until day 15 (Figure 3.4D). 
The majority of the infiltrating cells at day 2 were CD11bGr1+ cells (40-45%), and NK cells 
(25-30%) (Figure 3.4D). The CD11b+ and Gr1+ cells observed at day 2 p.c. were 
polymorphonuclear cells (Figure 3.4Bi-iv). While NK cells were still largely detected in 
salivary glands at day 5 (Figure 3.4Ci) and day 8 p.c., the CD11bGr1+ cells showed a 
significant decrease after day 2 (Figure 3.4D).  
ILCs were identified as IL-7Ra+Lineage- cells, with the lineage markers including CD3, B220, 
CD11b, CD11c, CD5. The highest percentage of ILC (i.e. 2-3%) was observed in salivary 
glands at resting conditions. This population did not increase post infection (Figure 3.4D).  
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Figure 3.4 Investigation of other leukocyte populations found in cannulated 
salivary glands. Immunoflurorescence of WT cannulated salivary glands at day 0 (Ai) 
and 15 (Aii) p.c. CD4 (blue), CD11c (green), CD8a (red). Original magnification 25X. 
Immunoflurorescence of WT cannulated salivary glands at day 2 p.c. DAPI (grey), 
CD11b (Bi-ii) and Gr-1 (Biii-iv) (green) and NK1.1 (Ci) (red). Original magnification 
25X (Bi-iv and Ci) and 60X (Bii and iv). Graph summarizing the relative distribution of 
different leukocyte cells (D) within cannulated salivary glands at day 0, day 2, day 5, 
day 8, day 15 and day 23 p.c. Data are representative of three different experiments 
with three mice per experiment 
Figure 3.4 
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3.5 CXCL13 and CCL21 expression increases with increasing level of lymphoid 
organization of the inflammatory foci in cannulated salivary glands 
To evaluate the expression of constitutive lymphoid chemokines as factors in the progressive 
acquisition of the lymphoid organization of submandibular inflammatory foci, the expression 
of CXCL13 and CCL21  in relationship  to lymphoid aggregates was examined. Diffuse weak 
expresion of CXCL13 was observed at early time points  (Figure 3.5.1Ai). From day 8 p.c. 
when progressive increase in B cell infiltration was observed, we  noticed a significant 
increase in CXCL13 expression. The CXCL13 expression appeared to be more prevalent in 
segregated versus non-segregated aggregates (Figure 3.5.1Bi-ii). Expression of CXCL13 
was mainly confined to B cell areas and B cell/FDC–rich areas suggesting relationship 
between ectopic expression of CXCL13 and B cell infiltration  (Figure 3.5.1Ci-ii). CXCL13 
could also be detected in salivary gland epithelial ducts, surrounded by periductal infiltrates 
and non-infiltrated ducts (Figure 3.5.1Aii).  
CCL21 expression was first detected as early as day 5 in CD3+ foci (Figure 3.5.2Ai). Its 
expression was always confined to T-cell rich areas (Figure 3.5.2Ai-iii) and showed a strict 
association with CD31+/LYVE-1+ lymphatic vessels (Figure 3.5.2Bi). Interestingly, CD3+ T 
cells were often seen in close association or within these CCL21+ lymphatic vessels (Figure 
3.5.2Bi-ii). 
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Figure 3.5.1 
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Figure 3.5.1 CXCL13 expression increases with the increasing level of 
lymphoid organization of the inflammatory foci in salivary glands of 
cannulated mice. Microphotographs showing CXCL13 protein expression 
(green) with T cell (CD3; red) and B cell (CD19; blue) aggregates in 
cannulated salivary glands of wt mice at day 5 (Ai-ii), day 8 (Bi-ii) and day 
15 (Cii). Original magnifications 25X. CXCL13 staining is also detected in 
salivary gland ductal epithelial cells (Aii). CXCL13 expression in in non-
segregated (Bi) versus segregated (Bii) lymphocytic aggregate at day 8 p.c. 
(Ci) Day 15 p.c. salivary gland section stained with CD3 (red) , CD19 (blue) 
and FDC marker FDC-M1 (green).  (Cii) Sequential section of day 15 p.c. 
salivary gland showing CXCL13 (green) expression in FDC rich area in T 
cell (red) and B cell (blue) aggregate. 
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Figure 3.5.2 
Figure 3.5.2 Patterns of CCL21 expression with increasing level of lymphoid 
organization increasing level of lymphoid organization of the inflammatory 
foci in salivary glands of cannulated mice. Microphotographs of CCL21 staining 
(green) by immunofluroscence show a trend in the colocalization of CCL21 with the 
CD3+ (red) T cell-rich area of aggregates at day 5, day 8 and day 15 p.c. B cell are 
also shown with CD19 (blue) staining (Ai-iii). At day 5 is CCL21 expression was 
scarce (Ai) but showed progessive increase with higher degree of infiltration (Aii-
iii). CCL21+ cells were mostly present on the edge of the aggregates at day 8 and 
day 15 p.c. (Aii-iii). CCL21 (green) was detected in association with LYVE-1+ (red) 
CD31+ (blue) lymphatic vessels (Bi) in the CD3+ (red) T cell area (Bii). 
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3.6 Vascular organization of lymphoid aggregates in cannulated salivary 
glands 
The lymphocyte aggregates were characterized by formation of CD31+ vessels, some of 
which showed a cobblestone-like appearance resembling HEVs. MECA-79 staining was 
performed on salivary glands of cannulated mice in order to assess the presence of HEV-like 
vessels identified by expression of PNAd, known to regulate naïve cells homing in secondary 
lymphoid organs.  PNAd+ expression was detected on all the HEVs like structures in close 
association with the T-cell rich area of the inflammatory foci. The PNAd+ HEVs were 
primarily observed at the edges of the lymphoid aggregates at day 8 and day 15 p.c. (Figure 
3.6Ai-iii). Additionally, the presence of lymphatic vessels was ascertained by examining the 
expression of LYVE-1 and gp38. Lymphatic vessels, positive for LYVE- and gp38, were 
found mainly in the periphery and occasionally in the midst of lymphocytic infiltrates (Figure 
3.6Bi-ii and Ci). These vessels were more abundant in the areas containing aggregates than 
in the non-infiltrated areas.  
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Figure 3.6 Histological characterization of vascular compartment in the virus infected 
salivary glands of WT mice. Immunofluorescence analysis of CD31 (green), PNad 
(white), CD3 (red) and CD19 (blue) showed that some CD31+ vessels acquired HEV-like 
phenotype i.e. cobblestone appearance with PNad expression and were mainly confined to 
the periphery of aggregates (Ai-iii). Original magnification at 25X (Ai) and 60X (Aii-iii). 
Immunofluorescence staining for DAPI (green in Bi-ii), Lyve (red in Bi-ii and green in Ci) 
and gp38 (blue) showed lymphatics, characterized by gp38 and Lyve co-expression (Bi-ii), 
engulfed with cells. Lymphatic vessels were found both at the periphery and midst of 
lymphoid aggregates (Bi-ii and Ci). Original magnification at 10X (Bi) and 25X (Aii and 
Ci). 
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3.7 Local expression of genes regulating TLO formation and functionality 
characterise disease evolution in salivary glands of cannulated mice 
Development of TLOs is believed to be reliant on ectopic expression of a critical set of 
genes, such as lymphotoxin and lymphoid chemokines [14, 160]. Additionally, presence of 
various lymphoid cytokines/growth factors is required for lymphocyte survival, proliferation, 
and function within TLOs. Thus, we examined whether evolution of TLOs in salivary glands 
of virus-cannulated mice was accompanied with a concomitant up-regulation of these genes. 
CXCL13/CXCR5 and CCL19/CCR7 mRNA transcripts (Figure 3.7A-D) were significantly up-
regulated in the salivary glands of virus-canulated mice as compared to non-cannulated 
mice, and their expression was consistent with the progressive detection of TLO in the 
salivary glands, reaching their peak of expression between day 8-15 p.c. Interestingly, 
CXCL13/CXCR5 and CCL19/CCR7 mRNA showed significant up-regulation already at day 5 
p.c. and thus preceded the development of TLO. Importantly, both LTα and LTβ, recognised 
to be essential for the induction of lymphoid chemokines [115, 117], were highly expressed in 
virus cannulated salivary glands, but not non-cannulated mice. Moreover, LTα and LTβ 
expression displayed a similar trend to lymphoid chemokine expression (Figure 3.7E-F). 
LTβR expression was also abundantly up-regulated in virus infected salivary glands as 
compared to resting salivary glands (Figure 3.7G).  
IL-7 has been suggested to play an key role in ectopic lymphoid neogenesis, analogous to its 
role in the development and homeostasis of SLOs [254]. In contrast to chemokines and 
(LTβ), signal for IL-7mRNA (Figure 3.7H) was detected as early as day 2 p.c. with a 
significant deflection at day 8 and its level were maintained until the resolution phase of the 
inflammatory process.  
Formation of B cell rich aggregates coincided with the in situ up-regulation of BAFF, a crucial 
B cells survival and proliferating factor [153, 155]. Of interest, the acquisition of functional 
features of TLOs was also associated with the significant expression of BAFF at day 15 p.c. 
(Figure 3.7I). Of notice, IL-2 mRNA (Figure 3.7J) expression in cannulated salivary glands 
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appeared to mirror expression pattern of the lymphoid chemokines and LTβ. Gene 
expression profiles of TNFα and IFNγ show a significant increase early in the inflammatory 
process between day 5 and day 8 p.c. with a significant drop observed in their levels from 
day 8 onwards (Figure 3.7K-L). 
Of notice, the expression of germinal center cytokines IL-21 and IL-4 [155, 156], was also 
observed in cannulated salivary glands from day 8 onwards coinciding with appearance of 
TLOs (Figure 3.7M-N). 
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Figure 3.7 Development of aggregates in cannulated salivary glands is accompanied by 
upregulation of genes regulating tertiary lymphoneogenesis. A-N, Graphs showing 
mRNA transcript levels of CXCL13 (A), CCL19 (B), CCR7 (C), CXCR5 (D), LTβ (E), LTα (F), 
LTβR (G), IL-7 (H), BAFF (I), IL-2 (J), TNFα (K), IFNγ (L), IL-21 (M), IL-4 (N) in wt mice 
salivary glands at day 0, day 2, day 5, day 8, day 15 and day 23 p.c. Transcripts were 
normalized to β-actin or pdgfrβ (for CXCL13, CCL19, LTβR, IL-7 and BAFF) and results are 
presented as relative quantitation (RQ) values calculated with calibrator day 0 untreated 
salivary glands. Data are representative of three-four different experiments with atleast three 
mice per experiment (*p<0.033, **p<0.005, ***p<0.0005).  
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3.8 Humoral response in the cannulation model of salivary gland inflammation 
 
FACS analysis showed the presence of CD138+ cells in cannulated salivary glands and both 
CD138+B220+ plasmablasts and CD138+B220- plasma cells were detected (Fig 3.8A-B). 
Furthermore, GL7+ B cells (Figure 3.8C-D) were also present in cannulated salivary glands 
of mice at day 8 (4-5%; p<0.01) and day 15 (9-10%; p<0.001). Of interest, AID mRNA 
(Figure 3.8E) was strongly up-regulated in the cannulated salivary glands; its expression 
parallels the histological detection of ectopic GC formation, as the peak of AID expression 
signal was observed at day 15 p.c. These findings suggested to us that the machinery, able 
to sustain the process of class switch recombination and somatic hyper-mutation [153-156], 
is present within our target organ. 
To probe for virus-specific B-cell responses, serum samples were collected from cannulated 
WT mice at day 5, 8, 15, 23 p.c. and analysed for viral-specific Ig isotypes; IgM and IgG by 
ELISA (Figure 3.8F-G). Significant levels of adenoviral-specific IgM and IgG were detected 
in the serum of cannulated mice as compared to controls (non-cannulated animals). IgM 
antibodies peaked early in the time course by day 5 p.c. but showed a significant increase by 
day 15 p.c. (p<0.055), while viral-specific IgG antibodies continued to increase significantly 
up to day 26 p.c (p<0.03-0.005). 
We next investigated whether there was any evidence of anti-nuclear (ANA) IgG 
autoantibody in this model. ANA were observed by week 3 p.c. in ~66% of cannulated mice 
(Figure 3.8H-I). Remarkably, ANA detection closely paralleled the development of AID 
expression in the salivary glands, suggesting that salivary gland TLOs contribute towards 
breach of tolerance towards auto-antigens and development of class-switched antibodies. 
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Figure 3.8 Humoral response in the cannulation model of salivary gland inflammation. (A), Flow 
cytometry analysis for B220 and CD138 was performed in cannulated salivary glands. Representative 
dot plot shows presence of both plasmablasts (B220+CD138+) and plasma cells (B220+CD138+) in 
salivary glands at day 15 p.c. (B), Graph summarising the dynamic of plasmablasts and plasma cells 
at day 0, day 5, day 8, day 15 and day 23. (C), Representative dot plot presenting percentage of GL7+ 
B cells at day 15 p.c. (D), Graph displaying percentage of GL7+ B cells at day 0, day 5, day 8, day 15 
and day 23 p.c. (E), AID mRNA transcripts levels that were normalized to β-actin and results are 
presented as relative quantitation (RQ) values calculated with calibrator day 0 untreated salivary 
glands. (F-G), Quantitative evaluation of serum viral antibodies in cannulated mice demonstrate an 
anti-viral IgM response (F) early in the inflammatory process whereas anti-viral IgG antibodies (G) 
increase is concomitant with the formation of TLOs from day 15 p.c. onwards. (H), Representative 
microphotographs of immunofluorescent detection of anti-nuclear autoantibodies (ANA) using Hep2 
cells as substrate. (J), Sera (a dilution 1:80) from 75% mice three weeks p.c. was positive for ANA. 
Data are representative of three experiments with atleast three mice per experiment (*p>0.033, 
**p>0.005, ***p>0.0005).  
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3.9 Histological characterization of Lymphoid like stromal cell (LLSc) in 
inflamed salivary glands 
Expression of the lymphoid stromal cell marker gp38 on non-lymphoid tissue stromal cells 
has been described during inflammation [226]. Therefore, the stromal cells underlying the 
lymphoid aggregates were examined for the presence of gp38+ lymphoid like stromal cells in 
cannulated salivary glands.  
Expression of gp38 by EPCAM+ myoepithelial cells on acini and ducts in resting salivary 
glands has been reported by Hata et al. [255]. In accordance with these reports, we detected 
constitutive gp38 expression on EPCAM+ epithelial cells while little expression of this 
glycoprotein was detected on CD45-EPCAM- stromal cells in salivary glands at day 0, 
(shown in Figure 3.9Ai). However, in inflamed salivary glands, gp38 expression showed an 
increased diffuse web-like staining pattern in close association with the inflammatory foci 
denoted by CD4+ cells by day 5 p.c. (Figure 3.9Avi-x). Lack of co-localization between gp38 
and EpCAM was observed in the aggregate area, suggesting that gp38+ cells within the foci 
are non-epithelial cells (Figure 3.9Avi). The gp38+ cells also expressed other lymphoid 
stromal cells markers, such as ICAM-1, VCAM-1 and ER-TR7, in inflamed salivary glands 
(Figure 3.9Avii-ix); however expression of these markers was negligible in day 0 salivary 
glands (Figure 3.9Aii-iv). gp38 expression on stromal cells underlying lymphoid aggregates 
was observed in TLOs at day 8 and day 15p.c. (Figure 3.9Bi-iv), and at these sites, gp38 
expression was found to correlate with the increase in size of the aggregates as measured 
by image analysis (Figure 3.9C). Since gp38 expression can also be found on lymphatic 
vessels, day 8 cannulated salivary gland sections were stained with CD3, CD19, gp38 and 
CD31 to understand the distribution of the gp38+ endothelial component in relation to the 
aggregates, as shown in Figure 3.9Di-ii. gp38+ detected within the aggregate did not show 
co-localization, thus confirming the non-endothelial nature of the gp38+ cells observed within 
aggregates.  
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Overall, the histological data showed an accumulation of non-epithelial, non-endothelial 
lymphoid stromal cells within inflamed salivary glands when compared to non-cannulated 
resting salivary glands. 
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Figure 3.9 Histological characterization of Lymphoid like stromal cell (LLSc) in inflamed 
salivary glands. (Ai-x) Immunofluorescence of WT cannulated salivary glands at day 0 and 5 p.c. 
CD4 (blue), gp38 (green), EpCAM, ICAM-1 and VCAM-1 (red). Original magnification 25X. 
Histological analysis illustrates increased non-epithelial gp38 expression (Avi) in the areas covered 
by the aggregates shown here by CD4+ cells (Avi and x) in salivary glands at day 5 p.c. as 
compared to day 0 p.c. gp38 expression at day 0 is mostly confined to epithelial (EPCAM+) cells 
(Ai). Expression of other lymphoid stromal markers: VCAM-1/ICAM-1/ER-TR7 by gp38+ stromal 
cells sitting under the aggregate confirmed their lymphoid phenotype (Avii-ix). (Bi-iv) gp38 (green) 
expression showed a web-like staining pattern in close association with the CD3+ (red) and CD19+ 
(blue) lymphocytic foci and appear to progressively increase from day 8 (Bi-ii) upto day 15(Biii-iv) 
p.c. in association with aggregate size (C) Image analysis of gp38 and CD4 positive areas in salivary 
gland tissue sections at different time-points p.c. Area expressed as number (no.) of pixels per unit 
area. Dots represent mean of aggregate area in each gland. Eleven glands from different mice were 
analysed in total. (Ci) Representative immunfluorescence picture of CD4 (red) and gp38 staining 
(blue) in salivary glands, as described in Materials and Methods. (Di-ii) Immunofluorescence of WT 
cannulated salivary glands at 8 p.c. CD3 (red), gp38 (green), CD3 (red) and CD31 (white). Original 
magnification 25X. 
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3.10 Phenotypical and functional analysis of Lymphoid like stromal cell (LLSc) 
in inflamed salivary glands 
We next performed a detailed FACS analysis of the changes occurring in the stroma post-
cannulation. Following viral cannulation of the salivary glands, we observed progressive 
enrichment of EPCAM-CD45-gp38+CD31- cells (Figure 3.10.1Ai day 0 and Figure 3.10.1Ai 
day 5 p.c.). RANKL (Figure 3.10.1B) and MadCAM-1 (Figure 3.10.1C) expression was 
detected on the EPCAM-CD45-gp38+CD31- cells in salivary glands at day 5p.c. when 
compared to day 0 salivary glands. Expansion of these gp38+CD31- cells was accompanied 
by enrichment in CD45-EPCAM-CD31-VCAM-1intICAM-1int and VCAM-1highICAM-1highcells 
(Figure 3.10.1D-F), similar to that observed in the early phases of lymph node anlagen 
embryogenesis and has been associated with stromal cell maturation in the embryonic lymph 
node anlagen [60, 79, 256]. Between 50-70% VCAM-1intICAM-1int cells and upto 10% and 
VCAM-1highICAM-1high cells were observed in cannulated salivary glands (p<0.01-0.05). gp38 
expression was primarily confined to these two VCAM-1intICAM-1int and VCAM-1highICAM-
1highcells (Figure 3.10.1G-H). 
FACS sorting of the gp38+CD31- cells at day 5, 8 and 15 p.c. identified mRNA expression 
the lymphoid chemokines CXCL13 (Figure 3.10.2A), CCL19 (Figure 3.10.2B)  and CCL21 
(Figure 3.10.2C)  as well as the lymphoid cytokines BAFF (Figure 3.10.2D)  and IL-7 
(Figure 3.10.2E)  that progressively and significantly increased in the gp38+CD31- 
component but not in the double negative gp38-CD31- cells (in the CD45-EPCAM- 
compartment), epithelial cells (CD45-EPCAM+ compartment) or in the small gp38+cd31- 
cells present in resting salivary glands. Furthermore, LTβR (Figure 3.10.2F) and TNFR1 
(Figure 3.10.2G) mRNA was significantly up-regulated on the LLSc when compared to the 
DN and epithelial cells, thus demonstrating the enhanced ability of LLSc to be able to 
respond to lymphotoxin stimulation and up-regulate lymphoid chemokines similar to the 
lymphoid stromal cells. 
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We named the CD45-EPCAM-CD31-gp38+ stromal cells, lymphoid like stromal cells or LLSc 
because their phenotypical appearance and ability to secrete lymphoid chemokines and 
survival factors was not confined to just one cell type but resembled different lymphoid 
stromal cell subsets (i.e. both T cell and B cell stroma).  
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Figure 3.10.1 
Figure 3.10.1 Phenotypical and functional analysis of Lymphoid like stromal cell (LLSc) 
in inflamed salivary glands. FACS histogram representing LLSc expansion in WT mice 
salivary glands at day 5 p.c. as compared to day 0 p.c. (A). Induction of lymphoid stromal 
markers MadCAM (B) and RANKL (C) on gp38+CD31- cells is shown in histograms from 
cannulated salivary glands at day 5 p.c. (red line) compared to day 0 salivary glands (grey 
line). FACS plots representing expansion of ICAM-1
hi
VCAM-1
hi
 and ICAM-1
int
VCAM-1
int 
cells 
within CD45-EPCAM-CD31- component in WT mice salivary glands at day 5 p.c. (Dii) as 
compared to day 0 salivary glands (Di). Time course of CD45-EpCAM-CD31- ICAM-1
hi
VCAM-
1
hi
 (E) and ICAM-1
int
VCAM-1
int 
(F) cells following cannulation as determined by flow cytometry 
in cannulated WT mice at day 0, day 2, day 5, day 8 and day 15 p.c. Histogram (G)  and graph 
(H) showing the MFI of gp38 on ICAM-1
hi
VCAM-1
hi
, ICAM-1
int
VCAM-1
int
 and ICAM-1-VCAM-1- 
cells. 
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Figure 3.10.2 Phenotypical and functional analysis of Lymphoid like stromal cell (LLSc) in 
inflamed salivary glands. Expression of CXCL13 (A), CCL19 (B),  CCL21 (C), BAFF (D), IL-7 
(E), LTβR (F) and TNFR1 (G) on sorted CD45-EpCAM-CD31-gp38+ cells (black bars) in 
comparison to CD45-EpCAM-CD31-gp38- cells (white bars) and CD45-EPCAM+ epithelial cells 
(grey bars). Transcripts encoding the indicated genes were quantified by quantitative RT-PCR 
and normalized to housekeeping gene β-actin. Relative quantitation (RQ) calculated with 
calibrator day 0 CD45-EpCAM-CD31-gp38- cells. Data are representative of two independent 
experiments with three mice per group. * p < 0.05; ** p < 0.01; unpaired t test.  
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C 
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3.11 LLSc expansion during the inflammatory process 
In order to evaluate the changes occurring to the LLSc in the salivary glands post-infection, 
we performed FACS analysis of the single cell suspensions isolated from salivary glands at 
different time-points post cannulation (Figure 3.11A-B). We observed a significant increase 
in the percentage of LLSc between 3 hours (p<0.05) to day 2 p.c. (p<0.01). The highest 
percentage of LLSc were observed at day 5 p.c. (over 40% LLSc are observed in the CD45-
EPCAM- stromal component as compared to only 7% gp38+CD31- cells detected within the 
CD45-EPCAM- stromal compartment in a resting non-cannulated glands; p<0.001). Day 8 
p.c. shows a deflection in percentage of this population compared to day 5, nevertheless, the 
gp38+LLSc are maintained between a percentage of 20-25% from day 8 to day 20 p.c. 
(p<0.0002). A gradual decline in percentage of LLSc is observed from day 23 p.c. which 
coincides with resolution of lymphoid aggregates. By day 26 p.c. the proportion of gp38+ 
fibroblasts detected in salivary glands is similar to day 0 salivary glands.  Absolute number of 
LLSc was also determined at different time-points p.c., and it showed similar trend in LLSc 
expansion as mentioned above (Figure 3.11C). 
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Figure 3.11 Dynamic of LLSc expansion during the inflammatory process. FACS 
histogram representing LLSc expansion in WT mice salivary glands at day 0, day 2  and 
day 5 p.c. (A). Time course of the percentage (B) and absolute number (C) of CD45-
EpCAM-CD31-gp38+ cells (LLSc) following cannulation as determined by flow cytometry 
in cannulated WT mice. Data presented as the mean ± s.e.m. of two-three independent 
experiments with at least two mice analysed per time-point. * p < 0.05; ** p < 0.01; *** p 
< 0.001, unpaired t test, comparing LLSc population at each time point with day 0 p.c. 
C 
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3.12 Proliferative status of LLSc at different time-points post-cannulation 
In order to study the proliferative status and understand the proliferating ability of the LLSc 
population, both Ki67 and BrdU staining was performed on the digested stromal cells from 
salivary glands at different time-points (Figure 3.12A-C). This approach exploited the 
differences in the properties of the data obtained by Ki67 and BrdU staining, i.e that Ki67 
only stains active proliferating cells whereas BrdU is incorporated in all proliferating cells, 
thus labelling both actively proliferating cells and also cells that have proliferated since BrdU 
was first administered to the mice. For the purpose of this experiment, mice were given BrdU 
water from day 0. Ki67 data (Figure 3.12B) exhibited that LLSc were undergoing active 
proliferation from as early as 3 hours p.c to day 15 p.c. (p>0.01-0.05) between 5-10% of 
LLSc were Ki67+. However, negligible percentage of cell showed Ki67 staining at day 23 p.c. 
which coincides with the resolution of inflammation in salivary glands. The BrDU staining 
(Figure 3.12C) demonstrated that LLSc were undergoing multiple rounds of proliferation and 
more than 50 percent of LLSc observed between day 2-day 15 p.c. (p<0.001-0.05) was 
derived from proliferation. The maximum proliferative activity is observed between day 2 and 
day 5 p.c. leading to expansion of LLSc compartment observed at day 5 p.c.  
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Figure 3.12 Proliferative status of LLSc at different time-points post-cannulation. 
FACS histogram representing Ki67+ (Aii) and BrDU+ (Aiii) LLSc in WT mice salivary 
glands at day 5 p.c. (Ai). Graphs showing proliferation, both Ki67 (B) and BrdU (C), of 
CD31-gp38+ (LLSc) in the CD45-EPCAM- cell population. ** p < 0.01, *** p < 0.001 
versus day 0 wt mice. Data are from three to four independent experiments with two to 
four mice analysed per group. 
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Discussion 
Current understanding of the fundamental cellular and molecular events that trigger and 
regulate the formation of TLOs in the salivary glands, is insufficient and restricted to cross-
sectional analysis of salivary glands patients with Sjogren’s Syndrome (SS) and spontaneous 
autoimmune prone murine models of exhibiting Sjogren’s-like syndrome [237, 257, 258]. The 
most commonly used model to study SS is the NOD mice, which develop salivary gland 
inflammation that resembles many features of the human SS. However, this model has major 
limitations which prevent its use to address functional aspects of ectopic lymphoid 
neogenesis. Firstly, the onset of disease in NOD mice is quite variable, i.e. not all mice 
develop the disease at the same age. Secondly, the penetrance of disease is not one 
hundred percent i.e. not all mice develop the disease. Thirdly, it’s a spontaneous model of 
autoimmunity, where the exact triggers of disease are unknown. Finally, NOD mice have a 
complex genetic background, hence, crossing these mice with other mice strains, such as 
knockout mice for inflammatory genes, is not easy and this limits the feasibility to study role 
of specific genes in these mice. When SS is studied in NOD mice, it is important to take in 
consideration the presence of type 1 diabetes. All mice develop diabetes by 15 weeks of 
age, and thus the highly activated inflammatory environment provides additional confounding 
factors to study and manipulate the disease process in NOD mice [259-262].  
Other models of SS are dependent on transgenic expression of inflammatory cytokines, such 
as IL-14 and BAFF [259-262]. Additional models of inducible salivary gland inflammation, 
that share some features of SS, have been reported. Nonetheless, these models rely either 
on the use of replication-deficient adenovirus vectors harbouring pro-inflammatory genes 
[237, 263] or infection of autoimmune prone mice (such as lpr/lpr mice) with fully infectious 
and replicating sialotropic viruses [237, 264, 265]. The dependence of these models on pro-
inflammatory mediators or autoimmune prone mice prevents the study of the inflammatory 
process in physiological settings.  Additionally, to our knowledge, models using viral induced 
inflammation do not provide a clear demonstration as to whether they can progress towards 
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the formation of functional TLOs and exhibit the main characteristic of SS, which is the 
formation of autoantibodies [237]. Furthermore, in humans it is unethical to perform a 
dynamic evaluation of the cellular and molecular mechanisms involved in the formation of 
ectopic lymphoid structures, and thus AN understanding of the role played by stromal cells in 
this process is prevented by the impossibility of performing repeated biopsies from a patient 
or other functional studies in vivo. Therefore, in order to overcome this limitation, we 
developed a mouse model of inducible salivary gland inflammation [237].  
The work presented in this chapter established that upon delivery of replication-deficient AdV 
vector, directly into the salivary glands of wild-type mice, a true phenomenon of ectopic 
lymphoneogenesis occurs within virus infected salivary glands which resemble SS. In this 
model, immune cell infiltration rapidly progresses from a diffuse inflammatory process 
towards the formation of periductal lymphocytic aggregates which further evolve into highly 
organised TLOs. This process is highly reproducible and synchronous with the lymphocytic 
foci development in one hundred percent of the mice by day 5 p.c. It evolves between 8-15 
days p.c. into fully formed TLOs characterized in over 70% of mice by T/B cell segregation, 
and formation of FDC-M1 and GL-7 positive GC-like structures displaying high similarity to 
the human counterpart SS patient salivary glands [178, 180, 237]. The development of FDC 
was exclusively present within the B cell area and associated with the presence of 
segregation of T and B cells in distinct areas.  
In this chapter, we also showed that post-virus infection, there is early up-regulation of 
lymphoid chemokines CXCL13, CCL19, and CCL21 mRNA which precedes the development 
of TLOs, and their expression peaks in parallel with full acquisition of lymphoid organization 
of lymphocytic foci. Lymphoid chemokines retained their distinct expression pattern observed 
in secondary lymphoid tissues, with CXCL13 confined to the B cell-rich areas of the lymphoid 
aggregates and CCL21 in the surrounding T cell area and lymphatic vessels [3, 237]. During 
embryonic secondary lymphoid organogenesis, the expression of lymphoid chemokines 
CXCL13, CCL19 and CCL21 by VCAM-1+ICAM-1+LTβR+ mesenchymal “organizer” (LTo) is 
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chiefly dependent on LTβR/LTα1β2 signalling axis. This signal establishes a positive 
feedback loop between lymphoid chemokines and LTβ which is absolutely crucial in 
promoting further immune cell recruitment and development of mature LNs [11, 36]. 
Consistent with this evidence, we showed that LTβ and LTα are significantly up-regulated in 
parallel with CXCL13/CCL19 induction, suggesting that LT/chemokine positive feedback loop 
is active within salivary glands during TLO formation [160]. 
In our model, despite the detection of FDC-M1+ reticular staining in the B cell zone, the FDC 
structures did not display the typical FDC network pattern observed in SLOs. In SLOs it has 
been demonstrated that B cells and sustained B cell-derived LT/TNF is important for 
formation and maintenance of FDC networks [144, 266] However, in our model major B cell 
infiltration is only detected between day 8-day 15 p.c. and resolution of lymphocytic 
structures is observed from day 23 onwards Therefore, we hypothesize that the late and 
transient B cell-derived LT/TNF signal, present in the salivary gland, is not sufficient to allow 
full formation of FDCs.  
TLO have been shown to support functional B cell activation with expression of AID, the 
enzyme which initiates somatic hypermutation (SHM) and class switch recombination (CSR) 
of the Ig genes [194, 267], leading to affinity maturation and differentiation of memory B and 
plasma cells [155, 156, 268]. We demonstrated that in our model, increased expression of 
AID in the salivary glands coincided with the formation of TLOs acquiring markers of 
germinal centres such as FDC networks and GL7. Of relevance, ectopic induction of AID 
associated with the expression of several cytokines such as BAFF, IL-21 and IL-4, known to 
support a germinal centre reaction by enhancing B cell survival and promoting AID 
expression in B cells. [154-156, 269]. Moreover, both plasmablasts and plasma cells were 
detected in cannulated salivary glands. Overall, the data demonstrates that following AdV 
infection, TLOs acquire the molecular machinery required for the development of functional 
niches for B cell activation.  
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Because the cellular and molecular features of TLO in this model were remarkably similar to 
those observed in SS [18, 178, 180, 183], we looked for the presence of circulating 
autoantibodies [178, 237, 270, 271].  Of interest, at week 3 pc, sera from 75% of the AdV-
cannulated mice showed positivity for IgG anti-nuclear autoantibodies (ANA) [237]. The 
presence of these circulating antibodies in the blood of the cannulated animals indicates the 
possibility of breakage of tolerance, likely by exposure of nuclear material in the context of 
the formation of TLOs with active GCs in the salivary glands. The possibility of in situ 
production of anti-viral antibodies and ANA is currently under investigation. We suspect this 
to be the case since the ectopic GCs seem to possess the machinery for their active function 
[194, 237]. 
Altogether, the data demonstrates that this inducible model of TLO formation, during salivary 
gland inflammation, is a suitable tool to dissect the dynamic and hierarchical significance of 
the critical factors regulating stromal cell activation, thus, allowing us to better understand 
functional relevance of this phenomenon during TLO formation in vivo.  
It is increasingly becoming clear, that non-lymphoid tissue stromal cells are not merely 
sessile bystanders during an inflammatory responses, but many factors, such as 
chemokines, cytokines, that we detect in TLO-associated inflammatory disease are derived 
from these non-hematopoietic stromal cells [1, 222, 248]. In physiologic lymphoid organs, 
gp38+ lymphoid stromal cells secrete factors and chemokines that are responsible for 
leukocyte organization, survival and function [6]. Large body of evidence indicates towards 
presence of lymphoid-like stromal cells at the site of inflammation [76, 159, 160, 177-179, 
185, 226, 248, 249]. However, formal realization came from the work of Peduto et al., who 
demonstrated that during inflammation, the tissue-resident fibroblasts acquire the 
phenotypical and functional ability of lymphoid stromal cells  that allows recruitment and 
organized aggregation of lymphocytes inside tissue target of inflammatory processes [226]. 
These cells were identified and isolated by their expression of gp38. However, currently none 
of the studies provide the dynamic of stromal cell activation during inflammatory process and 
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moreover the identity of signal/s regulating this pathological conversion of tissue resident 
fibroblasts is still obscure.  
This chapter also examined the presence of lymphoid-like stromal cells and ascertains a 
dynamic of stromal cell activation during TLO formation. gp38 or podoplanin is a stromal cell 
marker, expressed on specialized stromal cells present in secondary lymphoid organs [1, 
226, 272, 273]. On resting conditions fibroblasts in non-lymphoid organs express only 
negligible amount of gp38, while EpCAM+ salivary glands and kidney epithelial cells, alveolar 
cells in the lung and lymphatic vessels, express intermediate/high level of the molecule [255, 
274-277]. In accordance with previous reports, gp38 was found to be expressed on epithelial 
(EPCAM+) cells in resting salivary glands by histology. However, enrichment of 
gp38+EPCAM-CD31- cells within the inflamed salivary glands was observed as soon as 
inflammation was established at day 5 p.c. This population of gp38+EPCAM-CD31- cells was 
observed mainly within the foci. Further histological characterization also showed acquisition 
of other lymphoid stromal cell markers such as ICAM, VCAM, ER-TR7 on these cells. This 
data supports the classification of gp38+ cells within the aggregates as lymphoid like stroma. 
Moreover, an increase of gp38 expression, in relationship with the size of the lymphoid 
aggregates, was also observed, and which is a clear indication of the cross-talk between 
haematopoietic and stromal cell compartment. 
FACS analysis of collagenase digested salivary gland tissue demonstrate that the earliest 
phases of TLO formation are characterized by the differentiation of a gp38+ (non-
hematopoietic, non-endothelial and non-epithelial) stromal cell component that 
progressively acquires lymphoid associated markers (ICAM-1, VCAM-1, gp38) and 
precedes lymphocyte accumulation and LTβ up-regulation within the tissue.  This is 
followed by a rapid expansion and maturation phase of gp38+ fibroblasts that coincides 
with increased influx of lymphocytes and LT expression. During this period an increase in 
gp38+ stromal cell numbers and up-regulation of lymphoid chemokines and cytokines 
expression is observed in the stromal cells. 
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This is in agreement with reports on lymphoid stromal cells during organogenesis or immune 
response. Peduto et al, has also reported that the induction of gp38+ cells in the LN anlage 
precedes LTi arrival or LTβR signalling [226]. Furthermore, Benezech et al., demonstrated 
that early maturation of the embryonic mesenchyme into lymphoid tissue stromal organizer 
cells requires a dual step. Initial expression of ICAM-1 and VCAM-1 at intermediate levels, a 
process that is lymphotoxin  (LT) independent and a second stage, in which small 
aggregates of RORγt dependent lymphoid tissue inducer cells (LTi) [46] provide the LTR+ 
mesenchyme with LT, favouring integrin up-regulation and stabilization of the aggregates 
[66]. This is followed by secretion of CXCL13, CCL21, CCL19 and CXCL12, that drive 
leukocyte recruitment, inducing further stromal cell maturation and establishment of the 
anlagen [278, 279].  In adult LNs, during an immune response, FRCs are rapidly activated 
within hours after the onset of inflammation and is independent of lymphocytes and LTβ. Of 
notice, a strong increase in gp38 expression on FRC was detected within few hours post-
infection in these LNs but no change in transcript levels of IL-7, CC19 and CCL21 was 
observed [280].  
Collectively, using this mouse model of TLO formation, we have demonstrated pathogenic 
transition of tissue stromal cells during the establishment of TLOs.  We have shown that 
tissue fibroblasts acquire markers such as gp38, ICAM-1, VCAM-1, RANK-L, MadCAM-1 and 
LTβR and are able to respond to LTβ stimulation, up-regulating CXCL13, CCL19, IL7 and 
BAFF. This population of (EPCAM-CD45-) CD31-gp38+ cells recapitulates phenotypically 
and functionally the population of fibroblastic reticular cells (FRC) found in the lymph node T-
cell zone. However, as these stromal cells also share features with follicular dendritic cells 
(FDC) and marginal zone reticular cells (MRC) [6], we have referred to them as lymphoid-like 
stromal cells (LLSc).  
Our observations using this model suggests that the acquisition of LLSc can be split into 
three distinct but overlapping phases; (i) induction phase (day 0-2-p.c.), (ii) expansion phase 
(day 2-5 p.c.) and (iii) maturation/maintenance phase (day 5-15 p.c.). The next three 
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chapters will explore the signals that regulate these different phases of stromal cell 
activation.  
. 
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Chapter 4 
Unexpected role of IL-13 and IL-4 in regulating tissue-
resident stromal cells in the induction phase of TLO 
formation  
Introduction 
The previous chapter clearly demonstrated that during TLO formation, otherwise quiescent, 
tissue resident stromal cells undergo dramatic changes, which enable them to acquire 
stromal lymphoid features and functions which could contribute to regulate the formation and 
maintenance of TLOs. However, little is known about the cell/s and signalling pathway/s 
involved in the transition of normal resident mesenchyme stromal cells towards a lymphoid 
like/pathological phenotype. A role for IL17 has been suggested in the context of stromal cell 
activation in a neonatal model of TLO formation in the lung [214]. In this study IL-17 was 
demonstrated to induce the expression of lymphoid chemokines in isolated pulmonary 
fibroblasts. However, the inability to reproduce this model in adult mice has questioned the 
role of IL17 in post-natal TLO formation, where normal bacterial flora inhabit the mucosal 
target site [281]. Fleige et al., reported normal iBALT development in il17ko mice upon intra-
nasal challenge with replication-deficient poxvirus modified vaccinia virus ankara (MVA) 
[282]. Further data on the role of IL17 in TLO formation has been provided in an elegant 
study [283] from Peters et al., which established the requirement of gp38+ Th17 cells for 
EAE development in the brain. In our model, LLSc expansion precedes T cell infiltration, 
suggesting that Th17 lymphocytes are not involved in early LLSc induction. Despite the 
controversy, these findings suggest a new and fascinating paradigm of how ectopic 
organogenesis can be driven by an inflammatory cytokine as opposed to lymphoid cytokines, 
such as LT, which is the central cytokine in secondary lymphoid organogenesis. 
Preliminary data, generated by our collaborator M. Coles in York, revealed that when human 
adipocyte derived stromal cells (ADSCs) are stimulated with IL-4Rα agonist cytokines IL-4 or 
IL-13, a significant increase in lymphoid stromal cell markers gp38, ICAM and VCAM was 
observed as compared to classical TNF/LTβR agonist stimulation. This suggested that IL4-R 
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signalling in adult mesenchyme has a role in lymphoid stroma specification (Mark Coles, 
Personal communication). Recent work has also shown that type 2 cytokine activity is able to 
modulate mesenchyme differentiation in muscle or adipose tissue upon injury [284]. Two 
different forms of IL4R have been documented, classical and alternative. Classical IL4R is 
composed of IL4α and IL-2Rγ chains and is predominantly expressed by hematopoietic cells, 
whereas the alternative form of the IL4R consists of IL4Rα and IL13Rα and is primarily 
expressed by non-hematopoietic cells, such as human skin and lung fibroblasts, as well as 
non-hematopoietic cancer cell lines such as A431, PA-1 and HT-29 [285-288]. IL-13Rα1 has 
been shown to be expressed on B cells, especially GC B cells and peritoneal macrophages 
in mice [289].  
IL4Rα staining has been reported on human LN FRC networks [290]. Moreover, expression 
of IL-13Rα1 has been described on follicular dendritic networks (FDCs) in murine LNs and is 
suggested to be involved in increased production of IL-6 from FDCs, which is important for 
terminal differentiation of GC B cells [289].  While there is no reported function of IL-4 and IL-
13 in conventional secondary lymphoid organogenesis, these cytokines are able to trigger 
expression of the adhesion molecules VCAM-1 and ICAM-1 in human lung fibroblasts [287]. 
These data suggest a fascinating possibility that, during inflammation, expression of IL-4Rα 
targeting cytokines might be involved in stromal cell reprogramming to a lymphoid-like 
phenotype. We therefore explored whether the IL-4/IL-13 axis might play a role in the 
induction phase of TLO formation. 
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Results 
4.1 Direct administration of IL-4Rα signalling cytokines regulates LLSc 
induction in salivary glands 
To evaluate in vivo the effect of IL-13 and IL-4 directly on stromal cell activation, recombinant 
(r) cytokine IL-13, IL-4 or TNFα+LTβR agonist were cannulated into the salivary glands. A 
30% increase (p<0.001) in the LLSc component was observed in the rIL-13 cannulated 
salivary glands when compared to PBS cannulated salivary glands (Figure 4.1A-B). 
Increase in the LLSc by 20% (p<0.05) and 15% (p<0.05) were observed when rIL-4 and 
rTNFα+LTβR agonist were directly administered into salivary glands respectively (Figure 
4.1A-B). Furthermore, MFI data exhibited a greater increase in the gp38 expression on LLSc 
when salivary glands were cannulated with rIL-13 as compared to PBS (p<0.001). An 
increase in gp38 expression was also observed in rIL-4 and rTNFα+LTβR agonist cannulated 
salivary gland but it was lower (p>0.05) to that detected on LLSc in rIL13 treated glands 
(Figure 4.1C). When ICAM-1 and VCAM-1 expression was examined in the rIL-13, rIL-4, 
rTNFα+LTβR agonist and PBS treated salivary glands, we observed induction of 11% 
(p<0.01), 5% (p<0.01), 6% (p<0.01) and 1% of ICAM-1hiVCAM-1hi cells (Figure 4.1D). The 
percentage of ICAM-1intVCAM-1int cells (Figure 4.1E) was 55% (p>0.01), 43.1%, 50% 
(p>0.05) and 32% in the rIL-13, rIL-4, and rTNFα+LTβR agonist and PBS cannulated mice 
respectively. The induction of ICAM-1 and VCAM-1 was significantly higher (p>0.05) in the 
rIL-13 treated glands compared to rIL-4 and rTNFα+LTβR agonist treated salivary glands 
(Figure 4.1D-E). 
This data clearly indicates a role for IL-4R signaling, mainly via IL-13 and only partially by IL-
4 stimulation, in induction of lymphoid stroma in vivo. 
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Figure 4.1 Direct administration of IL-4Rα signaling cytokines regulates LLSc 
induction in salivary glands. WT mice salivary glands were directly cannulated with IL13, 
IL4 recombinant cytokine or recombinant TNF𝛼 +LTβR agonist (rIL13, rIL4 or rTNF𝛼 +LTβR 
agonist ) or PBS and analysed at day 2 p.c. Representative dot plots showing expansion of 
the epcam-cd45-component post treatment with rIL13, rIL4, TNF𝛼 +LTβR agonist or PBS. 
Graphs summarising flow cytometry results, demonstrating increased frequency of the 
epcam-cd45-cd31-gp38+ cells (B) and increased gp38 expression (shown as MFI values) on 
epcam-cd45-cd31-gp38+ cells (C) in the recombinant il13, il4 or TNF𝛼 +LTβR agonist 
cannulated samples compared to recombinant PBS control. *, p < 0.05; ***, p < 0.001; versus 
PBS cannulated mice. Data are representative of two experiments (two to three mice per 
group). Graphs summarising percentage of VCAM-1
hi
ICAM-1
hi
 cells (D) and VCAM-1
int
ICAM-
1
int 
cells (E)  obtained by flow cytometry in the recombinant il13, il4 or TNF𝛼 +LTβR agonist 
cannulated samples compared to recombinant PBS control. Data is representative mean of 
two independent experiments (two to three mice per group); * p<0.0.5; **, p<0.01. 
A 
rTNFα+LTβR agonist 
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4.2 LLSc, DN stromal cells and epithelial cells express IL4R  
The next important question was to determine which stromal cell subsets are capable of 
responding directly to IL4R signaling, both in resting and cannulated salivary glands. In order 
to asses this, IL4Rα and IL13Rα gene expression was studied on isolated LLSc, DN stromal 
cells and epithelial cells. The mRNA data showed that LLSc and epithelial cells express 
higher transcript levels of IL-4Rα (Figure 4.2A) and IL13Rα (Figure 4.2B) at day 0 when 
compared to DN stromal cells. A further increase was observed in the expression of IL-4R 
chains on LLSc and epithelial cells post-cannulation, particularly day 2 p.c. (Figure 4.2A-B). 
FACs analysis for IL-4Rα was performed to analyze the protein expression of the receptor on 
non-hematopoietic cells in resting salivary glands (Figure 4.2C). Salivary glands from il4rαko 
were also stained to confirm specificity of the antibody. No staining for IL4Rα was observed 
in the ko mice (Figure 4.2D). All three CD45- components, LLSc, DN and epithelial cells, 
expressed the receptor at day 0, however at day 2 p.c. a 4.5 fold increase in the IL4Rα+LLSc 
(p>0.01) and ~2–fold increase in IL4Rα+EPCAM+ (epithelial) cells was observed, whereas 
no increase was identified in IL4Rα+DN cells (Figure 4.2E). 
Overall, this data suggested that the non-hematopoietic cells in salivary gland have the 
machinery to respond to an IL-4R signal. 
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Figure 4.2 
Figure 4.2 LLSc, DN stromal cells and epithelial cells express IL4R. IL4Rα transcripts 
(A) and IL-13Rα (B) on FACS sorted gp38+CD31-LLSc (black bars) in comparison to gp38-
CD31- double negative cells (DN, white bars) and CD45-EPCAM+ (epithelial) cells (grey 
bars). Transcripts were assessed by quantitative RT-PCR and normalized to housekeeping 
gene β-actin. Relative quantitation (RQ) calculated with calibrator day 0 DN cells. Data 
expressed as mean ± s.e.m of two independent experiments with two-three mice per group.  
*, p<0.05; **, p<0.01 unpaired t test, comparing LLSc with DN at each time point. 
Representative dot plots showing flow cytometry for IL-4R𝛼+ cells in the CD45-EPCAM+ 
(epithelial) cells and CD45-EPCAM-CD31- stromal component component at day 0 p.c. 
salivary glands in wt (C) and il4rαko (D). Graph representing flow cytometry data for IL4Rα 
expression (E) on LLSc (black bars), DN (white bars) cells and EPCAM+ (epithelial) cells 
(grey bar) from wt mice showing selective expansion of IL4Rα+gp38+ cells at day 2 p.c. as 
compared to day 0. Data representative of three different experiments with atleast two mice 
per group, expressed as mean ± s.e.m **, p<0.01. 
A 
il-4rαko day 0 p.c. wt day 0 p.c. 
D C 
E 
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4.3 IL-4 Receptor engagement is required for LLSc induction 
To investigate whether IL-4Rα is involved in LLSc induction and formation, the salivary 
glands of il4rαko and wt mice were cannulated and the dynamic of LLSc was examined in 
these mice. As expected, wt mice showed an increase of nearly 15% in the LLSc component 
at day 2 whereas il4rαko were unable to increase the LLSc. The percentage of LLSc 
detected at day 2 in the il4rαko mice was analogous to the small population of LLSc 
generally observed at day 0. This significant defect (p<0.01) in LLSc induction was 
maintained until day 5. Surprisingly, it was restored from day 8 onwards (Fig 4.3A-B). A 
defect in LLSc induction was further confirmed by failure of il4rαko mice to form ICAM-
1highVCAM-1high cells and reduction in ICAM-1intVCAM-1int stromal cells compared to wt mice. 
Salivary glands of day 2 p.c. il4rαko showed baseline percentage ~1.5% of ICAM-1highVAM-
1high (p<0.01) whereas wt mice displayed ~8% of these cells in the CD45-EPCAM-CD31- 
stromal compartment. In addition, a decrease from 56.2% of ICAM-1intVCAM-1int stromal cells 
in wt mice to 44.1% in il4rαko was observed at day 2 p.c. (Fig 4.3C-D).  
In order to asses, if the decrease in the LLSc that was observed in the il4rαko mice was due 
to their inability to proliferate, we performed BrdU and Ki67 staining on the LLSc from il4rαko 
and wt mice. The il4rαko mice showed a normal increase in proliferation at day 2, ~20% 
LLSc were BrdU+ and ~12% were Ki67+ in contrast to ~15% BrDU+ and ~8% Ki67+ LLSc in 
wt mice. The proliferation status of the LLSc in il4rαko mice was comparable to that of wt 
mice at all other time points (Fig 4.3E-F). This data suggested that IL4Rα engagement is not 
crucial for the LLSc proliferation but clearly important for the induction of LLSc at the site of 
inflammation.   
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Figure 4.3 IL-4 Receptor engagement is required for LLSc induction. A, Dynamic of 
LLSc expansion during the inflammatory process determined by flow cytometry (percentage 
of gp38+CD31- population in the CD45-EPCAM- component) from infected wt (black 
squares)and  il4rαko (open triangles) mice at 0, day 2, day 5, day 8, day 15, day 23 p.c. Data 
is representative of two-three independent experiments with atleast two mice  per group. **, 
p<0.01, unpaired t test, comparing ko LLSc population at each time point with corresponding 
wt LLSc population. B, Representative dot plots showing flow cytometry for percentage of 
gp38+CD31- population in the CD45-EPCAM- component from day 2 p.c. salivary glands in 
wt and il4rαko. C-D, Flow cytometry of VCAM-1 and ICAM-1 expression in CD45-EPCAM- 
cells from salivary glands of wt and il4rαko mice. The graphs show percentage of VCAM-
1
hi
ICAM-1
hi
 cells (C) and VCAM-1
int
ICAM-1
int 
cells (D) obtained by flow cytometry on day 0 
and day 2 p.c. salivary glands from il4rαko mice (white bars)  in comparison to wt mice (black 
bars). Data is representative mean of two independent experiments; **, p<0.01. E-F, Flow 
cytometry to show dynamic of Ki67+ LLSc (E) and BrDU+ LLSc (F)  in wt (open squares) and 
il4rαko (black triangles) mice from day 2, day 5, day 8, day 15 and day 23 p.c. salivary 
glands. . ∗, p<0.05; ∗∗, p<0.01, versus virus cannulated wt mice. Data are representative of 
two to three experiments with atleast two mice per group. 
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4.4 IL-4 signalling via IL-4R is not fundamental for LLSc induction but critical 
for its maintenance 
To ascertain the role of IL-4 in induction of LLSc via IL4Rα engagement, il4ko mice salivary 
glands were cannulated and FACS analysis for the LLSc was performed in comparison to wt 
mice. The il4ko showed intact LLSc induction until day 5. However, at day 8 and day 15 a 
significant reduction (p<0.05) of ~15% was observed in the LLSc percentage in il4ko 
compared to wt mice (Figure 4.4A-B). This data indicates that IL-13 and not IL-4 is 
responsible for the early induction defect observed in the il4rαko mice. Conversely, IL-4 
appears to play a role in maintenance of LLSc. 
The involvement of IL-13 and not IL-4 in induction of LLSc was also confirmed by PCR, 
performed to detect IL-4 and IL-13 gene expression in the whole salivary gland at all time-
points post-cannulation. Significant IL-13 mRNA level was detected as early as 3 hours p.c. 
(p<0.05) whereas mRNA for IL-4 was detected (p<0.01-0.05) only from day 5 onwards 
(Figure 4.4C-D). 
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Figure 4.4 IL-4 signalling via IL-4R is not fundamental for LLSc induction but critical for 
its maintenance. Dynamic of LLSc expansion (A) during the inflammatory process 
determined by flow cytometry (percentage of gp38+CD31- population in the CD45-EPCAM- 
component) from infected wt (black squares) and il4ko (open circles) mice at 0, day 2, day 5, 
day 8, day 15, day 23 p.c. Data is representative mean of five independent experiments. **, p 
< 0.01, unpaired t test, comparing ko LLSc population at each time point with corresponding 
wt LLSc population. Representative dot plots (B) showing flow cytometry for percentage of 
gp38+CD31- population in the CD45-EPCAM- component from day 2 p.c. salivary glands in 
wt and il4ko. C-D Quantitative RT-PCR analysis of mRNA transcript for IL-13 (C) and IL-4 (D) 
in wt mice at day 0, 3hours, 6 hours, 24 hours, day 2, 5, 8, 15 and 23 post cannulation (p.c.).  
Transcripts were normalized to housekeeping gene β-actin. The relative expression values 
were calibrated to day 0 p.c. salivary gland values. Data are representative of three 
experiments with two to three mice analysed per group. 
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4.5 LLSc induction during inflammation is dependent on IL-13 
To validate our hypothesis that IL-13 is crucial for LLSc induction, we cannulated the salivary 
glands of il13ko mice. il13ko mice displayed exactly the same phenotype (Figure 4.5A-B) in 
LLSc induction that was observed in cannulated salivary glands of the il4rαko mice. The 
percentage of LLSc at day 2 (Figure 4.5B) and day 5 showed no increase, as compared to 
wt salivary glands (p<0.01) where a progressive increase in this population was observed. 
Interestingly, an increase in the percentage of LLSc was observed from day 8 onwards, 
(Figure 4.5A) similar to il4rαko mice. Overall, these results establish the central role of IL-13 
signalling via IL-4Rα in early induction of lymphoid like stromal cells during TLO formation.  
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Figure 4.5 LLSc induction during inflammation is dependent on IL-13. Dynamic of LLSc 
expansion (A) during the inflammatory process determined by flow cytometry (percentage of 
gp38+CD31- population in the CD45-EPCAM- component) from infected wt (black squares) 
and il13ko(open triangles) mice at 0, day 2, day 5, day 8, day 15, day 23 p.c. Data presented 
as means of five independent experiments. **, p<0.01, unpaired t test, comparing ko LLSc 
population at each time point with corresponding wt LLSc population. Representative dot 
plots (B) showing flow cytometry for percentage of gp38+CD31- population in the CD45-
EPCAM- component from day 2 p.c. salivary glands in wt and il13ko.  
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4.6 Different leukocyte cell subpopulations are responsible for IL13 production 
in inflamed salivary glands 
In order to investigate the cellular source of IL13 in the inflamed mouse salivary glands we 
examined leukocytes from digested salivary glands at 3 hours, day 2 and day 5 p.c.  A large 
number of IL13 producing cells were found at 2 hours p.c. (Figure 4.6A-B). We found that 
the largest source of IL13 production at 3 hours p.c. was mainly innate lymphoid cells (ILCs). 
By day 5 p.c. this was mostly produced by T lymphocytes. Other cell populations responsible 
for early IL13 production were CD11b+Gr1+ cells, CD11c+ cells and CD3+CD11c+ cells 
(Figure 4.6C).  
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Figure 4.6 Different leukocyte cell subpopulations are responsible for IL13 production 
in inflamed salivary glands. Representative dot plot (A) showing percentage of CD45+ IL13 
producing cells at day 2 p.c. Graphs showing absolute number of IL13 expressing cells (B) 
within cannulated salivary glands at 3hours, day 2 and day 5 p.c. Graph summarizing the 
relative distribution of IL-13 producing cells at 3 hours , day 2 and day 5 p.c. (C). Data are 
representative of two different experiments with two mice per experiment.  
B 
day 2 p.c. 
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4.7 IL-13 from both bone-marrow derived hematopoietic cells and tissue 
resident stromal cells contributes to the induction of LLSc 
Studies in asthma biology have demonstrated that in pathological conditions IL13 can be 
produced by non-hematopoietic cells such as lung epithelial cells [291]. To better understand 
the role of bone-marrow versus non bone-marrow derived IL-13 producing cells in induction 
of LLSc, salivary gland cannulation was performed on bone-marrow chimeras with bone-
marrow from wt and il13gfp/gfp mice, in which, in place of il13 gene, gfp gene had been 
knocked in (details of mice in chapter 3). Unexpectedly, the FACS analysis of LLSc in the 
cannulated mice with il13ko bone-marrow (Figure 4.7.1A-B) showed no defect in the 
induction of LLSc as observed in il4rko and il13ko mice. Immunofluorescence for detection of 
gfp+ cells demonstrated, as expected, presence of cd45+ il13gfp+ cells in the cannulated 
salivary glands of mice with il13gfp bone-marrow (Figure 4.7.1C).   
This observation led us to the question whether the early expression of IL-13, observed early 
in cannulated salivary glands, was produced by tissue resident non-hematopoietic cells. 
FACs analysis for IL-13 intracellular cytokine production was performed on single cell 
suspension from digested salivary gland stromal cells. In addition, PCR for IL-13 gene 
expression was performed on isolated salivary gland stromal cell subsets. As expected, 
tissue resident epithelial (EPCAM+) cells showed intracellular production of IL13, but 
interestingly the CD45-EPCAM- stromal cells also showed IL-13 production (Figure 4.7.2A-
B). This data was confirmed by PCR epithelial and CD45-EPCAM- stromal cells, where up-
regulation in IL13 mRNA was detected (Figure 4.7.2C). 
Altogether these data suggests a significant role of non-hematopoietic cells in the production 
of IL13 during TLO formation. 
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Figure 4.7.1 
Figure 4.7.1 IL-13 from both bone-marrow derived hematopoietic cells and stromal 
cells contributes to the induction of LLSc. Graph (A) showing no significant differences in 
the dynamic of LLSc expansion obtained by flow cytometry on day 2  p.c. infected wt (black 
bars) and il13ko bone-marrow chimera (white bars) salivary glands. Representative dot plots 
(B) showing flow cytometry for percentage of gp38+CD31- population in the CD45-EPCAM- 
component from day 2 p.c. salivary glands in wt and il13ko bone-marrow chimera. 
Representative microphotograph (C) showing induction of il13 expression in salivary gland 
upon inflammation in il13gfp bone-marrow chimera mice salivary glands (3 hours (Ci-ii) and 
day 2 (Ciii-iv) p.c.) probed with anti-gfp (green) and CD45 (red). Original magnification 10X 
(Ci-iii) and 63X (Cii-iv).  
i ii 
iii iv 
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Figure 4.7.2 IL-13 production by from tissue resident stromal cells. Dot plots (A) showing 
flow cytometry acquisition of il13 intracellular expression in CD45-CD31-EPCAM+ and CD45-
CD31-EPCAM- cell components from in-vitro virus stimulated or unstimulated digested salivary 
gland cells for 3 hours. Graphs summarising (B) flow cytometry results, showing fold-increase 
in IL-13  intracellular expression in the stimulated (black bars) CD45-CD31-EPCAM- stromal 
cells and EPCAM+ cells as compared to their corresponding unstimulated (white bars) cellular 
components and (C) summarizes transcripts encoding for IL-13  gene quantified by qRT-PCR 
and normalized to housekeeping gene β-actin in sorted CD45-CD31-EPCAM- and EPCAM+ 
cells (relative quantitation to IL-13 mRNA in unstimulated population. *, p<0.05; **, p< 0.01; ***, 
p<0.001. Data are representative of three independent experiments. 
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4.8 Lack of IL-4Rα engagement results in reduced but not diminished TLO 
formation 
In order to understand the consequence of the early defect observed in the LLSc induction 
on LLSc maturation and hence their ability to support TLO formation, the expression of LLSc 
derived lymphoid chemokines (Figure 4.8.1A-B) were studied in the cannulated salivary 
gland of il4rαko. Expectedly, a ten-fold and nearly thirty-fold decrease was observed in the 
CXCL13 gene expression within il4rαko mice salivary glands at day 5 and day 8 respectively, 
as compared to wt mice. Furthermore, a severe deficiency was also detected in up-regulation 
of CCL19 transcript in the il4rko mice at day 5 (p<0.001) and day 8 (p<0.01). Interestingly, 
normal expression in these genes was witnessed at day 15 when compared to wt mice, and 
was further confirmed by immunofluorescence (Figure 4.8.2A). This increase in lymphoid 
chemokines appeared to be due to the expansion in LLSc from day 8 onwards (shown in 
section 5.1).  
To ascertain the importance of IL-4Ra signal in TLO formation, the TLO were investigated in 
cannulated salivary glands of il4rαko mice. These animals showed defective CCR7+ and 
CXCR5+ cell accumulation at day 5 and day 8 (Figure 4.8.1C-D), though an increase in 
CXCR5+ cells was witnessed at day 15, but not CCR7+ cells. The B/T cell ratio increased at 
day 15 confirming increased recruitment of B cells (Figure 4.8.2B). Moreover, the average 
size of lymphoid aggregates in il4rαko increased from 4x104µm2 at day8 to 8x104µm2 at 
day15 (Figure 4.8.2C). Nevertheless, B/T cell ratio observed in the salivary glands of il4rko 
mice was still significantly lower (p<0.05) to wt mice, and the lymphoid aggregates were not 
only lesser but significantly smaller (p<0.05) when compared to lymphoid aggregates present 
in wt mice at day 15 (Figure 4.8.2B-C). Interestingly, the total lymphoid area was 
significantly lower in il4rko mice, ~ 4% total lymphoid aggregate area was observed in il4rko 
mice compared to ~10% in wt mice at day 8 (Figure 4.8.2D). Furthermore, less than 10% 
segregated aggregates were found in the inflamed salivary glands of il4rαko mice whereas 
40-50% aggregates exhibited segregation in wt mice (Figure 4.8.2E). Germinal centres in 
TLO are known to express AID, which is critical for their functionality and leads to local 
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production of antibodies. The il4rαko displayed a significant decrease of nearly hundred and 
fifty-fold in AICDA transcript expression at week 3 post cannulation (Figure 4.8.2F). 
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Figure 4.8.1 Lymphoid chemokines and their cognate receptor expression in il4rαko 
mice.  A-D, Diagrams representing qRT-PCR analysis of the mRNA obtained from salivary 
glands at day 5, 8, 15 and 23 p.c. showing lymphoid chemokines (CXCL13 and CCL19) and 
their cognate receptors (CXCR5 and CCR7) in il4rαko mice (white bars) in comparison to 
their wt counterparts (black bars). CXCL13 and CCL19 mRNA transcripts were normalized to 
PDGFRβ mRNA and CXCR5 and CCR7 mRNA transcripts were normalized to β-actin 
mRNA. Results are presented as relative quantitation (RQ) values calculated with calibrator 
day 0 salivary glands *, p<0.05; **, p<0.01 versus virus cannulated wt mice. Data are 
representative of two replicates (3-4 infected mice per group).  
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4.8.2 Lack of IL-4Rα engagement results in reduced but not diminished TLO formation. 
Microphotograph of lymphoid aggregates (A) from infected salivary glands (day 15 pc.) from 
wt (Aiii-iv) and il4rαko (Ai-ii) mice stained for CD3 (red), CD19 (blue) and either CXCL13 
(green in i and ii) or CCL21 (green in iii and iv). Salivary glands from wt and il4rαko day 8 
and 15 p.c. were examined by immunofluorescence for CD3 and CD19. B-E, Graphs 
representing % of total lymphoid aggregate area (B), lymphoid aggregate size (C), % of 
segregated aggregates (D) and ratio between the area covered by CD19+ B cells and CD3+ 
T cells (E) at day 8 and day 15 p.c. for wt (black bars) and il4rαko (white bars) mice. Data is 
representative of two different experiments with two to three mice per group, mean ± s.e.m. *, 
p < 0.05, unpaired t test, comparing il4rαko to wt mice. (F), Transcripts encoding for AID 
gene (normalized to housekeeping gene β-actin), in week 3 p.c. salivary glands from wt and 
il4rαko mice, were quantified and expressed as RQ values relative to day 0 p.c. AID mRNA. 
Data shown as mean ± s.e.m. of three independent experiments.  
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4.9 Absence of IL13 results in reduced but not diminished TLO formation 
In order to confirm that the defect observed in il4rαko mice in terms of LLSc-derived lymphoid 
chemokines and TLO formation was due to inability of IL-13 to signal via the receptor, we 
analysed the cannulated salivary glands of il13ko. Similar to il4rαko mice, reduced 
expression was detected in expression of CCL19 mRNA (p<0.05) in the il13ko mice at day 5 
and day 8 p.c. No difference was detected in CXCL13 mRNA levels in il13ko mice as 
compared to wt mice at day 5 and day 8 p.c. However, significantly increased expression in 
CXCL13 and CCL19 genes was witnessed at day 15 when compared to wt mice (Figure 
4.9.1A-B). Expression of lymphoid chemokines in cannulated salivary glands of il13ko was 
further confirmed by immunofluorescence (Figure 4.9.2A).  
Analogous to il4rko, il13ko mice also showed defective CCR7+ and CXCR5+ cell 
accumulation at day 5 and day 8 (Figure 4.9.1C-D), though an increase in CXCR5+ and 
CCR7+ cells was witnessed at day 15 p.c. in these mice. Expectedly, the total lymphoid area 
was significantly lower in il13ko mice at day 8 but not at day 15 p.c. (Figure 4.9.2B). 
Moreover, the size of lymphoid follicles and B/T cell ratio within lymphoid follicles showed an 
increase between day 8 and day15 p.c. (Figure 4.9.2C-D). Nevertheless, lymphoid follicle 
size and B/T cell ratio observed in the salivary glands of il13ko mice were always lower than 
wt mice (Figure 4.9.2C-D). Furthermore, lymphoid aggregates found in inflamed salivary 
glands of il13ko exhibited lower segregation when compared to aggregates in wt mice 
(Figure 4.9.2E). The il13ko also displayed a significant decrease of nearly hundred and fifty-
fold in AID transcript expression at week 3 post cannulation (Figure 4.9.2F). 
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Figure 4.9.1 A-D, Lymphoid chemokines and their cognate receptor expression in 
il13ko mice.  Diagrams representing qRT-PCR analysis of the mRNA obtained from salivary 
glands at day 5, 8, 15 and 23 p.c. showing lymphoid chemokines (CXCL13 and CCL19) and 
their cognate receptors (CXCR5 and CCR7) in il13ko mice (white bars) in comparison to their 
wt counterparts (black bars). CXCL13 and CCL19 mRNA transcripts were normalized to 
PDGFRβ mRNA and CXCR5 and CCR7 mRNA transcripts were normalized to β-actin 
mRNA. Results are presented as relative quantitation (RQ) values calculated with calibrator 
day 0 salivary glands *, p<0.05 versus virus cannulated wt mice. Data are representative of 
two replicates (3-4 infected mice per group).  
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Figure 4.9.2 Absence of IL13 engagement results in reduced but not diminished TLO 
formation. Microphotograph of lymphoid aggregates (A) from infected salivary glands (day 
15 pc.) from wt (Aiii-iv) and iI13ko (Ai-ii) mice stained for CD3 (red), CD19 (blue) and either 
CXCL13 (green in i and ii) or CCL21 (green in iii and iv). Salivary glands from wt and iI13ko 
day 8 and 15 p.c. were examined by immunofluorescence for CD3 and CD19. B-E, Graphs 
representing % of total lymphoid aggregate area (B), lymphoid aggregate size (C), % of 
segregated aggregates (D) and ratio between the area covered by CD19+ B cells and CD3+ 
T cells (E) at day 8 and day 15 p.c. for wt (black bars) and iI13ko (white bars) mice. Data is 
representative of two different experiments with two to three mice per group, mean ± s.e.m. *, 
p<0.05, unpaired t test, comparing iI13ko to wt mice. (F), Transcripts encoding for AID gene 
(normalized to housekeeping gene β-actin), in week 3 p.c. salivary glands from wt and iI13ko 
mice, were quantified and expressed as RQ values relative to day 0 p.c. AID mRNA. Data 
shown as mean ± s.e.m. of three independent experiments.  
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4.10 Absence of IL-4 results in defective TLO formation 
Detailed analysis of TLO and TLO-associated genes in salivary glands of il-4ko mice 
demonstrated an unpredicted phenotype.  
Quantitative PCR for lymphoid chemokines demonstrated a eighty-fold increase (p<0.01-
0.001) in CXCL13mRNA within salivary glands of il4ko mice at day 5 and day 8 p.c. 
compared to a ten-fold and forty-fold increase in CXCL13 transcript levels observed in wt 
mice salivary glands at day 5 and day 8 p.c. respectively (Figure 4.10.1A). Similarly, CCL19 
gene expression was increased by nearly thirty fold (p<0.05) in il4ko mice as compared to wt 
mice at day 5 p.c. (Figure 4.10.1B). il4ko mice exhibited a failure to maintain the lymphoid 
chemokine expression, and CCL19mRNA (p<0.01-0.001) level was reduced from day 8 p.c. 
onwards (p<0.01-0.001) and CXCL13 (p<0.05) at day 15 p.c. (Figure 4.10.1A-B). 
Histological examination for CXCL13 and CCL21, presented a severe reduction in 
expression of these lymphoid chemokines (Figure 4.10.1E). mRNA detection for both 
CXCR5 and CCR7 revealed considerably reduced expression for these genes from day 5 
onwards (Figure 4.10.1C-D). Even though, early expression of both CCL19 and CXCL13 
was intact in the il4ko mice, they displayed inadequacy to recruit CXCR5+ and CCR7+ cells. 
Histological analysis of lymphoid aggregates confirmed this observation, and the total 
lymphoid area (Figure 4.10.2A) and percentage of segregated aggregates (Figure 4.10.2B) 
were significantly lower in il4ko mice compared to in wt mice at day 8 and day 15. 
Furthermore, fewer and significantly smaller size aggregates (Figure 4.10.2C), with lower 
B/T cell ratio (Figure 4.10.2D) were found in il4ko mice. As expected, marked suppression of 
AID mRNA transcripts was observed in treated mice (Figure 4.10.2E). 
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Figure 4.10.1 Lymphoid chemokines and their cognate receptor expression in il4ko 
mice. A-D, Diagrams representing qRT-PCR analysis of the mRNA obtained from salivary 
glands at day 5, 8, 15 and 23 p.c. showing lymphoid chemokines (CXCL13 and CCL19) and 
their cognate receptors (CXCR5 and CCR7) in il4ko mice (white bars) in comparison to their 
wt counterparts (black bars). CXCL13 and CCL19 mRNA transcripts were normalized to 
PDGFRβ mRNA and CXCR5 and CCR7 mRNA transcripts were normalized to β-actin 
mRNA. Results are presented as relative quantitation (RQ) values calculated with calibrator 
day 0 salivary gland *, p<0.05; **, p<0.01 versus virus cannulated wt mice. Data are 
representative of two replicates (3-4 infected mice per group). Microphotograph of lymphoid 
aggregates (E) from infected salivary glands (day 15 p.c.) from wt (Eiii-iv) and il-4ko (Ei-ii) 
mice stained for CD3 (red), CD19  blue) and either CXCL13 (green in i and ii) or CCL21 
(green in iii and iv).  
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Figure 4.10.2 
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A B 
C D 
Figure 4.10.2 Absence of IL-4 results in defective TLO formation. Salivary glands from wt 
and iI4ko day 8 and 15 p.c. were examined by immunofluorescence for CD3 and CD19. A-D, 
Graphs representing % of total lymphoid aggregate area (A), % of segregated aggregates 
(B), lymphoid aggregate size (C) and ratio between the area covered by CD19+ B cells and 
CD3+ T cells (D) at day 8 and day 15 p.c. for wt (black bars) and iI4ko (white bars) mice. 
Data is representative of two different experiments with two to three mice per group, mean ± 
s.e.m. *, p<0.05, unpaired t test, comparing iI4ko to wt mice. (E), Transcripts encoding for 
AID gene (normalized to housekeeping gene β-actin), in week 3 p.c. salivary glands from wt 
and iI4ko mice, were quantified and expressed as RQ values relative to day 0 p.c. AID 
mRNA. Data shown as mean ± s.e.m. of three independent experiments.  
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Discussion 
This chapter illustrates a previously unappreciated role for IL-4R signaling, mediated by IL-
13, in the induction of quiescent tissue-resident stromal cells towards lymphoid-like stromal 
cells during inflammation. This was an exciting finding, as IL-13 (and IL-4) is known to drive 
Th2 type immune responses, which are also associated with allergy, asthma, gastrointestinal 
nemadote infections and fibrosis [292-295], but they have not previously been implicated to 
have a role in lymphoid stromal cell activation and differentiation during inflammation.  
Activated stromal cells have been shown to have the ability to initiate TLO formation in 
transplantation studies [212, 224]. Nonetheless, the specific signals that could lead to 
stromal cell activation during TLO formation are still obscure [296]. Most of our current 
knowledge about signals regulating TLO formation is dependent upon transgenic mice over-
expressing lymphoid molecules such as TNFα, LTα, LTα/LTβ, CXCL13 and CCL21 in ectopic 
sites [4, 157, 158, 165, 169, 173, 174, 227, 232]. Even though these models have provided 
important insights into TLO development, they lack the pathophysiological complexity that 
underpins in vivo generation of TLOs destruction [166-168]. Some recent studies have 
suggested a role for inflammatory effector cytokines in the initiation of stromal cell activation 
during inflammation [214, 230]. 
While conducting experiments to identify cytokines involved in the regulation of lymphoid 
stroma, our collaborator, Mark Coles identified that treatment of mesenchymal adipose-
derived stem cells (ADSC), with either interleukin 4 (IL-4) or interleukin 13 (IL-13) in 
conjunction with LT and TNF, significantly induced expression of gp38, ICAM and VCAM. 
Doucet et al., in 1998 have demonstrated that the effect of IL-4 and IL-13 on fibroblasts is 
mediated by type 2 IL-4 receptor composed of IL-4Rα and IL-13Rα chains and not by type 1 
that is composed of IL-4Rα and IL-2Rγ chains [287].  
Studies have shown that IL-4 can signal via type 1 and type 2 IL-4R whereas IL-13 only uses 
type 2 IL-4 receptor. Type 1 IL-4R expression is mainly confined to hematopoietic cells 
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whereas type 2 IL-4R receptor is majorly found on non-hematopoietic cells such as epithelial 
cells, fibroblasts [285-288] . In fact, IL-13Rα expression has been documented to be 
expressed on non-inflamed gut epithelium and myofibroblasts [295, 297]. Additionally, in 
Crohn’s disease and ulcerative colitis, increased expression IL-13Rα has been observed 
[295, 298]. We detected IL4Rα and IL13Rα expression on salivary gland CD45-EPCAM- 
stromal cells and epithelial cells in resting conditions. However, upon inflammation, LLSc 
further up-regulate the expression of these receptors. Inflammatory cytokines such as TNFα 
have been demonstrated to induce up-regulation of IL-4R on fibroblasts [289]. In our model 
TNFα production is observed very early in inflammatory process, potentially representing a 
signal that might promote further expression of IL-4R chain on LLSc. Moreover, IL-13 has 
been shown to promote its own receptor expression [293, 295].  
These observations prompted our in vivo studies in which we demonstrated that 
administration of recombinant IL-13, in absence of virus, to wild-type mice salivary gland was 
sufficient to induce lymphoid stromal cell activation. Interestingly, the induction of the 
lymphoid phenotype was less efficient when recombinant IL-4 or TNFα and LTβR agonist 
were administered to salivary glands. Of note, there was no significant difference observed 
between the expression of gp38, ICAM and VCAM on the CD45-EPCAM-CD31- stromal 
compartment in recombinant IL-4 and TNFα plus LTβR agonist cannulated salivary glands. 
Overall, this data suggested that IL-13 is a more potent inducer of the stromal cell transition 
to a lymphoid phenotype than IL-4, and even classical lymphoid cytokines such as LT and 
TNF [4, 16].  
Intriguingly, Raza et al., during their analysis of synovial fluid cytokine profiles in rheumatoid 
arthritis patients at different stages, found that IL-13 was transiently detected in early 
rheumatoid arthritis patients but not patients with established rheumatoid arthritis. Moreover, 
early rheumatoid arthritis patients with significantly increased levels of IL-13 went on to 
develop established autoantibody positive rheumatoid arthritis. This data indicates a 
pathological role for IL-13 early in inflammation [299]. IL-13 has also been implicated in 
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inducing fibroblast proliferation and differentiation during fibrosis in Th2 mediated diseases 
such as schistosomiasis [300].  
We hypothesised that IL-4R signalling might play a role in regulating early transition of 
normal resident stromal cells towards a lymphoid like/pathological phenotype. In order to test 
this hypothesis, salivary glands of C57BL/6 mice wild type and knockout mice (IL-4Rα, IL-4, 
IL-13) were cannulated and analysed for LLSc induction and TLO formation. We observed a 
significantly reduced percentage of gp38+LLSc in il4rαko and il13ko mice at day 2 p.c. as 
compared to wild-type mice. Moreover, il4rαko and il13ko mice exhibited failure to up-
regulate the expression of other stromal cell markers such as ICAM-1 and VCAM-1. 
Our results from Ki67 and BrDU staining on LLSc confirmed that the defect observed in the 
lymphoid stroma (LLSc), of il4rαko and il13ko, was not due the inability of LLSc to proliferate. 
Other studies have shown that IL-13 can prevent apoptosis of tumour cells and activated 
fibroblasts during inflammatory and fibrotic diseases [293, 295, 301-304] and this proposed 
anti-apoptotic role of IL-13 cannot be ruled out with the present set of data.  
In our model, IL-13 is produced in significant quantities by CD4+Th2 cells [305]. However, 
innate immune cells such NK cell, NKT cells and CD11b+ myeloid cells including eosinophils, 
basophils and mast cells, have also been reported to produce IL-13 [293, 295]. Group 2 
innate lymphoid cells (ILC) subset has been shown to produce canonical Th-2 cytokines IL-
13 and IL-5 in response to epithelial cell–derived cytokines IL-25, IL-33, that are themselves 
released in response to inflammation and infection [306].  Group 2 ILC cells have also been 
shown to mediate allergic lung inflammation [307, 308]. ILCs require IL-7Ra signalling for 
their development and maintenance. Thus, they are broadly identified as lineage negative IL-
7Rα positive cells [306]. FACs analysis identified ILC as the major source of IL-13 at 3 hours 
p.c. We have demonstrated that virus infects the epithelial cells [237] and thus one can 
speculate that epithelial derived cytokines IL-25/IL-33 are produced which stimulate the ILC 
(already shown in previous chapter to be present in resting salivary glands) to produce IL-13. 
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However, at day 2, various IL-13 producing cell types were observed which included 
granulocytes, ILC and T cells. Though, at day 5, the majority of IL-13 was produced by T 
cells, which coincides increased IL-4 expression detected in cannulated salivary glands. It 
has been previously shown that IL-4 is required for priming and differentiation of CD4+ Th-2 
cells, thus production of IL-13 from T cells is dependent on IL-4.  
Cannulated salivary glands of bone-marrow chimera mice reconstituted with il13ko 
hematopoietic cells demonstrated intact LLSc induction, clearly suggesting that non-
hematopoietic cells were sufficient to produce IL-13 upon inflammation and activate lymphoid 
stroma induction. Accordingly, epithelial cell have been implicated to be the chief source of 
IL-13 during airway inflammation [291]. Moreover, microarray analysis of thymic epithelial 
cells (TECs) revealed significantly up-regulated IL-13 expression in these cells (Immgene). 
We identified epithelial cells and also CD45-EPCAM-CD31- stromal cells as the major source 
of IL13, after adenovirus infection. This suggests that tissue-resident stromal cells (epithelial 
cells and fibroblasts) provide the first signal in lymphoid stromal cell activation in response to 
inflammatory stimuli. 
Detailed analysis of LLSc and TLO-associated features, and lymphoid genes in il4ko mice, 
revealed a defect in maintenance of LLSc and production of lymphoid chemokines and 
cytokines from day 8 onwards. In agreement with this data, significant decrease was 
observed in the size of lymphoid aggregates and B/T cell ratio in the salivary glands of these 
mice. However, these results in il4ko are under further investigation as these observations 
were not replicated in il4rαko, which would be expected, since IL4Rα subunit is common to 
both type1 and type 2 IL-4R and is utilized by IL-4 to mediate its biologic functions. Such 
discrepancy has been observed in experimental mouse model of autoimmune diabetes, 
where IL-4 administration has been reported to play a protecting role [309]. Conversely, 
another study reported that lack of IL-4Rα protected the mice against the induction of  
diabetes in a spontaneous mouse model . One speculation for our finding is that IL-4 mainly 
mediates its function on immune cells whereas IL-13 mediates its effect mainly on stromal 
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cells. Because immune cells express IL-4Rα and yc chain, there is a possibility that in the 
absence of IL4Rα, its function is probably transferred to the gamma chain of the IL-2 receptor 
complex, as suggested by Wang et al., in 1996 [310].  
In agreement with our data, both in vitro and in vivo, we propose that IL-13 signalling through 
the IL-4Rα is critical for induction of lymphoid stromal cells. However, data in this chapter 
indicates that there are other signals operating during the initial phases of TLO formation 
which seem to compensate for the early defect observed in the absence of IL13/IL4Rα 
signalling axis.  
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Chapter 5 
IL22 regulates antibody-mediated autoimmunity by 
inducing lymphoid like stromal cell proliferation in TLOs 
Introduction 
IL22 is a member of IL-10 cytokine family, and it signals via a heterodimeric receptor 
consisting of IL-22Rα and IL-10Rβ  [311-313]; the expression of IL-22R is largely confined to 
non-hematopoietic cells [314]. Keratinocytes, colonic epithelial cells and hepatocytes are well 
established IL-22- target cells in literature [313]. IL22 is a paradoxical cytokine. It has been 
shown to be involved in tissue homeostasis and wound healing at barrier surfaces [315] and 
has also recently been shown to regulate thymic regeneration, following tissue damage 
[316]. During infection with C.rodentium, IL-22 has been demonstrated to help maintain 
normal architecture of colonic patches and most interestingly sustain the number of ILFs 
[317]. In addition to promoting tissue repair via induction of epithelial cell proliferation and 
survival, it has also been implicated in the development of skin pathology [318] as well as 
epithelial tumors in the gut [319]. Furthermore, IL-22 has been shown to induce podoplanin 
(gp38) expression on epidermal keratinocytes that are associated with wound and psoriatic 
hyper-proliferative epidermis [320]. An association between IL22 expression and 
autoimmune conditions has also been suggested [321, 322]. IL-22R1 expression has been 
reported by Ikeuchi et al., on synovial fibroblasts derived from RA patients (RASF). Authors 
further demonstrated that IL-22, promoted proliferation and chemokine production of synovial 
fibroblasts [323]. Moreover, IL-22 stimulated lung fibroblasts have been shown to up-regulate 
lymphoid chemokine expression, particularly CXCL13 [324].  In SS, serum levels of IL22 
correlate with clinical manifestations of the disease, including autoantibody production [325].  
Moreover, IL-22 has been associated with IL-17 in various inflammatory diseases, and in 
some disease conditions such as psoriasis it has been demonstrated to be required for IL-17 
mediated pathology [326]. In il22ko mice, CIA was shown to be less severe due to decreased 
germinal centre formation, plasma cell formation and IgG2a antibody production, suggesting 
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a pathogenic role for IL-22 in B cell autoimmunity. The authors confirmed that il22ko did not 
have defect in IL-17 production and thus the reduction in arthritis was due to absence of IL-
22 and not IL-17 [19]. Th17 cells have been thought to be the major producers of IL-22. 
However, it is now known that IL-22 can also be produced by a novel CD4+ T cell subset, 
Th22 cells as well as NK cells and ILC [306, 313]. In fact, IL-22+IL-17-CD4+T cells have 
been reported in patients with rheumatoid arthritis and active SLE [327, 328]. 
Taken together, these studies provided a rationale to examine if IL-22 plays any role in 
regulating LLSc within TLOs and in particular whether IL-22 might be responsible for the 
proliferation phase, observed in our model after IL-13 induction of LLSc. 
 
 
 
  
157 
 
Results 
5.1 IL22 is expressed early in salivary gland inflammation and T cells are the 
major cellular source of IL22 in inflamed salivary glands 
In order to explore a potential role of IL22 in driving transition from constitutive fibroblastic 
stroma to “lymphoid like stroma”, and the subsequent formation of TLOs, quantitative 
analysis of total salivary gland mRNA was used to identify the temporal expression of IL22 in 
cannulated salivary glands. IL22 was significantly up regulated as early as 3 hours p.c. 
(~6000 fold increase was detected in comparison to day 0 p.c. salivary gland),  and a second 
peak of 1000 fold increase in IL22 mRNA transcript levels was detected at day 5 p.c. (Figure 
5.1A).   
We next investigated the cellular source of IL22 in single cell suspensions from cannulated 
salivary glands at different time-points p.c. (3 hours, day 2 and day 5 p.c.) (Figure 5.1B-D).  
The highest numbers of IL22 producing cells were found within the CD45+ cell population by 
3 hour p.c. (Figure 5.1B). The largest source of IL22 was T cells at all time-points examined 
(Figure 5.1C). While at 3 hours p.c. IL22 production was mainly derived from γδ T cells 
(~80% of the IL22+ cells were γδ T cells (Figure 5.1C-D)), by day 5 p.c. 85% of IL22 
producing cells were αβ T lymphocytes (Figure 5.1C-D). Other leukocyte populations, 
responsible for early IL22 production, were innate lymphoid cells (ILCs) and natural killer 
cells (NK).  At 3 hours and day 2 p.c. ILC represented ~20-30% of the IL22+ cells in the 
cannulated glands. In addition, at day 2 p.c. ~20% of IL-22+CD45+ cells were NK cells 
(Figure 5.1C).  
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Figure 5.1 IL22 is expressed early in salivary gland inflammation and T cells are the major 
cellular source of IL22 in inflamed salivary glands. Quantitative RT-PCR analysis of mRNA 
transcripts for il22 (A) in wt mice at various time points post-cannulation (p.c.).  Transcripts were 
normalized to β-actin. The relative expression values were calibrated to day 0 p.c. salivary gland 
values. * p < 0.05; ** p < 0.01; *** p < 0.001 versus day 0. Data are representative of three to four 
experiments with two to three mice analysed per group. (B) Graphs showing absolute number of 
IL22 expressing cells contained within the digested CD45+ leukocyte population from cannulated 
salivary glands at 3h, day 2 and day 5 p.c. (C) Graph summarizing the relative distribution of IL22 
producing cells in the CD45+ leukocyte population at 3h, day 2 and day 5 p.c. (D) Representative dot 
plots identifying IL22 producing cells at 3 hours and day 5 p.c. in the γδ+ T cell population at 3h and 
in the +T cells at day 5 p.c. Data are representative of two different experiments with three mice  
per experiment.  
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5.2 Lack of IL22 results in abortive TLO formation and suppression of 
autoantibody production 
IL22 and IL22 producing cells have been reported in salivary glands of patients with SS. 
Furthermore, IL22 serum level in SS patients has been shown to correlate with clinical 
manifestations of the disease and autoantibody production. However, the mechanistic 
contribution of IL22 to TLO development and autoantibody production remains unknown. In 
order to investigate the role of IL22 in TLO formation, salivary glands of il22ko mice were 
cannulated with adenovirus and compared to wt controls. Detailed histological analysis of 
lymphoid aggregates at day 8 and day 15 p.c. was performed for il22ko versus wt mice 
(Figure 5.2.1A-F). Interestingly, the fraction lymphoid area was significantly lower in il22ko 
mice as compared to the wt. Indeed,  less than 4% total lymphoid aggregate area was 
observed in il22ko mice compared to ~10% and 8% in wt mice at day 8 and day 15 p.c. 
respectively (Figure 5.2.1B). il22ko mice showed abortive follicle formation with the 
generation of small T-cell aggregates and defective B-cell accumulation at day 8 and 15 p.c. 
reflected by reduced lymphoid follicle size (4-5um2x104 in il22ko versus 7.5-11 um2x104 in wt 
mice (Figure 5.2.1C) and lower B/T cell ratio (ratio of CD19/CD3 positive area was less than 
0.25 and 1 at day 8 and day 15 respectively compared to a ratio of 0.6 at day 8 and ratio of 2 
at day 15 in wt mice (Figure 5.2.1D). Less than 10% segregated aggregates were found in 
the inflamed salivary glands of il22ko mice, whereas 40-50% aggregates exhibited 
segregation in wt mice (Figure 5.2.1E).  A significant decrease in AID transcript expression 
was observed in the salivary glands of il22ko at week 3 post cannulation (Figure 5.2.1F),  
which coincided with a marked suppression of ANA autoantibody production as compared to 
wt mice (Figure 5.2.2A-B). 
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Figure 5.2.1 Lack of IL22 results in abortive TLO formation. Microphotograph of lymphoid 
aggregates (A) from infected wt (Ai-iii) and il22ko (Aii-iv) mice salivary glands at day 8 (Ai-
ii) and day 15 (Aiii-iv) p.c. stained for CD3 (red) and CD19 (blue). % of total lymphoid 
aggregate area (B) and % of segregated aggregates (C) at day 8 and day 15 p.c. for wt 
(black bars) and il22ko (white bars) mice. Lymphoid aggregate size (D) at day 8 and day 15 
p.c. for wt (black bars) and il22ko (white bars) mice. Ratio between the area covered by 
CD19+ B cells and CD3+ T cells (E) at day 8 and 15 p.c. for wt (black bars) and il22ko (white 
bars) mice. Data is representative of two different experiments with two to three mice per 
group, mean ± s.e.m. **, p < 0.01; ***p<0.001 unpaired t test, comparing il22ko to wt mice. 
(F), Transcripts encoding for aicda gene (normalized to housekeeping gene β-actin), in week 
3 p.c. salivary glands from wt and il22ko mice, were quantified and expressed as RQ values 
relative to day 0 p.c. AID mRNA. Data shown as mean ± s.e.m. of three independent 
experiments.  
AID mRNA  
Week 3 p.c. 
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Figure 5.2.2 Lack of IL22 results in suppression of autoantibody production. 
Representative microphotographs of immunofluorescence detection of ANA (Ai-vi) 
using Hep2 cells as a substrate demonstrating strong nuclear reactivity in sera of day 
23 p.c. wt (Ai-iii) mice, but not in il22ko (Aiv-vi) mice (nuclear staining in grey, ANA 
reactivity in green)(serum dilution 1:80). Original magnification 40X. (B) Detection of 
ANA reactivity in wt mice compared to il22ko mice. * p < 0.05 wt versus day 23 p.c 
il22ko mice. Data are representative of two experiments with five cannulated mice 
(biological replicates expressed as percentage of mice positive for ANA at 1:80 dilution 
or more, mean ± s.e.m.).  
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5.3 Abortive TLO formation observed in il22ko mice can be attributed to the 
deficiency in the lymphoid chemokines and cytokine production in these mice. 
Further examination of the cannulated il22ko mice revealed significantly decreased 
production of the B-cell recruiting chemokine CXCL13 at all time-points compared to their wt 
counterparts. Nearly 5-fold, 35-fold and 55-fold difference was observed in the cxcl13 
transcript levels between il22ko and wt mice at day 5, day 8 and day 15 p.c. respectively 
(Figure 5.3B). Reduced CXCL13 expression in the il22ko salivary glands was confirmed by 
IF (Figure 5.3Ai-ii). il22ko additionally exhibited a defect in B cell survival factor BAFF 
mRNA up-regulation (Figure 5.2C). Moreover, a significant decrease of 15-fold, 55-fold and 
20-fold in the T-cell associated chemokine CCL19 was also observed in il22ko as compared 
to wt salivary glands at day 5, day 8 and day 15 p.c. respectively (Figure 5.3D). To further 
support the lymphoid chemokine expression and aggregate histological data, q-PCR analysis 
for CXCR5 and CCR7 mRNA also showed a significantly lower transcript levels when 
compared to wt mice (Figure 5.3D-E). Finally, a substantial reduction in LTβ mRNA in the 
il22ko mice was observed which was most likely due to defective recruitment of LTβ 
expressing lymphocytes (Figure 5.3F). Altogether, the data indicated defective recruitment 
and ability of lymphocytes to organize and form TLO within cannulated salivary glands in the 
absence of IL22.  
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Figure 5.3 Abortive TLO formation observed in il22ko mice can be 
attributed to the deficiency in the lymphoid chemokines and cytokine 
production in these mice. Microphotograph of lymphoid aggregate (A) from 
infected salivary glands (day 15 p.c.) from wt (Ai) and il22rαko (Aii) mice 
stained for CD3 (red), CD19 (blue) and CXCL13 (green). Quantitative PCR 
analysis of CXCL13 (B). CCL19 (C), CXCR5 (D), CCR7 (E) and LTβ (F) and 
BAFF (G) mRNA obtained from salivary glands at day 5, 8, 15 and 23 p.c. 
Expression of these genes is shown for il22rαko mice (white bars) compared 
to their wt counterparts (black bars); CXCL13, CCL19 and BAFF mRNA 
transcripts were normalized to PDGFRβ mRNA. CXCR5, CCR7 and LTβ 
mRNA transcripts were normalized to β-actin mRNA. Results are presented as 
relative quantitation (RQ) values calculated with calibrator day 0 salivary gland 
* p < 0.05; ** p < 0.01. Data are representative as mean ± s.e.m. of three 
independent experiments with three to four mice per group.  
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5.4 IL22 Receptor engagement is required for LLSc proliferation 
Since analysis of LLSc in chapter 1 had shown that these cells were responsible for the 
production of lymphoid chemokines and cytokines in the salivary gland inflammation model, it 
was postulated that the defect in TLO formation observed in the il22ko might be due to an 
effect on LLSc maturation or expansion.  
First, to investigate whether IL22 exerted its effect directly on LLSc, the expression of IL22r 
on the LLSc was examined. FACS analysis performed on digested tissue revealed that 
IL22R was expressed, both on gp38+LLSc and on the gp38-CD31-EPCAM-CD45- stroma 
in non-stimulated tissue (Figure 5.4.1A). Five days p.c. the percentage of IL22R+ 
expression increased in the LLSc, but not in the gp38-CD31-EpCAM-CD45- cells (p<0.01), 
suggesting preferential up-regulation of IL22r in this population (Figure 5.4.1A-B). The 
specificity of the IL22Rα staining was confirmed by staining the digested salivary glands of 
il22rαko mice, both at day 0 and day 5 p.c (Figure 5.4.1A). The up-regulation of IL22Rα was 
further confirmed at mRNA level in the LLSc. As expected, IL-22Rα expression was also 
observed in the EPCAM+ epithelial cells (Figure 5.4.1C). Analysis of cell proliferation, 
comparing IL22R+ and IL22R- cells within the LLSc and double negative (gp38-CD31-
EPCAM-CD45-) populations, showed a significant proliferative advantage (p<0.01) for 
IL22R+LLSc as compared to IL22R-LLSc (Figure 5.4.1D).  
In order to further examine the formation of LLSc in the salivary glands of both Il22ko and 
Il22rako, as compared wt mice, these mice were cannulated with replication deficient 
adenovirus, and FACs analysis of the lymphoid stromal cell compartment was performed 
(Figure 5.4.2A-B). The il22ko and il22rαko mice exhibited an intact activation of LLSc up to 
day 2 p.c., confirmed by a ~20% increase in percentage of LLSc observed in these ko mice, 
similar to wt mice. However, the wt mice at day 5 (p<0.05) showed further increase of nearly 
20% in the LLSc component, whereas both the il22ko and il22rαko demonstrated failure to 
expand the LLSc at day 5. This significant decrease in LLSc was further maintained at day 8 
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(p<0.01-0.001) and day 15 (p<0.01) p.c., with nearly 10% difference observed in the wt 
compared to il22ko and il22rαko at these time points (Figure 5.4.2A-B).  
In order to assess the proliferative status of LLSc in absence of il22 signal, BrdU and Ki67 
staining was performed on the LLSc from il22rαko ko and wt mice. Interestingly, the il22rαko 
mice showed decreased proliferation at day 5 (~10% LLSc were BrdU+ and ~2.5% were 
Ki67+ in contrast to ~40% BrDU+ and ~8% Ki67+ LLSc in wt mice). BrdU staining on LLSc at 
other time-points revealed the reduced proliferative ability of the LLSc in il22rαko mice at all 
other time points as well. A moderate increase in Ki67+ LLSc was observed at day 15 p.c. 
(Figure 5.4.2C-D).  
Overall, this data suggests that IL22Rα engagement is crucial for the LLSc proliferation but 
not required for LLSc induction at the sites of TLO formation.   
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Figure 5.4.1 IL22 Receptor engagement is required for LLSc proliferation. Representative dot 
plots showing flow cytometry for IL-22Rα+ cells in the CD45-EPCAM-CD31- gp38+ and gp38- 
stromal component at day 5 p.c. salivary glands in il22rako and wt mice (A). FACS analysis of the 
fold increase in IL22rα+ expressing cells (B) within CD45-EPCAM-CD31-gp38+ cells and CD45-
EPCAM-CD31-gp38- cells at day 5 p.c. as compared to day 0. Data representative of two different 
experiments with two mice per group, expressed as mean ± s.e.m ** p < 0.01. IL22Rα transcripts 
(C) on FACS sorted gp38+CD31-LLSc (black bars) in comparison to gp38-CD31- double negative 
cells (DN, white bars) and CD45-EPCAM+ (epithelial) cells (grey bars). Transcripts were assessed 
by quantitative RT-PCR and normalized to housekeeping gene β-actin. Relative quantitation (RQ) 
calculated with calibrator day 0 DN cells. Data expressed as mean ± s.e.m.  of two independent 
experiments with three mice per group. *, p<0.05; **, p<0.01; *** p<0.001 unpaired t test, 
comparing LLSc with DN at each time point. BrdU (D) incorporation in IL22Rα+ (black bars) and 
IL22Rα- (grey bars) cells within CD45-EPCAM-CD31-gp38+ (LLSc) and CD45-EPCAM-CD31-
gp38- (DN) cell populations  at day 5 p.c. Graph representative of two different experiments with 
three mice per group. Data expressed as mean ± s.e.m ** p<0.01.   
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Figure 5.4.2 il22ko and il22rαko exhibit defective LLSc expansion. FACS histogram 
representing (A) LLSc expansion in il22ko and il22rαko compared to wt mice at day 5 p.c. Graph 
summarising (B) the FACS data, il22rαko (open circles), il22ko (open triangles) and wt mice (open 
squares). Data are presented as mean ± s.e.m. of three independent experiments with at least two 
mice for each experiment.  * p<0.05; ** p<0.01, *** p<0.001, unpaired t test. Graph summarizing 
flow cytometry data of BrdU incorporation (C) and Ki67+ (D) in LLSc from wt (black bars) and 
il22rαko (white bars) mice from day 2, 5, 8, 15 and day 23 p.c. * p<0.05; ** p<0.01, *** p<0.001 
versus cannulated wt mice. Data presented as mean ± s.e.m. of three independent experiments 
with at least three mice for each experiment.  
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5.5 IL22 administration up-regulates IL-22Rα expression and regulates LLSc 
proliferation 
To confirm whether IL22 alone was responsible for the induction of LLSc proliferation, IL22 
recombinant protein or PBS was directly cannulated into the salivary glands of wt mice in the 
absence of virus.  
A 30% increase (p<0.05) in the LLSc component was observed in the recombinant (r) IL-22 
(Figure 5.5.1A and C) cannulated salivary glands when compared to PBS cannulated 
salivary glands. As expected nearly 30% of LLSc were positive for Ki67 in rIL22 (p<0.001) 
cannulated salivary glands compared to 1% of Ki67+ LLSc in PBS cannulated salivary 
glands (Figure 5.5.1A and D). Further analysis of LLSc and DN cells in rIL22 cannulated 
mice, showed an increased proliferative ability of the LLSc (p<0.001) compared to DNs 
(Figure 5.5.1E). IL22 is known to induce cell proliferation via the phosphorylation of Akt and 
mTOR activation [329]. Hence, IL22rα activity in LLSc was confirmed by showing increased 
phosphorylated Akt in LLSc compared to DN cells in rIL22 cannulated glands and LLSc from 
PBS cannulated salivary glands (Figure 5.5.1B). MFI data exhibited almost three fold 
increase (p<0.001) in the gp38 expression on LLSc when salivary glands were cannulated 
with rIL-22 as compared to PBS (Figure 5.5.1F).  
IL22 administration, but not PBS, demonstrated the ability of IL-22 to induce up-regulation of 
IL22R on the LLSc, four-fold increase in IL22Rα expression was observed in LLSc 
compared to DN cells (Figure 5.5.2A-B). 
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Figure 5.5.1 Direct IL22 administration induces LLSc proliferation. wt mice salivary 
glands were directly cannulated with IL22 recombinant cytokine (rIL22) or PBS and analysed 
at day 2 p.c. Representative dot plots (A) showing expansion of the CD45-EpCAM- CD31-
gp38+ cells post treatment with IL22 or PBS. Histogram showing increased phosphorylation 
of AKT (B) at day 2 p.c. in CD45-EpCAM-CD31-gp38+ cells as compared to CD45-EpCAM-
CD31-gp38- cells taken from salivary glands stimulated with IL22 (black and blue lines) 
compared to PBS (grey line). Proliferation was assessed by Ki67 staining for CD45-EpCAM-
CD31-gp38+ and CD45-EpCAM- CD31-gp38- stromal cells. Graph summarizing the flow 
cytometry data showing a significant increase in the percentage of CD45-EpCAM-
gp38+CD31- (C) and percentage of Ki67+ cells (D) within CD45-EpCAM-CD31-gp38+ cell 
population and  the difference in proliferation rate (E) between CD45-EpCAM-CD31-gp38+ 
and CD45-EpCAM-CD31-gp38- cells and increased gp38 expression (shown as MFI values) 
on CD45-EpCAM-CD31-gp38+ cells (F) in IL22 treated mice (day 2 p.c.). Data are presented 
as mean ± s.e.m. of three independent experiments two mice per group * p<0.05; *** p < 
0.001.  
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Figure 5.5.2 
A 
Figure 5.5.2 IL22 administration up-regulates IL-22Rα expression. wt mice 
salivary glands were directly cannulated with IL22 recombinant protein (rIL22) or 
PBS and analysed at day 2 p.c. Flow cytometry for IL22rα expression on CD45-
EpCAM-CD31- cells from PBS and recombinant IL22 cannulated mice. Graph 
representing the FACS data for the fold increase in IL22rα+ expressing cells within 
CD45-EPCAM-CD31-gp38+ cells and CD45-EPCAM-CD31-gp38- cells in IL22 
treated mice as compared to day PBS treated mice. Data are presentated as mean ± 
s.e.m. of three independent experiments two mice per group. 
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5.6 IL22Rα engagement on LLSc up-regulates lymphoid chemokines and 
cytokines 
Given the severe impairment observed in expression of lymphoid chemokine and cytokines 
in il-22ko mice and the suggestion in literature that IL-22 can directly up-regulate CXCL13 
expression in lung fibroblasts [324], we hypothesized that IL-22 not only promotes expansion 
of LLSc but also supports their production of lymphoid chemokines and cytokines. To test 
this hypothesis, LLSc were isolated from salivary glands of mice, cultured in vitro for 24 
hours with rIL22, rTNFα+LTβR agonist, rIL22+rTNFα+LTβR agonist or PBS and analyzed for 
the expression of CXCL13 (Figure 5.6A), CCL19 (Figure 5.6B)  and BAFF (Figure 5.6C) by 
quantitative PCR. As expected, treatment with TNFα+LTβR agonist promoted increased 
expression (p<0.05) of CXCL13, CCL19 and BAFF, but a significant up-regulation in these 
genes, and in particular, CXCL13 (p<0.05) was also observed in LLSc treated with only 
rIL22. Combined treatment with rIL22+rTNFα+LTβR agonist increased the expression of 
CXCL13 (p<0.01), CCL19 and BAFF (p<0.01) above the levels observed with the single 
cytokines. 
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Figure 5.6 IL22Rα engagement on LLSc up-regulates lymphoid chemokines and 
cytokines. Quantitative PCR analysis of CXCL13 (A) CCL19 (B) and BAFF (C) mRNA 
obtained from LLSc stimulated with recombinant cytokines; IL-22 (black bars), IL-
22+TNF𝛼 +LTβR agonist (grey bars), TNF𝛼 +LTβR agonist (light brown bars) or PBS 
(white bars). CXCL13, CCL19 and BAFF mRNA transcripts were normalized to β-actin 
mRNA. Results are presented as relative quantitation (RQ) values calculated with 
calibrator day 0 salivary gland * p < 0.05; ** p < 0.01. Data are representative as mean ± 
s.e.m. of three independent experiments with three to four mice per group.  
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5.7 Therapeutic IL22 blockade inhibits stromal cell proliferation and abolishes 
autoantibody production 
In order to explore therapeutic consequences of our findings in il22ko mice, cannulated mice 
were treated with blocking anti-IL22 antibody starting at either day 2 or day 8 p.c. IF analysis 
revealed defective lymphoid aggregate formation in IL-22 blocking antibody treated mice 
compared to untreated mice, both in terms of TLOs size (Figure 5.7.1A-B) and B/T-cell 
organization (Figure 5.7.1A and C). This impairment was more pronounced if mice were 
treated from day 2 p.c. compared to day 8 p.c. (Figure 5.7.1A-C). Quantitative RT-PCR 
analysis of the salivary glands from treated mice showed significant reduction in the 
production of cxcl13, ccl19 and baff, as observed in the il22ko mice (Figure 5.7.1D-F). This 
was accompanied by a significant defect in the expansion and proliferation of the LLSc in the 
treated mice (Figure 5.7.1G-H). Marked suppression of aicda mRNA transcripts was also 
observed in mice treated with IL-22, blocking antibody (Figure 5.7.2A) that coincided with a 
significant decrease in ANA autoantibody production (Figure 5.7.2B-C). 
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Figure 5.7.1 
Figure 5.7.1 Therapeutic IL22 blockade inhibits stromal cell proliferation. Cannulated wt mice were 
treated with IL22 blocking antibody every three days from day 2 p.c. or every three days from day 8 p.c. 
Microphotographs of lymphocytic aggregates (A) from wt cannulated salivary glands from untreated mice and 
mice treated with anti IL22 blocking agent from day 8 or day 2 p.c. analysed at day 15 p.c. for CD3 (red), 
CD19 (blue) and CXCL13 (green). Original magnification 25X. Lymphoid aggregate (B) for untreated mice 
(black bars) compared to mice treated from day 8 p.c. (white bars) and mice treated from day 2 p.c. (grey 
bars) for aggregates at day 15 p.c. *** p < 0.001. The ratio between the area covered by CD19+ B cells and 
CD3+ T cells (C)  at day 15 p.c. for untreated (black bars) vs. treated from day 8 p.c. (white bars) and treated 
from day 2 p.c. (grey bars) mice. Data are represented as mean ± s.e.m. of two independent experiments 
with two to three mice per group. * p < 0.05; *** p < 0.001, unpaired t test between each group. Quantitative 
PCR analysis for cxcl13 mRNA (D), ccl19 mRNA (E) and baff mRNA (F)   obtained from salivary glands at 
day 15 p.c. is shown for wt cannulated untreated mice (black bars) and mice treated with IL22 blocking 
antibodies from day 8 p.c. (white bars) and day 2 p.c. (grey bars). cxcl13 mRNA transcripts were normalized 
to pdgfrβ mRNA and results are presented as relative quantitation (RQ) values calculated with calibrator day 
0 untreated salivary glands ** p < 0.01; *** p < 0.001 versus untreated cannulated salivary gland.  Data are 
presented as mean ± s.e.m. of two independent experiments with two to three mice per group. Percentage of 
LLSc (G) in mice treated with IL22 blocking antibody from day 2 p.c. (grey bars) as compared to untreated 
controls at day 5 and 8 p.c. (black bars). Graph showing flow cytometry data for percentage of BrdU+ cells 
within LLSc (H) cells in mice treated with IL22 blocking antibody from day 2 p.c. (grey bars) as compared to 
untreated controls at day 5 and 8 p.c. (black bars). Data representative of two experiments with two to three 
mice per group, Data are expressed as mean ± s.e.m. ** p < 0.01, *** p < 0.001 versus untreated WT mice. 
E F 
Lymphoid aggregate size 
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Figure 5.7.2 Therapeutic IL22 blockade abolishes autoantibody production. 
Quantitative PCR analysis for aicda mRNA (A) obtained from salivary glands at day 23 pc., 
for wt cannulated untreated mice (black bars) and mice treated with IL22 blocking 
antibodies from day 8 p.c. (white bars) and day 2 p.c. (grey bars). Results are presented as 
RQ value as compared to day 0 resting salivary glands. * p < 0.05; ** p < 0.01. Data are 
presented as mean ± s.e.m. of two independent experiments with two to three mice per 
group. (B) Representative microphotographs of immunofluorescent detection of ANA on 
Hep2 cells showing nuclear reactivity in sera of day 23 p.c. untreated wt mice, (Bi) and 
loss of ANA antibody in the anti-IL22 treated mice (Bii) from day 2 p.c. at day 23 p.c 
(nuclear staining in grey, ANA reactivity in green)(dilution 1:80). Original magnification 40X. 
(C) Graph summarizing ANA reactivity in treated vs. untreated mice at day 23 p.c. Data are 
representative of two experiments with four cannulated mice (biological replicates 
expressed as percentage of mice positive for ANA at 1:80 dilution or more, mean ± s.e.m.).  
AID mRNA  
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Discussion 
IL22 regulates mucosal homeostasis and promotes epithelial repair following tissue damage 
[330, 331]. Recently, implicated in malignant epithelial cell proliferation [319], the role of IL22 
in chronic inflammation remains enigmatic. Studies in humans have detected IL22 mRNA in 
salivary glands of patients with SS [332], and in this disease, elevated serum levels of IL22 
correlate with disease parameters, including hyper-gammaglobulinemia and autoantibody 
production [325]. These clinical observations suggest a role for IL-22 in TLO-associated 
inflammatory diseases such as SS. This chapter documents data on IL22 and its role in 
regulating stromal cell proliferation during TLO formation in our model of salivary gland 
inflammation. 
Similar to IL-13, increased expression of IL22 was found to occur within hours of salivary 
gland cannulation, with different cell populations involved in IL22 production. Various immune 
cell populations particularly T cells, NK cells and innate lymphoid cells belonging to the LTi 
family have been reported to produce IL-22  [322]. In the earliest phases,  T cells represent 
the major source of IL22, although other cell types such as innate lymphoid cells (ILC) and 
natural killer cells (NK) also contributed to the production of this cytokine. By day 5, newly 
recruited  T cells were primarily responsible for the second wave of IL22 expression.  
Recently, IL22Rα expression has been observed in a population of non-epithelial stromal 
cells isolated from rheumatoid arthritis synovial tissue [329]. Similarly, in our model, IL-22Rα 
was detected on the LLSc and shown to play a non-redundant role in the proliferation of 
gp38+IL22Rα+ LLSc via AKT phosphorylation. Several cytokines such as TNFα or IFNα 
have associated with up-regulation of IL-22Rα on epithelial cells and keratinocytes [333, 
334]. TNFα expression is detected early in inflammation in our model and therefore could be 
possibly involved in IL-22Rα up-regulation that we observe. A role for IFN cannot be ruled 
out as this family of cytokines are expressed early as a first line of defence during adenovirus 
virus infection [17, 19].  
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We also showed that IL22 expression is able to induce up-regulation of IL22Rα on LLSc, 
thus establishing an amplificatory loop, which provides a feed forward proliferative advantage 
to this cellular component. We demonstrated that CXCL13, CCL19 and BAFF expression 
can be directly regulated by IL22Rα engagement as previously shown in vitro [324]. It has 
been elegantly demonstrated that CXCL13 expression is necessary and sufficient for the 
establishment of lymphoid follicles [36, 169] and for the regulation of functional germinal 
centres [335]. We propose that the impairment of CXCL13 and BAFF production, due to poor 
expansion and activation of LLSc, as observed in the il22ko and il22rαko, is most likely 
responsible for the impaired B cell accumulation, aberrant follicle formation and lack of 
autoantibody production observed.  
There is convincing evidence that AID expression, on locally activated B cells within TLOs, 
supports class switch recombination and somatic hypermutation, thus sustaining affinity 
maturation of autoreactive B cells to tissue autoantigens [194, 233]. In this study we showed 
that IL22-driven LLSc expansion is critical for the establishment of TLO and tightly 
associated with the development of ANA antibodies. It has recently been shown that 
exposure of salivary gland epithelial cells to anti Ro/SSA and La/SSB antibodies is able to 
induce IL22 production [336]. In agreement with these in vitro observations, there is evidence 
that B cell depletion, following treatment with Rituximab, decreased expression of IL22 in the 
salivary glands [337]. This strongly suggests the possibility of a feed forward loop established 
between IL22 expression, survival of autoreactive B cells and autoantibody production. Such 
an amplificatory loop may also be relevant to the well-known, but poorly understood 
association between Sjogren’s syndrome and the predisposition to B cell mucosal associated 
lymphoma [231], where an increase in IL22 production might play a role.  
Therapeutic blockade of IL22 using function blocking antibodies is sufficient to impair TLO 
formation and abolish autoantibody production. This effect, phenocopies observations in the 
il22-/- and il22r-/- mice, is also mediated by decreased LLSc proliferation, which leads to 
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decreased CXCL13 and BAFF expression as well as defective B lymphocyte accumulation in 
the salivary glands.  
Overall, these observations indicate a functional connection between the expression of IL22, 
the proliferation of pathogenic stroma and the production of autoantibody that provides a new 
therapeutic option, and suggests an important role for IL22 in humoral responses at sites of 
inflammation. 
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Chapter 6 
Maturation of lymphoid stromal cells to support TLO 
formation is dependent on lymphocytes and LTβR 
signalling  
Introduction 
Ltαko, ltβko and ltβrko mice lack LNs, underpinning the prime position of LTβR and its ligand 
in lymph node formation [11, 56, 117, 118]. Similarly, absence of lymphotoxin, expressing 
lymphoid tissue inducer cells (LTi), as in the rorγtko or id2ko mice, results in complete lack of 
lymph nodes, highlighting the absolute necessity of LTi cell-derived signals in secondary 
lymphoid organogenesis [11, 42, 48, 56, 338]. During development, LN formation is critically 
dependent on the interaction between LTβR expressed on mesenchymal cells (stromal 
organizer cells) and LTα1β2 produced by CD3-CD4+RORγ+ hematopoietic cells (LTi cells). 
The LTβR triggering subsequently leads to the production of chemokines, such as CXCL13, 
CCL19, CCL21 and CXCL12, and up-regulation of stromal adhesion molecules VCAM-1 and 
ICAM-1 expression. This results in accumulation of more haematopoietic cells, including T 
cells and B cells, resulting in an amplificatory loop. During this phase, organizer cells further 
differentiate to various lymphoid stromal cell subsets that organize lymphocytes into distinct 
T cell zones and B cell follicles. Moreover, sustained LT expression is also crucial for 
maintenance of lymphoid architecture in adult LNs [11, 16, 56, 117, 118].  
Evidence over the last few years has highlighted the role of lymphoid cytokines and lymphoid 
cells in supporting TLO formation [4, 12-14]. Most of the data, supporting the role of LT/LTβR 
involvement in TLO has come from transgenic models, overexpressing LT and its 
downstream products such as lymphoid chemokines or circumstantial evidence from human 
diseases where these molecules have been detected in patient tissues harboring TLO. 
However, transgenic models lack the complexity of a pathophysiological process and human 
studies just give us a snapshot of the dynamic inflammatory disease process.  
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Data presented in the previous chapters and in the recent literature clearly demonstrates that 
TLO formation can be initiated by inflammatory effector cytokines and does not necessarily 
requires the LTβR pathway, suggesting that SLO and TLO may use different pathways for 
their development [214, 230, 281, 339]. Nevertheless, blocking of LTβR has been shown to 
be beneficial in some established models of autoimmunity [257, 340, 341], supporting their 
crucial role in inflammatory disease. Therefore, the exact role that LT/LTβR interaction plays 
during TLO formation and maturation needs to be formally addressed.   
The identity of inducer cells, that provide LT during the development of TLO during 
inflammation, is still in debate. The literature is divided among adult LTi cells or lymphocytes 
[12-14]. In this chapter we used the adenoviral infected salivary glands mouse model of TLO 
formation to dissect the role of LT/LTβR axis in ectopic lymphoneogenesis and also aimed to 
identify the TLO-inducer cell. 
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Results 
6.1 Lack of LTβR signalling impairs full lymphoid conversion of LLSc 
In order to examine the role of LTβR in TLO formation and maturation, we cannulated the 
salivary glands of ltβrko mice. The development of TLOs was followed to evaluate the timing 
of T and B cell populations as well as the compartmentalization and expression of lymphoid 
chemokines. Even though, lymphoid cell infiltration was observed within the salivary glands 
of ltβrko, the  total lymphoid area was significantly lower in ltβrko mice (p<0.01), only ~3-4% 
of total lymphoid aggregate area was observed in these mice compared to 8-10% in wt mice 
at day 8 and day 15 p.c. (Figure 6.1.1A-B). Accordingly, the size of the lymphoid follicles 
(Figure 6.1.1D) was smaller at day 8 p.c., and this difference in size became significant at 
day 15 p.c. (p<0.05) when compared to lymphoid follicles formed in the wt mice.  Moreover, 
the lymphoid aggregates did not show clear segregation between the T and B cell area in 
ltβrko mice (Figure 6.1.1C).  In addition, the B/T cell ratio (Figure 6.1.1E) in ltβrko mice was 
significantly lower at day 8 and 15 p.c. (p<0.05) as compared to wt mice. In line with these 
observations, a significant decrease in AID mRNA expression was detected at week 3 p.c in 
the ltβrko mice salivary glands as compared to salivary glands of wt mice (Figure 6.1.1F) 
Expression of the lymphoid chemokines (CXCL13 and CCL19) was evaluated by quantitative 
PCR analysis of salivary gland tissue from ltβrko and compared to wt mice. Expression of 
CXCL13 was drastically reduced in the ko mice at day 5 (p<0.05), day 8 (p<0.001) and day 
15 (p<0.001) p.c. (Figure 6.1.2A). Of interest, the immunofluorescence analysis also showed 
a significant reduction in the expression of CXCL13 in cannulated salivary glands of ltβrko 
mice as compared to wt controls (Figure 6.1.1Ai and iii). CCL19 mRNA (Figure 6.1.2B) 
expression was intact at day 5 p.c. in the ltβrko mice but showed significant decline at day 8 
(p<0.01) and day 15 (p<0.001) p.c. This decrease in chemokines correlated with CXCR5 and 
CCR7 mRNA expression (Figure 6.1.2C-D). Finally, gene expression analysis revealed a 
significant reduction in the BAFF and IL7 transcript levels in ltβrko infected mice (Figure 
6.1.2E-F). Overall, these results indicate a defect in full TLO maturation in ltβrko mice. 
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Figure 6.1.1 Absence of LTβR signalling prevents formation and maintenance of fully 
mature TLOs. Microphotograph of lymphoid aggregates (A) from infected salivary glands 
(day 15 pc.) from wt (Aiii-iv) and ltβrko (Ai-ii) mice stained for CD3 (red), CD19 (blue) and 
either CXCL13 (green in i and ii) or CCL21 (green in iii and iv). Salivary glands from wt and 
ltβrko day 8 and 15 p.c. were examined by immunofluorescence for CD3 and CD19. B-E, 
Graphs representing % of total lymphoid aggregate area (B), % of segregated aggregates 
(C), lymphoid aggregate size (D) and ratio between the area covered by CD19+ B cells and 
CD3+ T cells (E) at day 8 and day 15 p.c. for wt (black bars) and ltβrko (white bars) mice. 
Data is representative of two different experiments with two to three mice per group, mean ± 
s.e.m. *, p<0.05, unpaired t test, comparing ltβrko to wt mice. (F), Transcripts encoding for 
AID gene (normalized to housekeeping gene β-actin), in week 3 p.c. salivary glands from wt 
and ltβrko mice, were quantified and expressed as RQ values relative to day 0 p.c. AID 
mRNA. Data shown as mean ± s.e.m. of three independent experiments.  
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Figure 6.1.2 Lack of LTβR impairs production of TLO-associated genes. 
Quantitative PCR analysis of CXCL13 (A) CCL19 (B), CXCR5 (C), CCR7 (D), 
BAFF (E) and IL-7 (F) mRNA obtained from salivary glands at day 5, 8, 15 and 
23 p.c. Expression of these genes is shown for ltβrko mice (white bars) 
compared to their wt counterparts (black bars); CXCL13, CCL19, BAFF and 
IL-7 mRNA transcripts were normalized to PDGFRβ mRNA and CXCR5 and 
CCR7 mRNA transcripts were normalized to β-actin mRNA. Results are 
presented as relative quantitation (RQ) values calculated with calibrator day 0 
salivary gland * p<0.05; ** p<0.01; *** p<0.001. Data are representative as 
mean ± s.e.m. of three independent experiments with three to four mice per 
group.  
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6.2 LLSc induction and expansion is not dependent on LTβR signalling 
Interestingly, LLSc induction and proliferation was not affected in ltβrko mice, and a 
significant decrease in LLSc was only observed from day 15 p.c. (Fig 6.2A-D). Furthermore, 
analysis of the LLSc phenotype in ko showed no significant differences as compared to wt 
mice in terms of percentage of ICAM-1int/VCAM-1int andICAM-1high/VCAM-1high+ cell at day 5 
p.c. (Fig 6.2E-F). However, the analysis for ICAM-1 and VCAM-1 on LLSc at day 15 p.c. 
showed a lower percentage of ICAM-1int/VCAM-1int and ICAM-1high/VCAM-1high+ cell (Fig 6.2E-
F). Moreover, reduced proliferation was observed in the LLSc compartment at day 8 p.c. 
demonstrated by Ki67 staining in the ltβrko mice (Fig 6.2C). 
Overall, this data indicated that even though LLSc induction and proliferation was not reliant 
on LTβR signalling during the early stages of stromal cell activation, but maintenance of 
LLSc phenotype and subsequent expansion was dependent on LTβR signalling at later 
stages of the inflammatory process (Fig 6.2D-E).  
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Figure 6.2 LLSc induction and expansion are not dependent on LTβR signalling. 
Representative dot plots (A) showing flow cytometry for percentage of gp38+CD31- 
population in the CD45-EPCAM- component from day 15 p.c. salivary glands in wt and ltβrko. 
Dynamic of LLSc expansion (B) during the inflammatory process determined by flow 
cytometry (percentage of gp38+CD31- population in the CD45-EPCAM- component) from 
infected wt (black squares)and ltβrko (open triangles) mice at 0, day 2, day 5, day 8, day 15, 
day 23 p.c. Data presented as means of five independent experiments. **, p < 0.01, unpaired 
t test, comparing ko LLSc population at each time point with corresponding wt LLSc 
population. C-D, Flow cytometry to show dynamic of Ki67+ LLSc (C) and BrDU+ LLSc (D)  in 
wt (open squares) and ltβrko (black triangles) mice from day 2, day 5 and day 8 p.c. salivary 
glands. ∗, p<0.05 versus virus cannulated wt mice. Data are representative of two to three 
experiments with three to four mice per group. E-F, Flow cytometry of VCAM-1 and ICAM-1 
expression in CD45-EPCAM- cells from salivary glands of wt and ltβrko mice. The graphs 
show percentage of VCAM-1
hi
ICAM-1
hi
 cells (E) and VCAM-1
int
ICAM-1
int 
cells (F) obtained by 
flow cytometry on day 0, day 2 and day 15 p.c. salivary glands from ltβrko mice (white bars)  
in comparison to wt mice (black bars). Data presented as means of two independent 
experiments ∗, p<0.05; **, p<0.01.  
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6.3 RORγ+ cells are redundant for LLSc generation and TLO formation  
In wt cannulated animals RORγt+ adultLTi (CD3-CD4+IL-7Rα+RORγt+) were first detected 
at day 15 p.c. (Figure 6.3.1A) where they were mainly confined to the periphery of the 
aggregates, suggesting that RORγt+ cells are unlikely to play a role in the early phases of 
stromal cell activation. To confirm these observations, we cannulated the salivary glands of 
adult rorγko mice. Aggregates formed normally in these animals with no significant difference 
in terms of size, organization and chemokine expression when compared to wt mice (Figure 
6.3.2A-E). Accordingly, AID expression did not show any significant difference when 
compared to wt mice (Figure 6.3.2F). Evaluation of lymphoid chemokines CXCL13 and 
CCL19, and their cognate receptor expression in salivary glands of cannulated rorγko mice, 
also revealed normal transcript levels at day 5 and day 8 p.c. However, a small but 
significant decline was observed at day 15 p.c. in mRNA expression of lymphoid chemokines 
(Figure 6.3.3A-D). mRNA expression of other lymphoid cytokine genes (Figure 6.3.3E-H) 
including BAFF, IL-7, LTα and LTβ was also found to be comparable to wt mice, though LTβ 
expression showed a 2-fold decrease at day 15 p.c.  
Induction and proliferation of the LLSc was maintained in rorγko mice up to day 15 p.c. when 
a decrease in LLSc number was observed (Figure 6.3.4A-C). Normal lymphoid stromal cell 
differentiation was also demonstrated by ICAM-1 and VCAM-1 staining that showed no 
significant difference in the percentage of ICAM-1int/VCAM-1int andICAM-1high/VCAM-1high+ cell 
at both at day 5 and day 15 p.c. in rorγko and wt mice (Figure 6.3.4D-E). These findings 
suggest that at sites of TLO formation, stromal cells acquire a lymphoid-like phenotype, 
independent of RORγt signals and that TLO formation and maturation is largely independent 
of RORγt+ cells. 
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day 15 p.c. 
A 
Figure 6.3.1 
Figure 6.3.1 RORγt+ cells are observed late in inflammation. Microphotograph 
RORγt+ cells in infected wt salivary glands at day 15 p.c. for CD3 (red), IL-7Rα (blue) and 
RORγt (green). 
10x 
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6.3.2 RORγt+ cells are indispensable for formation of mature TLOs. Microphotograph of 
lymphoid aggregates (A) from infected salivary glands (day 15 pc.) from wt (Aiii-iv) and 
rorγko (Ai-ii) mice stained for CD3 (red), CD19 (blue) and either CXCL13 (green in i and ii) 
or CCL21 (green in iii and iv). Salivary glands from wt and rorγko day 8 and 15 p.c. were 
examined by immunofluorescence for CD3 and CD19. B-E, Graphs representing % of total 
lymphoid aggregate area (B), % of segregated aggregates (C), lymphoid aggregate size (D) 
and ratio between the area covered by CD19+ B cells and CD3+ T cells (E) at day 8 and day 
15 p.c. for wt (black bars) and rorγko (white bars) mice. Data is representative of two different 
experiments with two to three mice per group, mean ± s.e.m. *, p<0.05, unpaired t test, 
comparing rorγko to wt mice. (F), Transcripts encoding for AID gene (normalized to 
housekeeping gene β-actin), in week 3 p.c. salivary glands from wt and rorγko mice, were 
quantified and expressed as RQ values relative to day 0 p.c. AID mRNA. Data shown as 
mean ± s.e.m. of three independent experiments.  
AID mRNA  
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Figure 6.3.3 
Figure 6.3.3 Expression of TLO-associated genes is intact in rorγtko 
mice. Quantitative PCR analysis of CXCL13 (A) CCL19 (B), CXCR5 (C), 
CCR7 (D), BAFF (E), IL-7 (F), LTα (G) and LTβ (H) mRNA obtained from 
salivary glands at day 5, 8, 15 and 23 p.c. Expression of these genes is shown 
for rorγtko mice (white bars) compared to their wt counterparts (black bars); 
CXCL13, CCL19, BAFF and IL-7 mRNA transcripts were normalized to 
PDGFRβ mRNA and CXCR5, CCR7, LTα and LTβ mRNA transcripts were 
normalized to β-actin mRNA. Results are presented as relative quantitation 
(RQ) values calculated with calibrator day 0 salivary gland * p<0.05; ** p< 
0.01. Data are representative as mean ± s.e.m. of three independent 
experiments with three to four mice per group.  
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Figure 6.3.4 
Figure 6.3.4 RORγt is redundant for generation of LLSc during TLO formation. 
Representative dot plots (A) showing flow cytometry for percentage of gp38+CD31- 
population in the CD45-EPCAM- component from day 15 p.c. salivary glands in wt and 
rorγtko . Dynamic of LLSc expansion (B) during the inflammatory process determined by flow 
cytometry (percentage of gp38+CD31- population in the CD45-EPCAM- component) from 
infected wt (black squares)and rorγtko (open triangles) mice at 0, day 2, day 5, day 8, day 
15, day 23 p.c. Data presented as means of three independent experiments. *, p < 0.05, 
unpaired t test, comparing ko LLSc population at each time point with corresponding wt LLSc 
population. C-D, Flow cytometry to show dynamic of Ki67+ LLSc (C) and BrDU+ LLSc (D)  in 
wt (white bars) and rorγtko (black bars) mice from day 2, day 5 and day 8 p.c. salivary 
glands. Data are representative of two to three experiments with three to four mice per group. 
E-F, Flow cytometry of VCAM-1 and ICAM-1 expression in CD45-EPCAM- cells from salivary 
glands of wt and rorγtko mice. The graphs show percentage of VCAM-1
hi
ICAM-1
hi
 cells (E) 
and VCAM-1
int
ICAM-1
int 
cells (F) obtained by flow cytometry on day 0, day 2 and day 15 p.c. 
salivary glands from rorγtko mice (white bars)  in comparison to wt mice (black bars). Data 
presented as means of two independent experiments.  
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6.4 Lack of lymphocytes impairs chemokine and cytokine production during 
TLO formation 
Lymphocytes have been shown to produce lymphotoxin [342]. In order to ascertain the role 
of lymphocytes in TLO formation and maintenance, we cannulated ragko mice. These mice 
are deficient in T and B lymphocytes and thus lack the ability to mount an adaptive immune 
response. This mouse provides us with a powerful tool to investigate the role of innate and 
adaptive immune factors in regulation of stromal cell activation and function during tertiary 
lymphoid structure formation. 
The percentage of LLSc at day 2 p.c. in ragko mice was similar to that observed in wt mice. 
However, the LLSc failed to increase in ragko mice from day 5 p.c. onwards.  A significant 
difference of ~10% was detected at day 5 p.c. (p<0.05), a further reduction of 10% and 12% 
was noticed at day 8 p.c. (p<0.01) and day 15 p.c. (p<0.01) in the gp38+ stromal cells of 
ragko mice in comparison to percentage of LLSc acquired on these days in the wt mice 
(Figure 6.4.1A-B). In addition, FACS analysis for ICAM-1 and VCAM-1 expression (Figure 
6.4.1C-D) on ragko cannulated salivary gland CD45-EPCAM-CD31- cells showed a lower 
percentage of ICAM-1int/VCAM-1int and ICAM-1high/VCAM-1high cells at day 5 p.c. and the 
decrease was significant at day 15 p.c. when compared to salivary glands from wt mice. 
Hence, this data clearly suggests towards importance of the lymphocytes to sustain lymphoid 
stromal cell activation. 
Interestingly, salivary glands of cannulated ragko mice failed to up-regulate lymphoid 
chemokine (CXCL13 and CCL19) expression at all time-points (day 5 p.c. p<0.01-0.001; day 
8 p.c. p<0.001; day 15 p.c. p<0.01; day 23 p.c. p<0.05 when compared with lymphoid 
chemokine expression in cannulated salivary glands of wt mice (Figure 6.4.2A-B). 
Significant reduction was also observed in the IL-7 and BAFF (Figure 6.4.2C-D) transcript 
levels from day 5 p.c. and day 8 p.c. onwards respectively (p<0.05). Additionally, expression 
of both LTα and LTβ mRNA (Figure 6.4.2E-F) was absent in ragko mice, clearly indicating 
that lymphocytes are the main source of lymphotoxin during TLO formation.  
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Overall, these results revealed an indispensable role for lymphocytes in the maintenance and 
maturation of lymphoid stromal cell within TLO and provide data that lymphocytes primarily 
provide the lymphotoxin signals during TLO formation.  
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Figure 6.4.1 
B 
Figure 6.4.1 ragko mice exhibit failure to maintain induction and expansion of LLSc. 
Representative dot plots (A) showing flow cytometry for percentage of gp38+CD31- 
population in the CD45-EPCAM- component from day 15 p.c. salivary glands in wt and 
ragko. (B) Dynamic of LLSc expansion during the inflammatory process determined by flow 
cytometry (percentage of gp38+CD31- population in the CD45-EPCAM- component) from 
infected wt (black squares) and ragko (open triangles) mice at 0, day 2, day 5, day 8, day 15, 
day 23 p.c. Data presented as means of three independent experiments with two mice per 
group. ∗, p<0.05; **, p<0.01 unpaired t test, comparing ko LLSc population at each time point 
with corresponding wt LLSc population. C-D, Flow cytometry of VCAM-1 and ICAM-1 
expression in CD45-EPCAM- cells from salivary glands of wt and ragko mice. The graphs 
show percentage of VCAM-1
hi
ICAM-1
hi
 cells (C) and VCAM-1
int
ICAM-1
int 
cells (D) obtained by 
flow cytometry on day 0, day 5 and day 15 p.c. salivary glands from ragko mice (white bars) 
in comparison to wt mice (black bars). Data presented as means of two independent 
experiments *, p<0.05; **, p<0.01.  
 .  
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Figure 6.4.2 
Figure 6.4.2 Lack of lymphocytes severely impairs production lymphoid 
chemokines and cytokines during TLO development. Quantitative PCR analysis 
of CXCL13 (A) CCL19 (B), BAFF (C), IL-7 (D), LTα (E) and LTβ (F) mRNA obtained 
from salivary glands at day 5, 8, 15 and 23 p.c. Expression of these genes is shown 
for ragko mice (white bars) compared to their wt counterparts (black bars); CXCL13, 
CCL119, BAFF and IL-7 mRNA transcripts were normalized to PDGFRβ mRNA and 
LTα and LTβ mRNA transcripts were normalized to β-actin mRNA. Results are 
presented as relative quantitation (RQ) values calculated with calibrator day 0 
salivary gland * p<0.05; ** p<0.01; *** p<0.001. Data are representative as mean ± 
s.e.m. of two independent experiments with two to three mice per group.  
.  
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6.5 T-cells are the central player in stromal cell maturation during TLO 
formation 
In order to determine if both T and B cells or only T or B cell population was instrumental in 
the defect observed in the ragko mice, the cd3εtg26 (deficient in T cells) and B-cellko (deficient 
in B cells) mice were cannulated.  
In agreement with ragko data on LLSc, both the cd3εtg26 (Figure 6.5.1A) and B-cellko 
(Figure 6.5.1B) mice displayed normal induction of the LLSc at day 2 p.c. The percentage of 
LLSc showed a significant decrease of nearly 10% at day 5 p.c. in cd3εtg26 (p<0.05 in 
contrast to wt day 5 p.c.), the defect in LLSc number was maintained at day 8 (p<0.05) and 
day 15 p.c. (p<0.05). No decrease in gp38+ lymphoid stromal cells was observed in the B-
cellko mice at day 5. However, a small yet significant decrease in percentage of LLSc was 
noticed at day 8 (p<0.05) and day 15 (p<0.05) within the salivary glands of B-cellko mice in 
comparison to wt mice. The analysis of LLSc in cd3εtg26 and B-cellko suggested that the 
deficiency noted in the ragko mice at day 5 p.c. is T cell dependent. Even though the 
maintenance of LLSc at day 8 and day 15 p.c. is centrally dependent on T cells, a further 
defect within the lymphoid stromal cells is augmented in absence of B cells, hence a more 
severe phenotype was observed in the ragko mice compared to T and B cell deficient mice 
on their own. 
Quantitative PCR analysis for lymphoid chemokines revealed that up-regulation of both 
CCL19 mRNA (Figure 6.5.1C) and CXCL13 mRNA (Figure 6.5.1E) was absent (p<0.05-
0.001) in salivary glands of cd3εtg26 mice at all time-points. In contrast the B-cellko displayed 
normal expression CCL19 (Figure 6.5.1D) at day 5 and day 8 p.c. but significant decrease of 
thirty-fold (p<0.01) and fifty-fold (p<0.05) was observed in CXCL13 mRNA (Figure 6.5.1F) 
levels at day 8 and day 15 p.c. respectively. BAFF transcript (Figure 6.5.2A) levels were 
decreased in B-cellko and cd3εtg26 mice (Figure 6.5.2B) from day 8 p.c. onwards (p<0.05). 
IL-7 mRNA expression (Figure 6.5.2C-D) was normal in absence of B cells (B-cellko). T cell 
deficiency (cd3εtg26) resulted in a three-fold decrease at day 5 p.c. (p<0.01), and nearly two-
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fold decrease in IL-7mRNA levels at day 8 (p<0.01) and day 15 p.c. (p<0.05). Transcript level 
of LTα and LTβ (Figure 6.5.2E-H) were also examined in these KO mice. The results 
exhibited baseline expression of both lymphotoxin molecules in cd3εtg26 mice at all time-
points (p<0.05-0.001) as compared to wt mice. The expression of LTβ was severely affected 
in the salivary glands of B-cellko mice (p<0.05-0.001), though B-cellko salivary glands 
showed higher expression of LTβ mRNA than salivary glands of cd3εtg26 mice.  
T cell deficiency resulted in a lack of up-regulation to inflammatory cytokines IL-22 and IL-4, 
which further explains the collapse in the lymphoid stromal cells in ragko and cd3εtg26 (Figure 
6.5.3A-D) . 
Overall, this data indicates that LLSc maturation and local expression of lymphoid genes is 
more severely impaired in T cell deficient mice than B cell deficient mice. 
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Figure 6.5.1 
Figure 6.5.1 T cells are the central players in stromal cell maturation within 
TLOs. Dynamic of LLSc expansion during the inflammatory process determined by 
flow cytometry (percentage of gp38+CD31- population in the CD45-EPCAM- 
component) from infected wt (black squares) and cd3εtg26 (A) or B-cellko mice (B) 
(open squares) mice at day 0, day 2, day 5, day 8, day 15, day 23 p.c. Data 
presented as means of two independent experiments with atleast two mice per 
group. ∗, p< 0.05 unpaired t test, comparing ko LLSc population at each time point 
with corresponding wt LLSc population. Quantitative PCR analysis of CCL19 (C-D) 
CXCL13 (E-F) mRNA obtained from salivary glands at day 5, 8, 15 and 23 p.c. 
Expression of these genes is shown for cd3εtg26 (C and E) and B-cellko (D and F), 
cd3εtg26 or B-cellko mice (white bars) compared to their wt counterparts (black 
bars); CXCL13 and CCL19 mRNA transcripts were normalized to PDGFRβ mRNA. 
Results are presented as relative quantitation (RQ) values calculated with 
calibrator day 0 salivary gland * p<0.05; ** p<0.01; *** p<0.001. Data are 
representative as mean ± s.e.m. of two independent experiments with two to three 
mice per group.  
 
 B-cell KO CD3ε
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Figure 6.5.2 
Figure 6.5.2 T cell deficient mice exhibit greater defect than B cell deficient 
mice in up-regulating expression of lymphoid cytokines. Quantitative PCR 
analysis of BAFF (A-B), IL-7 (C-D), LTβ (E-F) and LTα (G-H) mRNA obtained from 
salivary glands at day 5, 8, 15 and 23 p.c. Expression of these genes is shown for 
B-cellko (A,C,E and G) and cd3εtg26 (B, D, F and H), cd3εtg26 or B-cellko mice 
(white bars) compared to their wt counterparts (black bars); BAFF and IL-7 mRNA 
transcripts were normalized to PDGFRβ mRNA and LTα and LTβ mRNA 
transcripts were normalized to β-actin mRNA. Results are presented as relative 
quantitation (RQ) values calculated with calibrator day 0 salivary gland * p<0.05; ** 
p<0.01; *** p<0.001. Data are representative as mean ± s.e.m. of two independent 
experiments with two to three mice per group.  
 
199 
 
  
Figure 6.5.3 
C D 
A B 
Figure 6.5.3 Expression profiles of effector cytokines in cd3εtg26 and b-cellko 
mice. Quantitative PCR analysis of IL-22 (A-B) and IL-4 (C-D) mRNA obtained 
from salivary glands at day 5, 8, 15 and 23 p.c. Expression of these genes is 
shown for B-cellko (A and C) and cd3εtg26 (B and D), cd3εtg26 or B-cellko mice 
(white bars) compared to their wt counterparts (black bars); mRNA transcripts 
were normalized to β-actin mRNA. Results are presented as relative quantitation 
(RQ) values calculated with calibrator day 0 salivary gland * p<0.05; ** p<0.01; *** 
p<0.001. Data are representative as mean ± s.e.m. of two independent 
experiments with two to three mice per group.  
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Discussion 
During secondary lymphoid organogenesis, LTR signaling is necessary for maturation of 
mesenchymal-derived gp38+ICAM-1highVCAM-1high lymphoid organizer cells (LTo), including 
adhesion molecule up-regulation, production of lymphoid chemokines and cytokines [66, 75]. 
Moreover, LT signals are crucial for proliferation and survival of LTo within the LN anlage 
[60]. Over the past few years, studies have highlighted an LTβR independent stage of 
stromal activation during LN development [60, 66, 67, 75, 83, 142, 226]. Peduto et al., have 
shown that gp38 can be induced on LN stromal cells independent of LTβR. Similarly, other 
studies have also documented that the priming of mesenchymal precursor cells is 
independent of lymphotoxin. However, all these studies have emphasized the critical role of 
LTβR in providing the final maturation stimulus for LN stromal cells [60, 66].  
There is recent data in adult LNs, where there is an LTαβ independent phase of lymphoid 
stromal cell FRC activation during an immune response. However, the maintenance of FRC 
expansion and function was mediated by LTβR and its ligands [280]. Similarly, Chai et al, 
[60, 66] have demonstrated that LTβR signaling is central to full maturation of FRC, and 
hence their  immune-stimulatory capacity during an immune response [142].  
Interestingly, early LLSc induction and proliferation is not affected in ltβr-/- in our mouse 
model. Analysis of the LLSc phenotype at day 5 p.c. in ltβr-/- mice showed no significant 
differences as compared to wt mice in terms of percentage of ICAM-1int/VCAM-1int andICAM-
1high/VCAM-1high+ cells. Nonetheless, mRNA and immunofluorescence analysis showed 
significant reduction, especially from day 8 p.c., in the expression of CXCL13, CCL21, 
CCL19, BAFF and IL7 in ltβrko infected mice as compared to wt controls. Accordingly, 
lymphoid aggregates formed within the salivary glands of ltβr-/- were characterized by 
smaller size and partial T and B cell organization at day 8 and day 15 p.c. Moreover, ltβr-/- 
exhibited a defect in proliferation at day 8 p.c. and a significant decrease in ICAM-1int/VCAM-
1int and ICAM-1high/VCAM-1high+ LLSc at day 15 p.c. Thus, in cognizance with above 
mentioned studies, we also demonstrated that LTR is not required for the early acquisition 
201 
 
of a lymphoid-like phenotype by stromal cells during TLO formation within the inflamed 
salivary gland. LT/LTR interaction is, however, required for the full maturation and 
maintenance of LLSc to a functional lymphoid phenotype, because lack of LT/LTR signal 
affects the subsequent secretion of lymphoid chemokine and cytokines in these cells.  
The early expression of lymphoid chemokines and presence of lymphocytes can be 
explained by our findings in chapter 5 where we demonstrated that the cytokine IL-22 has the 
capability to induce chemokines and cytokines in the LLSc. Moreover, LLSc also express 
TNFR1 (shown in chapter 3) and therefore can respond to LTα3, which has also been shown 
to induce chemokines in lymphoid stromal cells [157, 158, 186].  
CD3-CD4+IL-7rα+RORγt+ lymphoid tissue inducer (LTi) cells represent the first source of 
LTβ in the LN anlagen. This signal is necessary for LTβR-mediated stromal cell maturation 
during lymphoid organogenesis [97]. The application of our model to rorγt-/- mice provided a 
useful tool to interrogate the role of adult LTi in TLO maturation. We found that adult RORγt+ 
LTi are recruited late in the formation of TLOs, well after LLSc become activated and 
proliferate. In addition, rorγt-/- mice had preserved induction and proliferation of the LLSc 
with normal TLO formation. Our findings are further supported by studies in other models in 
which id2-/- or rorγt-/- mice, which lack LTi cells, when infected with influenza virus or 
exposed to LPS. These mice develop normal iBALT structures in the lung [76, 214, 215]. 
Similarly, another study demonstrated development of TLOs in colon of rorγt-/-  mice [216]. 
However, in our model we observed a decrease in the LLSc and CXCL13 production at day 
15 p.c. A small, though non-significant decrease in TLO size and organization was also 
identified.  
In the spleen LTi have been demonstrated to be essential for T/B cell segregation and follicle 
size [343]. One cannot rule out the possibility that LTi can have a role in maintenance of 
TLOs, because our mouse model is a resolving model of TLO formation and will be an 
interesting question to address in a pathophysiological mouse model of persistent TLO 
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formation. In fact, there are some human TLOs, such as those seen in idiopathic pulmonary 
arterial hypertension (IPAH), where RORc+CD4-cKit+ LTi have been detected [12]. 
However, our observations suggest that LTi are not required for the formation of TLOs at 
least in our model.  
We found that lymphocytes and in particular T cells are necessary for the expansion and 
maturation of stromal cells and hence TLO formation. In fact, even during lymph node 
organogenesis the stromal activation phase occurs independently of lymphocytes but 
formation and maintenance of the mature LN has been demonstrated to be dependent on T 
and NK cells [27]. Moreover, lymphocytes are critical in adult SLOs for maintenance of 
lymphoid structures using LT/chemokine axis positive feedback loop. In adult SLOs, 
lymphocyte derived lymphotoxin promotes expression of CXCL13, CCL21 and CCL19 by 
stromal cells [115]. This regulates steady state homing and correct positioning of T and B 
cells, and also plays a role in maintenance of LTαβ expression on lymphocytes, thereby 
sustaining the positive feedback loop to maintain the structure and function of SLOs [16, 36, 
115-117]. Evidence suggests that the maintenance of homeostatic lymphoid chemokine 
expression and FDCs in B cell follicles is dependent on LTαβ and TNFα expression on 
mature B cells [16, 108, 118]. However, normal levels of chemokines, and B cell follicles with 
FDCs were detected in the LNs of mice that lack LTβ, specifically on B cells. Hence, in this 
case, it was been shown that LTαβ-expressing T lymphocytes are sufficient to maintain LN 
structure and function [16, 119, 120]. Altogether, this data indicates that expression of LTαβ 
by both T and B lymphocytes is necessary for appropriate conservation of lymphoid 
architecture in adult SLOs. 
It has been widely suggested that lymphocytes analogous to their function in adult SLOs can 
substitute for the inductive function of LTi cells within TLOs, particularly when they are 
activated [108, 111, 119, 120, 212, 342, 344]. CD4+ T cells have been shown to be crucial 
for development of TLO in the thyroid [217]. Moreover, in NOD mice LIGHT expressed on T 
cells has been demonstrated to be essential for formation and maintenance of TLO 
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structures. A similar role for LTα expressing T cells has been documented in mice model of 
colitis [116, 235, 341]. T cells are not only an important source of LTαβ but also of 
inflammatory cytokines IL-22 and IL-4 which have been demonstrated to be important for 
LLSc expansion and maintenance in chapters 4 and 5. This could possibly explain why the 
defect observed in LLSc maturation and maintenance is more severe in cd3εko mice than 
ltβrko mice.  
In agreement with our results, T cells have been identified to have a higher tendency to 
activate mesenchymal stromal cells to express both CCL19 and CXCL13, whereas B cells 
only induce CXCL13 expression when co-cultured with stromal cells (Mark Coles, 
unpublished data). When both B and T lymphocytes were added together, the production of 
CXCL13 significantly increased above the level induced by T lymphocytes alone, an effect 
which was not seen when the expression of either CCL19 or CCL21 was determined. This 
suggests that T lymphocytes could indirectly attract B lymphocytes into a site of inflammation 
by inducing stromal cells to express CXCL13 and this is exacerbated by a positive feedback 
loop as B lymphocytes begin to enter (Mark Coles, unpublished data). Thus, at later stages 
both T and B cells contribute to maintain the stromal cells in our model. This propensity of 
lymphocytes to instruct stromal cells to mature into lymphoid stromal cells requires the 
lymphocyte and stromal cell to be in physical contact, requires activation and crucial 
signalling within lymphocytes (Mark Coles, unpublished data), and these signals are currently 
under investigation in our lab.  
It will also be interesting to see if maintenance of lymphoid phenotype and function of LLSc is 
completely taken over by B cells in a model of persistent TLO formation. This might explain 
why rituximab (anti-CD20) therapy has been proved to be efficacious in patients with TLO-
associated chronic inflammatory diseases such as Sjogren’s syndrome.  
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Chapter 7 
Concluding Discussion 
TLOs form de novo in the target tissues of many inflammatory diseases, such as in the 
inflamed salivary glands of Sjogren's syndrome patients, the joints of rheumatoid arthritis 
patients and the lungs of pulmonary infection or inflammation patients, [14]. TLO 
development is characterized by the progressive organization of T and B-lymphocytes, 
formation follicular dendritic cells networks and maturation of high endothelial venules [236, 
345, 346]. There is accumulating evidence that naïve T cell priming and T cell epitope 
spreading can take place within TLOs [4, 161, 207]. This can contribute to the exacerbation 
of disease by activation of auto-reactive T cells due to presence of tissue auto-antigens at 
the site of TLOs, released by the destructive inflammatory process [4, 14]. Moreover, 
expression of AID, the enzyme that support class switch recombination and somatic hyper-
mutation has been shown on activated B cells within these structures [194]. Therefore, TLOs 
seem to be able to sustain B-cell affinity maturation and production of autoantibodies [194, 
233].  
Autoantibodies are one of the major hallmarks of chronic autoimmune diseases and are 
highly predictive of disease severity [14, 347-349]. In some cases, autoantibodies have been 
demonstrated to directly provoke damage and in Sjogren’s syndrome there are evidence that 
they can influence the gene expression profiles of epithelial cells to produce pro-
inflammatory cytokines [350]. TLO formation has been also associated with disease 
persistence and malignant transformation [4, 13, 14, 18, 160, 194, 210, 211, 236] 
Due to their pathogenic contribution to disease development and their correlation with more 
aggressive form of disease and development of malignancy there has been an increasing 
interest in targeting TLOs in clinical practice [14, 222]. Current treatments aimed to targeting 
leukocytes in autoimmune conditions have led to a dramatic change in the management of 
inflammatory diseases [222]. However, this approach does not result in a definitive cure and 
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even in patients that achieve clinical remission, relapse occur once the treatment is 
withdrawn [222]. This suggests the need to consider non-leukocyte targets.  
Over the past few years, it has become increasingly evident that at site of chronic 
inflammation and in particular within TLOs, resident stromal cells can undergo functional 
changes, which enable them to modulate the formation, organization and maintenance of 
ectopic lymphoid structures [221, 222, 351, 352]. In this thesis, we have explored the 
crosstalk between tissue resident stromal cells and immune cells, that is mediated by 
cytokines and provide mechanistic insights into how TLO develops. Our results provide a 
framework for selection of new therapeutic strategies aimed at silencing TLO associated 
stroma and to treat autoimmune conditions.  
The presence of stromal cells resembling lymphoid, stromal cells is well documented in many 
human chronic inflammatory diseases and mouse model of TLOs [76, 159, 160, 177-179, 
185, 248, 249] . In 2009 Peduto et al. were the first to perform a direct comparison of 
lymphoid stromal cells with activated stromal cells at  sites of inflammation in non-lymphoid 
organs [226]. Their findings suggested that during inflammation, tissue-resident stromal cells 
recapitulated features of lymphoid stromal cells [226].  gp38, a marker of lymph node stromal 
cells, was used to identify and isolate these inflammation-induced lymphoid stromal cells that 
acquired the capability to express genes, essential in lymphoid tissue genesis and in the 
recruitment and survival of leukocytes [226]. Strikingly, the early development of gp38+ 
stromal cells during inflammation was shown to be independent of LTβR and TNF signalling 
[226].  
In 2011, Randall’s group, using a mouse model of iBALT formation in the lungs of neonatal 
mic, provided evidence that pro-inflammatory cytokines such as IL-17 could initiate TLO 
formation [214]. This study demonstrated that iBALT formation did not require LTi and 
lymphotoxin mediated signals but it was dependent on IL-17 produced by CD4+ T cells [214]. 
Most striking finding in this study was that  IL-17, not only demonstrated an ability to induce 
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expression of inflammatory chemokines such as CXCL10, CXCL11 and CXCL9, but it could 
also directly stimulate the expression of CXCL13 and CCL21 in stromal cells [214]. In the 
same year, study from Kuchroo’s group also supported the role of effector cytokines such as 
IL-17 in initiating TLO formation [230]. 
Taken together these studies clearly indicated that acquisition of phenotypical and functional 
features of lymphoid stromal cells can occur in tissue-resident fibroblasts and challenged the 
current dogma that SLO and TLO development engage similar pathways and proposed 
probable role of proinflammatory cytokines in TLO development [353].  
The conjecture that TLO formation follows the same cellular and molecular routes used by 
SLOs comes from structural and partly functional resemblance of TLOs to secondary 
lymphoid organs, and  studies on transgenic mice over-expressing lymphoid cytokines (LT) 
and chemokines (CXCL13, CCL21) [12, 14, 158-160, 165, 169, 173, 174, 186, 227] in non-
lymphoid organs resulting in TLO formation. These findings were further fuelled by evidence 
from human studies which suggested a strong correlation between the expression of 
lymphoid cytokines such as LTα, LTβ, CXCL13, CCL21 and TLO development [13, 14, 160, 
179, 180, 183-186]. However, transgenic mice lack the pathophysiological complexity that 
underpins TLO formation during disease development.  
A major limitation of studies in humans is that they only provide us with a snapshot of the 
inflammatory process whereas it is well-known that inflammation is dynamic process, 
characterized by different stages namely activation, maintenance and resolution or 
persistence [351, 352, 354-356]. For example, a study conducted by Raza et al., to study 
cytokine profiles of patients with RA at different stages of the diseases, clearly indicated 
differences in the inflammatory cytokine profiles of patients with early RA compared to 
established RA [299], further establishing the idea that inflammation is an actively changing 
process. Robust data for most chronic diseases is lacking and many diseases are diagnosed 
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at established stages when TLOs have already developed and this could possibly explain the 
overestimation of the capability of certain cytokines to drive TLO formation.  
Nevertheless, lymphotoxin signalling has been demonstrated to be crucial for maintenance 
and organization of TLOs, as these lymphoid structures were highly disrupted in mice 
deficient in LT signalling or treated with anti-LTβR antibody [164, 193, 214, 257, 340, 341, 
357]. These evidences are more in line with role of LT in maintenance and function of adult 
SLOs [117, 357, 358]. Due to the perplexity in the current literature regarding the signals 
regulating TLO formation, we decided to dissect these signals in our model of salivary gland 
inflammation. Stromal cells occupy the centre-stage in the process of SLO organogenesis, 
and also fundamental for SLOs to mount an effective immune response during adult life [6, 
67, 126]. However, the role of stromal cells in TLOs establishment and pathology remains 
unclear.  Therefore, our prime focus was to first examine stromal cell activation during TLO 
formation and then understand signal/s modulating their phenotype and function during 
inflammation and TLO formation.  
Using a mouse model of TLO formation that mimics features of Sjogren’s syndrome [237], 
we demonstrated that lymphoid-like stromal cell (LLSc) expansion occurs early during the 
development of TLOs.  We have shown that LLSc acquire markers such as gp38, ICAM-1, 
VCAM-1, RANK-L, MadCAM-1 and LTβR and are able to respond to LTβ stimulation, up-
regulating CXCL13, CCL19, IL7 and BAFF. We showed that the acquisition of these features 
is the result of a concerted process mediated by few cytokines, namely IL-13, IL-22, LT and 
IL-4 that play different roles at different stages of the inflammation process. Based on our 
findings, we recognized three phases of stromal cell activation which were named induction, 
expansion and maintenance phase (Figure 7.1).  
We demonstrated that early after the inflammatory insult (in our case Adv infection) a 
significant increase in the expression of IL-13 occurs, mainly sustained by the resident 
stroma (both epithelial and non-epithelial/endothelial stromal cells). IL-4Rα/IL-13Rα 
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engagement on tissue stromal cells  then initiates the induction phase, which results in over-
expression of gp38 and adhesion molecules ICAM-1 and VCAM-1 on local non-epithelial 
non-endothelial stromal cells (fibroblasts) and transient expression of inflammatory 
chemokines including CXCL10, CXCL9 (M. Coles personal communication). These events 
cause the recruitment and retention of activated and memory effector T cells (which are 
known to express receptors such as CXCR3, specific for inflammatory chemokines) at the 
site of inflammation. During this period, resident γδT cells and incoming αβ T cells produce 
IL-22, which engages IL-22R on activated tissue gp38+ fibroblasts and induces their 
proliferation and also up-regulates early expression of lymphoid chemokines. This 
phenomenon contributes to the further recruitment of T as well as some B cells. 
Subsequently, LTα and LTβ production particularly by activated T cells engages LTβR and 
TNFR signalling on LLSc which further enhances production of chemokines (CCL19, 
CXCL13 and CCL21) and lymphocyte survival factors (IL-7 and BAFF) by LLSc. Besides, 
LTβR mediated signalling in LLSc further increases their proliferation. Overall, IL-22 and 
LT/TNF enable functional maturation of LLSc.  Additionally, LTβR triggering promotes 
maintenance of phenotypical and functional features acquired by LLSc. Expansion of 
functionally mature LLSc allows attraction of more T cells (apart from activated and memory 
effector cells, recruitment of naïve T cells is also observed) as well as B cells that results in 
establishment of a positive feedback loop and development of lymphoid aggregates with 
progressively organized of T and B-lymphocytes, formation follicular dendritic cells networks 
and maturation of high endothelial venules. During this phase, IL-4 produced by T cell can 
enhance expression of LTαβ on naïve T cells [175], which aids in enhancing LTβR triggering. 
Additionally, lymphoid chemokines such as CXCL13 are also reported to enhance 
expression of LT on lymphocytes [13, 36] and could possibly aid in further reinforcing the 
LT/CK/lymphocytes amplificatory loop that allows maintenance of TLOs. Thus the main 
components of lymphoid tissue are formed within organs where lymphoid tissue is not 
usually found.  
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Of note, IL22 has been previously demonstrated to promote organization and maintenance of 
mature colonic patches and isolated lymphoid follicles during infection with C. rodentium of 
the gut [317]. In this study IL-22 function was implicated to be downstream of LTβR. In 
contrast, we have established in chapter 5 and 6 that IL22 is necessary and sufficient to 
induce the proliferation LLSc and is able to induce the early production lymphoid chemokines 
independent of LTβR signalling. Interestingly, while LTβ signalling is not required in these 
early phases, it is necessary for the late maintenance of the follicle and full conversion of the 
LLSc to a functional lymphoid phenotype since full TLO formation is abrogated in ltβrko mice.  
In this study we also demonstrated that stromal activation can occur independently of RORγ+ 
cell. The application of our model to rorγko mice provided a useful tool, not only to 
interrogate the role of adult LTi but also of IL17 (since RORγ is master-regulator of Th17 
cells) in TLO maturation.  A role for IL17 has been suggested in the context of stromal cell 
activation in a neonatal model of TLO formation [214]. However, the inability to reproduce 
this model in adult mice has questioned the role of IL17 in post-natal TLO formation [282]. 
Further data on the role of IL17 in TLOs has been provided in a study [230] from Peters et 
al., which demonstrated the requirement of gp38+ Th17 cells for EAE development in the 
CNS. However, in our model, LLSc expansion precedes T cell infiltration, suggesting that 
Th17 lymphocytes are not involved in early LLSc expansion and proliferation. We 
demonstrated in chapter 6 that RORγ+ cells are not required for the LLSc generation and 
TLO formation, at least in this model. Therefore, role for RORγt+Th17 lymphocytes in LLSc 
differentiation and TLO formation in our model is highly unlikely. However, to formally rule out 
the possibility that IL-17 plays any role in our model, further work in il17ko will be required.  
Overall, our data establishes a functional connection between the expression of pro-
inflammatory cytokines (IL-13, IL-22, IL-4 and LT), the activation of pathogenic stroma and 
the development of TLOs which provides a rationale for new therapeutic options and 
suggests an important role for T lymphocytes in the expansion and maintenance of 
pathogenic stroma at sites of inflammation.   
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Figure 8.1 Illustration of the different phases (induction, expansion and 
maturation/maintenance) of stromal cell activation and the signals regulating each of 
these phase during TLO formation.  
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Future Work 
Even though we demonstrate that stromal cells have the ability to respond directly to virus 
and inflammatory cytokines to undergo transition into pathogenic stroma, however we cannot 
exclude the contribution of other mechanisms that have been implicated in the generation of 
stromal cells during development, inflammation and fibrosis [222]. Fibroblasts are believed to 
arise from three distinct cellular origins: primary mesenchyme, local epithelial-mesenchymal 
transition (EMT) or bone marrow derived precursors. It is widely accepted that the majority of 
fibroblasts originate from primary mesenchymal cells and that upon appropriate stimulation 
these fibroblasts can proliferate to generate new fibroblasts [222, 359-363]. In fact, it has 
recently been suggested by Krautler et al. that non-lymphoid tissue has myofibroblast 
(perivascular) precursor cells that can give rise to FDC upon appropriate stimulation [147].  
In the LN, gp38- subset of fibroblastic stromal cells have been shown to contain a population 
of α7+ perivascular cells which could serve as precursors of gp38+ FRC, as these two cell 
types share some common features [142, 296, 364]. In our model, we have observed a 
gp38- population of fibroblasts (termed DN cells), and demonstrated that these cells differ 
from LLSc, not only in their expression of lymphoid adhesion molecules ICAM-1 and VCAM-1 
but also have significantly lower ability to produce lymphoid chemokines and lymphocyte 
survival factors. Nonetheless, these DN cells were shown to express receptors for the 
various cytokines that we studied. 
Our experiments did not discriminate between the ability of DN and LLSc to respond to virus. 
Additionally, there is only a small population of gp38+ fibroblasts in resting salivary glands, 
and the substantial increase in this population within 48 hours cannot be attributed only to 
proliferation, since only 15% LLSc showed BrdU staining at this stage.  Altogether, it is 
tempting to speculate that the gp38- tissue fibroblasts respond to inflammatory stimulation 
and up-regulate gp38 and therefore contribute to generation of pathogenic stroma. This 
could be tested by fate mapping experiments.  
212 
 
Intriguingly, increased gp38 expression has been reported on epithelial cells that are 
undergoing EMT, a process that involves down-regulation of epithelial markers, such as 
adhesion molecules like E-cadherin which allows transition of sessile epithelial cells into 
more motile mesenchymal cells [365]. We demonstrated that epithelial cells not only produce 
IL-13 upon virus infection but also express both IL-13Rα and IL-4Rα. Moreover IL-13 has 
been implicated in EMT during fibrosis [298]. Hence, using genetic lineage tracing and 
ablation systems, it will be very interesting to address in future whether LLSc in TLOs arise 
from distinct progenitors during an inflammatory process. 
Another very important question for the future is to understand the function of gp38 
acquisition by tissue stromal cells. gp38 expression has been detected on cancer –
associated fibroblasts (CAFs) where it has been reported to promote plasma membrane 
extension and actin cytoskeleton rearrangement; thought to play an important role in tumor 
cell migration and metastais [365]. gp38 signalling have been demonstrated to have intrinsic 
effects on the proliferation and migration of cells expressing it [365, 366]. In fact, results 
presented in this thesis have also demonstrated that gp38+ fibroblasts exhibited higher 
proliferative ability than gp38- fibroblasts.  
Impaired B and T cell segregation within the white pulp of the spleen correlates with a lack 
of gp38 expression on the T zone stroma, thus suggesting a role for gp38 in the separation 
of lymphocytes [365, 367]. In SLOs, gp38 is expressed on fibroblastic reticular cells (FRCs). 
FRCs together with reticular fibers (RFs) and fibrous extracellular matrix (ECM) bundles 
forms the highly diverse reticular network that serves as a scaffold to maintain the 3-D 
structure of these SLO and also forms an enclosed conduit structure through which 
molecules such as chemokines and antigens can be delivered within SLOs [1, 3]. It has 
recently been demonstrated that gp38+ER-TR7+ reticular networks found at the site of 
TLOs, are functional and can mediate transport of fluid and small molecular weight 
molecules, such as chemokines and antigens, analogous to FRC found in SLOs [213]. This 
proposes an interesting possibility of gp38+LLSc delivering antigen directly to TLOs.  
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gp38 has been shown to bind chemokines such as CCL21 and CCL19 via its negatively 
charged glycosaminoglycans on the surface of FRCs, which helps to actively direct the 
migration of lymphocytes between and within separate lymphoid tissue compartments [3, 
126, 365, 368]. Moreover, gp38 has been shown to be important for motility of DCs along 
FRCs networks and this process is guided by engagement of gp38 by its receptor Clec-2 on 
LNs. Interestingly, a study has shown that gp38 expression is further up-regulated on LN 
FRCs within few hours of an immune response, suggesting that it acts as an activation 
marker [280]. This is line with evidence where gp38 was shown to be expressed by damaged 
keratinocytes during wounding [365]. Besides, another group recently demonstrated that LNs 
were unable to mount an appropriate immune response to virus insult in the absence of gp38 
on FRC [142]. In spite of the large number of descriptive studies, little is understood about 
podoplanin’s biological function. Currently, there are experiments undergoing in our lab to 
address the functional relevance of gp38 on tissue stromal cells during TLO formation, since 
gp38ko mice are embryonically lethal, we are using the conditional knockout 
Pdpnloxp/loxpRosa26ERT2Cre/Cre mice. 
Lymphatic endothelial cells (LEC) and blood endothelial cells (BEC) are also a part of tissue 
stromal cells, and have been demonstrated to be important players of inflammation [222]. 
Striking changes in the lymphatic vasculature are associated with inflammation, which 
include acute and chronic infections, autoimmune diseases such as RA, Crohn’s disease, 
wound healing, cancer, and transplant rejection [20, 21, 222]. Neo-lymphangiogenesis is a 
critical mechanism regulating changes in interstitial fluid. Deregulated activation of its 
cascade results in defective leukocyte drainage and persistence of the inflammatory process 
[222].   
Similar to the fibroblasts and lymphatic vessels, blood vessels undergo remodelling during 
inflammation. Blood endothelium changes its structure and phenotype and participates in the 
inflammatory response, mainly through regulating leukocyte recruitment into the tissue [222]. 
Furthermore, expression of co-stimulatory molecules such as OX40, ICOSL, and CD2, 
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known to be important in the formation and activation of T cell memory, has been 
documented in activated human endothelial vessels [22, 222]. Additional endothelial 
phenotypical changes are observed in various chronic inflammatory diseases, such as 
Sjogren’s syndrome, thyroiditis, RA [14, 179, 180, 182, 228]. The chronically inflamed organ 
acquires ectopic lymphoid-like structures with conversion of flat venular endothelial cells into 
tall and plump endothelial cells that very closely resemble the high endothelial venules 
(HEVs) found in the lymph nodes [222]. These ectopic HEVs also concomitantly express 
lymphoid chemokines CCL21 and mostly PNAd that allows large scale and at times 
misguided influx of CCR7+ memory T cells and potentially naïve cells into the inflamed 
tissue, leading to amplification and maintenance of chronic inflammation [222]. Moreover, 
endothelial cells are strongly implicated in LN development [74, 222].  
The role of lymphatic and blood endothelial cells in TLO formation and maintenance, as well 
as signals regulating TLO-associated lymphangiogenesis and changes in the blood vascular 
bed have not been addressed in this thesis. The presence of lymphatic vessels and HEVs 
has been documented in inflamed salivary during TLO formation in our mouse model. 
Therefore, this model provides an exciting tool to address these questions in future. 
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